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Inherited bleeding disorders are a heterogeneous group of conditions that reflect 
abnormalities of the vascular endothelium, coagulation factor proteins and platelets. Clinical 
diagnosis is often challenging despite patients having extensive bleeding histories and 60% of 
patients recruited to the Genotyping and Phenotyping of Platelets (GAPP) study remain 
undiagnosed. A novel assay was trialled in 71 affected patients to investigate platelet 
spreading ability. This identified patients with abnormal platelet area and circularity who were 
negative for defects in aggregation and revealed that this assay could identify platelet 
morphological defects that might be missed by lumi-aggregometry alone. In addition, whole 
exome sequencing was employed in 10 unrelated families in this undiagnosed patient cohort. 
The definitive genetic cause of disease was identified in 1 of these families, a missense variant 
in THBD, with several plausible candidate variants remaining for the other families. In 2 of 
these families, and a further family from the GAPP study cohort, novel and rare genetic 
variants in TTLL10 were identified. The protein tubulin tyrosine ligase-like 10 (TTLL10) shows 
a potential role in the post translational modification of tubulin microtubules in platelets 
thereby affecting normal platelet physiological processes. In conclusion, genetic variants 
identified in genes not previously known to cause bleeding could lead to further 
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Platelets are small anucleate cells that circulate in the blood to provide many important 
biological roles. Classically, their main role is to prevent excessive bleeding upon blood vessel 
injury. To do this, activated platelets employ multiple signalling pathways that lead to a 
cascade of reactions, release of chemical mediators and recruitment of other cell types, 
ultimately causing the cessation of a bleed. However, when one of these steps is interrupted, 
it can cause detrimental bleeding in affected individuals. Platelets have, more recently, been 
associated with other roles such as wound healing, inflammation and cancer metastasis. Due 
to their wide range of functions, it is important to understand the processes that modulate 
platelet activity in order to investigate these when they go wrong. Furthermore, dysfunctional 
platelets are not the only cause of detrimental bleeding as there are many other factors to 
take into account. Due to the complex nature of these disorders, it is often best to investigate 
these other causes of bleeding using a genetic approach.  
In this chapter, platelet production and physiology are introduced, as well as disorders of 
platelets and other non-platelet causes of bleeding. Platelet function testing will be described 
and the rise of genetics in general research and medicine is discussed, including the use of 
next-generation sequencing technologies in this field. Finally, the hypothesis and aims of this 
thesis will be discussed. 
1.1. Haematopoiesis and megakaryopoiesis  
Platelets are produced from haematopoietic stem cells (HSCs) that have differentiated 
through multiple precursor cell types to from megakaryocytes. These stem cells self-renew or 
commit to a specific cell lineage and therefore they lose their developmental potential and 
ultimately become a specific cell type through a number of differentiation steps  
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(Akashi et al., 2000). This is a complex cell differentiation process involving a great amount of 
regulation by cytokines and transcription factors (Schulze and Shivdasani, 2005). The whole 
process of haematopoiesis is summarised in Figure 1.1.   
HSCs typically reside in the unique bone marrow microenvironments or niches. The 
osteoblastic and vascular niche allow for HSC self-renewal and differentiation (Shiozawa and 
Taichman, 2012). However, these cells can migrate and there have been observations of 
platelet production in the lungs and in early development, where they have been found in the 
yolk sac, foetal liver and spleen (Lefrancais et al., 2017, Machlus et al., 2014).  
The first stage for the classic lineage HSC differentiation into megakaryocytes is the 
development of multipotent progenitors; these can commit to the myeloid or lymphoid 
lineage creating common myeloid progenitors or common lymphoid progenitors respectively. 
These progenitor cell types lack the ability to self-renew, however, remain multipotent. 
Common lymphoid progenitors predominantly produce T- and B-lymphocytes along with 
natural killer cells. Common myeloid progenitors can progress to generate erythrocytes and 
megakaryocytes.  The common myeloid progenitors can also progress to generate monocyte 
derived macrophages and dendritic cell types along with granulocytes including eosinophils, 
basophils, and neutrophils. However, increasing evidence is challenging this idea of the 
hierarchical lineage progression. Recent alternative models have suggested that the 
progenitor cells are likely to form more fluid lineage biases in a ‘continuum of low-primed 
undifferentiated haematopoietic stem and progenitor cells’ (CLOUD-HSCs) (Velten et al., 2017, 
















Figure 1.1. The main steps of haematopoiesis. Haematopoiesis is the formation of cellular components of the blood. Haematopoietic stem 
cells give rise to all the cell types that are then guided to commit to specific cell lineages by chemical messengers. The main steps of 










































1.1.1. The role of cytokines and transcription factors in megakaryopoiesis 
Megakaryopoiesis and platelet formation is regulated at different levels by multiple cytokines. 
Interleukin 3 stimulates the early stages of megakaryocyte development by differentiation of 
multipotent HSCs to myeloid progenitor cells (Segal et al., 1988). However, the main driver of 
megakaryopoiesis is thrombopoietin (TPO) which is considered the most important 
haematopoietic cytokine involved in platelet production (Tijssen and Ghevaert, 2013, 
Kaushansky, 1995).  
TPO, synthesised in the liver, acts on c-Mpl receptors primarily found on the surface of HSCs, 
megakaryocytes and platelets. TPO binds to the inactive c-Mpl receptor and creates an active 
receptor as it undergoes a conformational change, which allows the cytoplasmic tails of the 
receptor to become closer in proximity (Geddis, 2010, Kuter, 2007). c-Mpl does not have 
intrinsic kinase activity itself therefore, the conformational change initiates many downstream 
signalling events. Janus kinase 2 (JAK2) molecules associated with the receptor come together 
and are able to be activated by trans-autophosphorylation at multiple tyrosine residues 
(Varghese et al., 2017). Following the activation of JAK2, multiple signalling pathways are 
triggered; these include signal transducer and activator of transcription 5 (STAT5), mitogen-
activated protein kinase (MAPK)/ERK and phosphoinositol-3 kinase (PI3K)/AKT pathways 
(Geddis, 2010, Varghese et al., 2017). 
Transcription factors also play a critical role in haematopoietic cell lineage specific 
progression. They can bind to specific sequences of DNA neighbouring the genes they regulate 
to either promote or block the recruitment of RNA polymerase, thereby controlling the 
transcription of that exact region of DNA.  Transcription factors can exert their effects alone 
or with other proteins in a complex. The variance in expression levels of the transcription 
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factors in progenitor cells forms a linear hierarchy of transcriptional regulation, therefore 
allowing them to selectively differentiate into their respective cell types (Tijssen et al., 2011, 
Shivdasani, 2001). The following transcription factors are all essential regulators of the 
different stages of megakaryocyte differentiation. Runt-related transcription factor 1 (RUNX1) 
is a key regulator of haematopoiesis and megakaryopoiesis. RUNX1 acts to maintain, 
proliferate and differentiate HSCs (Schlegelberger and Heller, 2017). The zinc finger protein, 
GATA-binding factor 1 (GATA-1) is an important regulator of early and late megakaryopoiesis 
(Centurione et al., 2004). There are other members of the GATA subfamily that are also 
transcription factors involved in haematopoiesis, GATA-2 and GATA-3 (Ferreira et al., 2005). 
Friend of GATA-1 (FOG1) is an essential cofactor for the GATA family members that acts via 
the formation of a heterodimer with the transcription factors; this is essential to activate 
expression of nuclear factor erythroid 2 (NF-E2) (Mancini et al., 2012). NF-E2 is a basic leucine 
zipper transcription factor and again is a major regulator of megakaryocyte maturation. GATA-
1 and NF-E2 are increasingly expressed throughout the myelo-ethyroid lineage and most 
highly expressed in the megakaryocyte-erythroid progenitor cell population (Akashi et al., 
2000). NF-E2 is a critical regulator for lineage specific β1 tubulin expression essential for 
platelet production (Lecine et al., 2000). Furthermore, the ETS gene friend of leukaemia virus 
integration 1 (FLI1) is critical for late megakaryopoiesis (Vo et al., 2017). Therefore, mutations 
in haematopoietic transcription factors can cause disruption of transcriptional control. This 
dysregulation can lead to thrombocytopenia due to megakaryocyte maturation failure and 
impaired platelet function (Johnson et al., 2016a). 
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1.1.2. Endomitosis and polyploidisation 
In order to produce platelets, megakaryocytes undergo endomitosis whereby they become 
progressively larger and polyploid following multiple DNA replication cycles without cell 
division.  Megakaryocytes follow the normal cycle of cell division passing through G1, S and 
G2 phases successfully followed by a restricted M phase; the cycle then repeats resulting in 
multiple duplicates of DNA  (Zimmet and Ravid, 2000). It was revealed that within this altered 
form of mitosis, megakaryocytes have a cytokinesis defect which gives rise to impaired 
cleavage furrow formation, as well as impaired contractile ring formation (Bluteau et al., 2009, 
Lordier et al., 2008). This process is mediated by RUNX1 acting to downregulate non-muscle 
myosin IIB heavy chain (MYH10) in the contractile ring, of which filamentous actin is also part, 
and together they produce the contractile forces necessary for cell separation (Lordier et al., 
2012). As a result of this, megakaryocytes contain multiples of normal diploid chromosome 
numbers with ploidy values in the range of 4N to 64N within a single multi-lobulated polyploid 
nucleus (Zimmet and Ravid, 2000). 
The main reason for endomitosis is to generate large quantities of protein and lipids important 
for the formation of the invaginated membrane system (IMS) which was previously known as 
the demarcation membrane system (Machlus and Italiano, 2013). Therefore, following nuclear 
polypolidisation megakaryocytes form an IMS. A pre-IMS is initially formed which then 
expands (Eckly et al., 2014). The IMS is characterised as an extensive network of cisternae and 
tubules within the cytoplasm of the megakaryocytes continuous with the plasma membrane 
(Radley and Haller, 1982). The IMS is thought to be the membrane reservoir essential for the 
rapid increase of surface area within megakaryocytes and the formation of proplatelets 
(Schulze et al., 2006).  
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1.1.3. Platelet production 
After several different models of platelet formation were hypothesised, it was shown by 
Italiano et al. that proplatelets are made at the end of extended megakaryocyte microtubules 
in the form of tip swellings (Italiano et al., 1999). Therefore, once megakaryocytes have fully 
matured, they begin to branch and form long cytoplasmic extensions termed proplatelets, 
which are subsequently shed into sinusoidal blood vessels of the bone marrow as shown in 
Figure 1.2.  
Cytoskeletal rearrangements and microtubule reorganisation are of particular importance for 
these processes. β1 tubulin microtubules support the growing tip swellings  with microtubule 
coils, however is it the motor protein, dynein-facilitated sliding, that is critical in driving 
proplatelet elongation (Machlus and Italiano, 2013). Spectrin and actin are also present in 
proplatelet extensions, allowing branching and bending respectively, as when these are 
inhibited the functions are lost (Italiano et al., 1999). Megakaryocytes capitalise on this 
extensive cytoskeletal network as the network also acts as a transport system enabling 
granules (alpha and dense granules) and organelles to be delivered to the proplatelet tip 
swellings. The granules are moved from the cell main body to the proplatelets in a 
bidirectional movement until they reach the distal proplatelet (Richardson et al., 2005). 
Transport along microtubules by motor kinesins as well as myosin-facilitated transport along 
actin filaments could both play a role in organelle movement along with other potential 
methods, for example, transport vesicles. (Richardson et al., 2005).   
Once proplatelets have formed they are guided towards the bone marrow sinusoids by an 
increasing concentration gradient of sphingosine 1 phosphate (S1P) found in the blood  
(Zhang et al., 2012).  The presence of S1P leads to downstream signalling in the megakaryocyte 
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by the activation of S1P receptors causing proplatelet release into the blood flow (Zhang et 
al., 2012). Shear stress from the flowing blood also aids in the fragmentation of the proplatelet 
from the tip swellings (Junt et al., 2007). The fragments that are released are larger than 
mature platelets therefore suggesting another step in the platelet production journey; these 
fragments are termed preplatelets. Preplatelets are not uniform in size, in fact, they are 
discoid and range from 2-10 µm which then go on to form a characteristic barbell-shape with 
platelet size swellings on either end (Thon et al., 2012a). This final step is likely to be instigated 
by the biomechanical properties of the microtubules and the later separation of the platelets 
caused by polar action within microtubule coils (Thon et al., 2012a). This cytoskeletal 
regulation of platelet production ensures that the platelets produced are a constant size 
although this process does have a genetic component therefore platelet size does vary within 
the population (Gieger et al., 2011).  
While there is evidence for repression of apoptosis being required for successful proplatelet 
formation, once megakaryocytes have released their proplatelets, the resulting senescent 














Blood vessel lumen 
Blood flow 
Microtubule coil 
Figure 1.2. Megakaryocyte maturation and platelet release.  Platelets are produced in the bone 
marrow from mature megakaryocytes. Megakaryocytes mature by becoming progressively 
larger by endomitosis and polyploidisation. The megakaryocytes then produce tip swellings, 
lined with microtubules, which extend through the cells lining the blood vessel. Preplatelets are 
released into the circulation due to the shear stress within the blood flow. The preplatelets then 
split further to give rise to mature platelets.  
11 
 
1.2. Platelet physiology 
Platelets were first described by Schultze in 1865 however the association between platelets 
and their role as effectors of haemostasis and thrombosis was observed in vivo by Bizzozero 
in 1882 (Schultze, 1865, Bizzozero, 1882). The principal role of platelets is to prevent excessive 
blood loss by their activation, aggregation and the formation of a thrombus. Platelets are a 
highly specialised cell type and their structure allows them to carry out their functions 
successfully.   
1.2.1. Platelet structure 
Platelets are the smallest component of the blood measuring only 2-3 µm in diameter and 0.5 
µm in depth. Platelets do not have a nucleus but within their unique cytoplasm they do contain 
other organelles including but not limited to mitochondria, Golgi apparatus, endoplasmic 
reticulum and lysosomes. Platelets have an extensive and specialised cytoskeleton, of which 
actin is the most abundant protein along with microtubules (Hartwig and DeSisto, 1991). The 
actin is cross-linked by other proteins such as filamin to form a  strong framework to support 
the platelet (Hartwig and DeSisto, 1991). Filamin can initiate interactions between 
glycoprotein (GP) Ibα involved in initial platelet adhesion and αIIbβ3 involved in firm adhesion, 
therefore providing the mechanical force to stop and adhere the platelets from the blood flow 
(Clemetson, 2012). The actin and microtubule networks undergo rapid reorganisation upon 
platelet activation to form morphologically different shapes, characteristic of activated 
platelets. 
Due to the platelets’ small size and shape they are most abundant towards the peripheral 
blood flow within a blood vessel so they are in close contact with the vessel wall allowing quick 
and easy recruitment if necessary (Tangelder et al., 1985).  Under normal conditions, platelets 
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circulate in the blood in a quiescent state. They flow around unresponsive as they are inhibited 
by nitric oxide (NO) and endothelial derived prostacyclin (PGI2). The effect of NO on platelets 
is concentration dependant. Low levels of NO act to maintain the normal flow of blood and 
platelets however when platelets are activated, higher concentrations of NO are released and 
this acts to aid in the platelet aggregation response. Similarly, the antithrombotic effect of 
PGI2 can be overridden when platelets are activated and the physiological effects of 
thromboxane synthase (TXA2) predominate. 
1.2.2. Platelet granules 
Platelets contain granules which are vital to the normal functioning of platelets as previously 
mentioned in this chapter. Alpha (α-) granules are the most abundant granule type with each 
platelet containing approximately 50-80 α- granules, each measuring from 200-500 nm in size 
(Blair and Flaumenhaft, 2009). These golgi derived granules have a highly organised internal 
structure that contains membrane bound proteins that upon activation become expressed on 
the surface of the platelet. These include the cell surface receptors P-selectin, GPIb-IV-V and 
αIIbβ3. α- granules also contain soluble adhesive proteins which are released from the granule 
including:  platelet factor 4, fibrinogen, von Willebrand factor (vWF) and thrombospondin 
(Harrison and Cramer, 1993).  
Dense granules are smaller in size at approximately 250 nm, are less abundant within the 
platelets and characterised by an electron dense core when imaging using electron 
microscopy (Blair and Flaumenhaft, 2009). These granules contain serotonin, adenosine 
diphosphate (ADP), adenosine triphosphate (ATP) and calcium. The contents of both granule 
types are secreted upon platelet activation however, due to the differing contents of the 
granules, the release of α- granules facilitates platelet adhesion whereas dense granules aid 
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in the activation and release from other platelets and help to amplify the platelet response 
(Koseoglu and Flaumenhaft, 2013).  
Lysosomes are often known as the third platelet granule as they have been shown to release 
acid hydrolsases in vitro, but their physiological role remains understudied (Heijnen and van 
der Sluijs, 2015). T-granules have also been described and named referring to their tubular 
morphology (Thon et al., 2012b).  
1.2.3. Platelet activation and adhesion 
Platelets undergo a series of reactions through several different mechanisms, all acting in 
synergy to achieve adhesion, aggregation and hence effective haemostasis. Upon vessel 
injury, the endothelial cell lining is damaged and matrix proteins and the subendothelial 
membrane are exposed to the flow of blood. This allows platelets to interact with the proteins 
and begin to tether, even in regions of high shear. To achieve this, platelets express cell surface 
proteins, including protein tyrosine kinase (PTK) receptors, for the initial activation of the 
platelets, integrins to initiate platelet adhesion and G-protein coupled receptors (GPCRs) for 
the secondary wave of platelet activation from released soluble activation proteins  
(Figure 1.3).  
vWF is now present in the blood flow around the site of injury as circulating multimers and 
binds to exposed collagen (types I and III) leading to vWF elongation and exposure of an A1 
domain that can bind to GPIbα on the platelet surface (Clemetson, 2012). This is essential in 
small arteriole blood vessels where shear rates can reach >5000 s-1. Once the platelets have 
slowed to a roll, this allows platelet surface integrins to interact with other components of the 
subendothelial membrane to provide further activation signalling via PTKs. These interactions 
are the first critical steps for platelet adhesion by increasing platelet surface receptor 
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interaction with the subendothelial membrane and therefore initiating firmer adhesion 
reactions. The immunoglobulin-like surface receptor GPVI binds to collagen, inducing tyrosine 
phosphorylation dependent intracellular signalling, activating the FcRγ chain (Nieswandt et 
al., 2009). This leads to strong and sustained activation of the platelet and activates inside-out 
signalling of platelet integrins; the integrins are in a low-affinity state until the platelet is 
activated when they shift to a high-affinity binding state (Nieswandt et al., 2009). αIIbβ3 is the 
most abundant integrin on the platelet surface and mediates aggregation by binding to vWF, 
fibronectin and fibrinogen. α2β1 is the second most abundant integrin which binds to collagen 
(Watson, 2009, McGrath et al., 2010). Furthermore, integrins α5β1 and α6β1 bind to 
fibronectin and laminin respectively. C-type lectin receptor 2 (CLEC-2) is also important to 
consider in the process of platelet activation and thrombus formation. Its ligand podoplanin 
is a transmembrane glycoprotein widely expressed outside of the vascular system (Lorenz et 
al., 2015). When CLEC-2 binds to its ligand, this initiates platelet activation via the tyrosine 
phosphorylation cascade similarly to GPVI (Lorenz et al., 2015).  
When the platelets have fully adhered, they undergo conformational changes such as 
cytoskeletal remodelling. The binding of αIIbβ3 to fibrinogen allows for filamin and α-actinin 
mediated extensions of filopodia and lamellipodia, in order for the platelets to spread along 
the endothelium while increasing their surface area for further platelet-platelet interactions 
(Durrant et al., 2017).  
Secretory proteins within the platelet granules are also released following platelet activation 
and spreading. Dense granules secrete ADP which interacts with the P2Y12 receptor on the 
platelet surface to provide GPCR mediated platelet activation, it also interacts with PLA2 which 
forms TXA2 from arachidonic acid (AA), which then acts as a soluble agonist on the 
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thromboxane synthase receptor (TXA2R) (Watson, 2009). A positive feedback mechanism is 
created which leads to increased production and release of said agonists in order to recruit 
more platelets to the site of injury and aid in creation of the vascular plug (Salles et al., 2008).  
When platelets are activated, the exposure of platelet membrane phosphatidylserine (PS) 
promotes blood coagulation (Lentz, 2003). PS usually resides on the inner leaflet of the 
phospholipid bilayer. However, when activated, the enzyme scramblase catalyses the 
bidirectional movement of PS to flip to the outer leaflet providing a platform to facilitate the 
attachment of cofactors and clotting factors (Lentz, 2003, Bevers and Williamson, 2010). 
Platelets have the highest rate of scramblase activity accelerating the reactions of the 
coagulation cascade to generate thrombin and form fibrin (Bevers and Williamson, 2010, 
Schoenwaelder et al., 2009). The generation of thrombin again forms a positive feedback 
mechanism and further platelet activation by acting on protease activated receptors (PARs) 
namely PAR1 and PAR4 which signal via G-proteins (Coughlin, 2000). Finally, fibrinogen is 
converted to fibrin during the coagulation cascade to help form a fibrin mesh and thus further 
stabilises the thrombus. Once the thrombus has formed, it retracts in order to minimise 
obstruction of the normal blood flow in the vessel. This is due to contractile forces from non-
muscle myosin II on the actin cytoskeleton and fibrinogen bound to αIIbβ3 to pull 
neighbouring platelets closer together and reduce the overall thrombus size  




Tethering and rolling Activation, adhesion, secretion Thrombus formation 


















Figure 1.3. The main stages of thrombus formation. Vascular injury causes exposure of the subendothelial matrix. vWF binds to GPIb-IX-V 
resulting in initial tethering and platelet rolling. Other components of the matrix bind to platelet receptors causing activation, further adhesion 
and secretion. Contents of platelet granules amplify the activation response by recruiting cells to the site of injury. Platelets also undergo a 
conformation change by extending filopodia and lamellipodia. This process results in platelet aggregation and the formation of a thrombus.  
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1.2.4. Platelet lifespan 
Non-activated platelets have a lifespan of 7-10 days and this is due to a fine balance between 
platelet production and clearance which varies from individual to individual. Platelet 
production is tightly regulated to avoid too much clearance leading to spontaneous bleeding 
or excessive production leading to vessel occlusion. Like megakaryocytes, platelets also 
express the c-Mpl receptor and regulate TPO by binding and removing it from the circulation. 
When platelet counts are low, less TPO is bound and therefore it is able to stimulate 
thrombopoiesis to produce more platelets to keep the level physiologically stable. It has also 
been shown that chemokine ligand 5 (CCL5) signalling may act to help increase platelet 
numbers during eposides of physiological stress (Machlus et al., 2016). Platelets are cleared 
from the circulation by phagocytosis in the liver and spleen and recognised by clearance 
signals, PS, P-selectin exposure and autoantibodies to platelet receptors (Mason et al., 2007). 
The balance between apoptotic proteins BAX and BAK and pro-survival proteins from the Bcl-
2 family also govern their lifespan (Wagner et al., 2000). More recent research has shown that 
desialyation of platelet surface receptors leads to the exposure of galactose sugars in a time-
dependant manner. The Ashwell-Morrell receptor recognises the desialylated platelets and 
this receptor-ligand pairing directly regulates TPO synthesis in the liver, via the recruitment 
of JAK2 and STAT3 signalling molecules in order to promote thrombopoiesis (Grozovsky et al., 
2015). However, this regulatory mechanism requires further research in order to completely 
understand the maintenance of healthy platelet numbers in the circulation and how these 





1.3. Platelet function testing 
Platelet function testing is necessary when the ability of an individual’s platelet function is 
suspected to be impaired. This is important for the treatment and management of the 
frequent bleeding episodes in these individuals that can have a negative impact on their 
quality of life. Individuals normally present with a history of frequent bleeding episodes 
including easy bruising, epistaxis, menorrhagia, excessive bleeding after injury or minor 
surgery and post-partum haemorrhage. There are multiple platelet function assays that can 
test different parameters to produce both qualitative and quantitative results regarding the 
platelets’ function. Many of these tests are used in clinical practice however, these are 
constantly evolving to provide more rapid yet accurate tests to produce results for the clinical 
and research settings, in the most efficient manner.  
The first recorded platelet function test, from 1910, was known as the Duke Procedure. This 
test was designed to evaluate the bleeding of a small wound made to the skin and the time 
taken for the wound to stop bleeding; hence, the time taken for a platelet plug to form. This 
test has decreased in popularity due to the invasive nature of the procedure and because it is 
insensitive and of poor reproducibility (Harrison et al., 2011).  Platelet function testing is now 
more specialised and can focus on specific areas of platelet function from aggregation, 
adhesion and secretion under different conditions to the analysis of different cell surface 
markers in resting and activated platelet states.  
1.3.1. Light transmission aggregometry 
The Duke procedure was superseded by the gold standard platelet function assay- light 
transmission aggregometry (LTA), first described by Born (Rodgers and Levin, 1990, Born, 
1962). LTA is still the most widely used test for the identification and diagnosis of platelet 
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function disorders as the responses to multiple concentrations of different agonists can be 
monitored. The method simply measures the light transmission in real time through samples 
of platelet rich plasma or washed platelets from when the agonists are added. If the platelets 
are functioning normally, light transmission increases as more light can pass through the 
sample when the platelets aggregate. Furthermore, LTA can be coupled with lumi-
aggregometry to simultaneously measure the secretion of ATP from platelet granules. When 
the luciferin-luciferase reagent is added to the platelet mixture, the luciferase enzyme oxidises 
luciferin in the presence of ATP, which in turn produces a fluorescent product which can then 
be quantified (Holmsen et al., 1972). If a higher concentration of ATP is present in the platelet 
sample, a stronger fluorescent signal in the form of released light would be produced. 
However, the results of this assay vary between controls and so the use of standard control 
ranges is essential. This assay is also specialised and requires time and a fairly large volume of 
fresh blood which is not always possible for young children; an experienced scientist is also 
necessary to carry out the test and to interpret the results. This assay has given rise to 
alternative forms, for example, the Optimul assay; a 96-well platelet aggregation assay with 
high levels of sensitivity and specificity (Lordkipanidze et al., 2014, Chan et al., 2018). Multiple 
electrode aggregometry (MEA) is also increasingly used which measures whole blood 
impedance aggregation (Wurtz et al., 2014, Al Ghaithi et al., 2017). This assay allows for rapid 
platelet function analysis but the response is heavily influenced by platelet count (Toth et al., 




1.3.2. Platelet adhesion assays 
Platelet adhesion assays were developed to determine the ability of platelets to adhere and 
aggregate under the shear stresses of blood flow, therefore making these assays more 
physiologically relevant. Many of these assays require specialised microfluidic systems or chips 
that can be coated in particular proteins that cause platelet activation for example collagen or 
fibrinogen. The platelet function analyser (PFA-100®) tests the aggregation and adhesion of 
platelets under high shear.  In this test, platelet function is measured as a function of the time 
taken to occlude an aperture within test cartridges (Harrison, 2005a, Harrison, 2005b). The 
Total Thrombus Formation Analysis System (T-TAS) is an automated microchip flow chamber 
also developed to quantitatively assess the formation of thrombi. This system uses variable 
flow conditions to mimic both physiological and pathological shear rates using two types of 
thrombogenic surfaces (Hosokawa et al., 2012). The T-TAS measures the flow pressure 
through the chips, requiring very small blood volumes, whilst video recording in real-time. This 
test is deemed a useful preliminary test (Daidone et al., 2016) (Al Ghaithi et al., 2019). 
1.3.3. Flow cytometry 
In order to measure the platelet secretion and the expression of cell surface markers, flow 
cytometry is most commonly used. The basic principle of flow cytometry is the passage of 
single cells through a laser to be detected, counted and sorted. The fluorescently labelled cell 
components are excited by the laser beam which then emit different wavelengths allowing 
them to be measured. Flow cytometry can also be used to measure levels of platelet activation 
by the addition of agonists where the level of the platelet α-granule marker, P-selectin, is the 
most commonly used marker. In addition, the quantity of platelet glycoproteins can be 
measured (Gordon et al., 1995, Michelson, 1996, Cohn et al., 1997). The very small volume of 
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blood needed for this assay is advantageous particularly in cases of thrombocytopenia where 
specialist assays have been developed (De Cuyper et al., 2013). Again, fresh blood samples are 
required, and the test is restricted to specialised laboratories that possess flow cytometry 
instruments. These downfalls are being addressed with the evolution of a test that can be 
performed by activating then fixing the blood remotely, at the point of collection (Platelet 
Solutions, UK). These blood samples are then stable for up to 9 days while they are delivered 
to a specialised laboratory for analysis (Dovlatova et al., 2014).  
However, when a potential platelet function disorder is discovered as a result of the testing 
methods above, the outcomes usually stop short of giving the clinicians and patients a final 
and definitive diagnosis. This explains the need to involve a level of genetic analysis either to 
confirm the observed phenotype or to suggest candidate genetic variants when a diagnosis is 
not obvious.   
1.4. Inherited platelet disorders – Symptoms and treatments 
There are many diseases that affect the function and/or number of platelets present in the 
circulation. Functional disorders of platelets can be either inherited or acquired. An acquired 
platelet dysfunction is more common and normally due to medications, food/supplements 
but most often, secondary to another multisystem disease also affecting the immune system. 
With this cause, platelet function and/or number can decline in the disease state leading to a 
thrombocytopenia and clinical bleeding disorder, but this can return to normal levels during 
recovery. Thrombocytopenia is classed as a platelet count <150 x109/l (normal range 150-400 
x109/l) which results in bleeding diathesis that can again be either inherited or acquired. 
Inherited bleeding disorders, as well as being rarer, present with more variable severities.  
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Symptoms of these disorders can range from mild to severe, but most suffer from bleeding 
episodes including: unexplained cutaneous bruising, petechiae, epistaxis, bleeding from 
mouth and gums, menorrhagia, post-partum haemorrhage and bleeding following dental 
extraction or surgery. In some cases, the knowledge of a bleeding disorder in affected 
individuals can go undiagnosed due to the lack of haemostatic challenges in their lives. This is 
more common in males as females undergo monthly haemostatic challenges from puberty 
and face other challenges such as childbirth. Many individuals do not need treatment for their 
bleeding disorder however, the need for regular monitoring and clinical management is 
necessary to avoid bleeding risks especially in the case of pregnancy or planned surgery. 
1.4.1. Treatments 
There are some treatments for individuals with moderate to severe bleeding particularly in 
paediatric cases. Local antifibrinolytic treatments are often successful such as the application 
of gauze soaked with tranexamic acid/ thrombin to superficial wounds or nasal packing with 
thrombin (Bolton-Maggs et al., 2006).  These fibrinolysis inhibitors work to interfere with the 
formation of fibrinolytic enzyme plasmin from its precursor plasminogen to prevent the 
formed blood clot from breaking down. Desmopressin (DDAVP) is also a common therapy 
option for bleeding following trauma or for a planned surgical procedure. This synthetic analog 
of vasopressin induces a release of vWF from endothelial cells with subsequent release of 
coagulation factor VIII and tissue plasminogen activator, thereby reducing overall bleeding 
times (Kaufmann and Vischer, 2003). For severe bleeds or in preparation for surgery where a 
great bleeding risk is known, a platelet transfusion may need to be considered or the use of 
recombinant Factor VIIa (RVIIa) or a combination of the two (Bolton-Maggs et al., 2006). In 
cases of platelet transfusions either human leukocyte antigen (HLA) matched donors are 
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required or leukocyte depleted blood products must be used to avoid undesirable 
alloimmunisation. Furthermore, as advancements in medicine are being made, the use of 
treatments such as TPO mimetics and gene therapy have been used to improve outcomes in 
patients with specific bleeding disorders (Kuter, 2009, Morris et al., 2017). Gene therapy has 
even been used to cure individuals with haemophilia B and now haemophilia A (Nathwani et 
al., 2014, Rangarajan et al., 2017).  
1.4.2. Disorders of platelet adhesion and aggregation 
All disorders are shown in the brief guide Table 1.1. Bernard-Soulier syndrome (BSS) is a 
disorder of both platelet formation and platelet adhesion. The expression of glycoproteins 
(GP)Ibα, GPIbβ or GPIX are reduced or absent thus affecting the GPIb-IX-V receptor complex 
on the platelet surface membrane (Nurden et al., 2012). Most patients affected by BSS present 
with thrombocytopenia (platelet count <150x109/L) and atypically large platelets (Pecci and 
Balduini, 2014). This rare biallelic autosomal recessive disease presents clinically as a severe 
phenotype with severe bleeding episodes. Individuals with monoallelic mutations present 
with a milder phenotype and a diagnosis can easily be missed (Othman and Emsley, 2017). 
Platelet aggregation in an individual with BSS will show a decreased response upon the 
addition of ristocetin due to decreased vWF –GPIb binding. Flow cytometry is also used to 
diagnose this disease to confirm the absence of specific glycoproteins on the platelet surface 
(Beltrame et al., 2009).  
von Willebrand disease (vWD) is an autosomal dominant disorder, although Type 2N and Type 
3 are autosomal recessive, which are caused by a lack of, or defective von Willebrand factor. 
vWF binds to GP1bα through its A1 domain upon vessel injury when the protein is exposed 
within the subendothelial membrane. However, lack of this interaction can lead to increased 
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bleeding times. In Types 1 and 3 vWD, a quantitative deficiency of vWF causes the bleeding 
diathesis. In Type 2, individuals have qualitative defects of vWF. These are broken down into 
four subtypes: type 2A, Type 2B, Type 2M and Type 2N which depend on the presence and 
nature of the vWF multimers and chains of vWF. vWD Type 2B is caused by genetic variants 
affecting expression of the A1 domain; this causes a gain of function phenotype as GP1bα will 
more readily bind to circulating vWF leading to the presence of multimers in the blood and 
enhances platelet clearance (Nurden et al., 2006).  
Platelet P2Y12 deficiencies result in defects of platelet activation. This principal G-protein 
coupled receptor for the agonist ADP is required for normal platelet coagulation activity 
(Dorsam and Kunapuli, 2004). ADP acting on P2Y12 is responsible for the amplification of the 
platelet response to ADP and other soluble agonists including TXA2 and thrombin. P2Y12 
defects are inherited in an autosomal recessive manner and manifest by mild to severe 
prolonged bleeding times as well as other bleeding episodes. Diagnosis of this condition by 
platelet aggregation is followed by genetic analysis to confirm a suspected diagnosis of a P2Y12 
deficiency (Cattaneo et al., 2003).  
 Glanzmann thrombasthenia (GT) is a disorder of platelet aggregation caused by mutations in 
the genes ITGA2B and ITGB3 which lead to qualitative and quantitative defects of the integrin 
αIIbβ3 (Salles et al., 2008, Nurden and Nurden, 2011, Nurden and Pillois, 2018). This molecule 
is essential for platelet aggregation and blood clotting as without it, the platelets’ ability to 
bind fibrinogen and also form platelet-platelet interactions is severely disrupted (Nurden et 
al., 2012). This rare autosomal recessive disorder is normally characterised by severe bleeding 
episodes and affected individuals often have to undergo platelet transfusions. GT can be 
diagnosed after an abnormal result following platelet aggregation studies, confirmed by a 
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deficiency of αIIbβ3 using flow cytometry and genetic testing to identity and confirm genetic 
variant responsible for the disease (Nurden et al., 2011).  
Scott Syndrome is known as a defect of platelet procoagulant activity since there is defective 
scrambling of the phospholipid membrane. Upon platelet activation PS is normally 
transported from the inner to the outer leaflet of the platelet membrane where coagulation 
factors are converted to their active forms. This autosomal recessive disorder leads to failure 
in production of the procoagulant surface upon platelet activation  (Zwaal et al., 2004). The 
only treatment for this disorder is a platelet transfusion during bleeding episodes. 
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Table 1.1. Brief guide of the main inherited disorders that affect platelets. The disorders are classified by platelet abnormality. The disease and 
the gene causative of the disease is described as well as the phenotype and any additional findings associated with the disease; all disorders can 
be found described in the review for the United Kingdom Haemophilia Centre Doctors' Organisation by Bolton-Maggs et al.  
(Bolton-Maggs et al., 2006). 
Platelet abnormality Disease Inheritance Gene Phenotype and other findings 
Platelet adhesion and 
aggregation 
Bernard Soulier syndrome Autosomal recessive GPXI 
GPIbα 
GP1bβ 
Thrombocytopenia, large platelets 
Anomalies in components of the GPIb-IX-V complex 
Glanzmann thrombasthenia Autosomal recessive ITGA2B 
ITGB3 
Normal platelet count 
Absent aggregation with all agonists 
P2Y12 receptor defects Autosomal recessive P2Y12 Normal platelet count 
Transient aggregation  
Scott syndrome Autosomal recessive TMEM16F Normal platelet count 
Factor X activation deficiency  
Thromboxane A2 Autosomal recessive  TBXA2R Normal platelet count 
Aggregation reduced in response to arachidonic acid 
and U46619 









Reduced or absent vWF multimers 
Platelet secretion 
Chediak-Higashi syndrome Autosomal recessive LYST Normal platelet count 
Skin and hair hypopigmentation 
Immunodeficiency  
Reduced α-granules 
Grey Platelet syndrome Autosomal recessive NBEAL2 Thrombocytopenia, large platelets 
Grey platelet colour on blood film 
Absent α-granules 
Hermansky-Pudlak syndrome Autosomal recessive HPS1-9 Normal platelet count 
Decreased/absent dense granules 





Autosomal dominant FLI1 Thrombocytopenia, large platelets 
Developmental delay, facial abnormalities 
Quebec platelet disorder Autosomal dominant PLAU Thrombocytopenia 
Urokinase plasminogen activator storage in platelets 





Actin disorders Autosomal dominant ACTN1 Thrombocytopenia, large platelets 
Congenital amegakaroycytic 
thrombocytopenia  
Autosomal recessive MPL Thrombocytopenia 
Pancytopenia 
Absent megakaryocytes in bone marrow 
Tubulin disorders Autosomal dominant TUBB1 Thrombocytopenia, platelets not uniform in shape or 
size 
Wiskott-Aldrich syndrome X-linked WAS Thrombocytopenia, small platelets 
Immunodeficiency 
Disorders of platelet 
clearance and other 
disorders 
Familial platelet disorder 
with predisposition to acute 
myeloid leukaemia  
Autosomal dominant RUNX1 Thrombocytopenia 
Abnormal aggregation 
Increased platelet clearance 
disorders 
Autosomal recessive GNE Thrombocytopenia, large platelets 
Upshaw-Schulman syndrome Autosomal recessive ADAMTS13 Thrombocytopenia 
Ultra large vWF multimers 





1.4.3. Disorders of platelet secretion 
The disorders of platelet secretion and storage can affect platelet α- or dense granules with 
few patients having defects in both sets of granules (Bolton-Maggs et al., 2006). These are a 
heterogeneous group of disorders that can affect platelet responses upon activation; the 
disorders are shown in the brief guide Table 1.1.  
Grey Platelet syndrome (GPS) is characterised by a complete absence of platelet α-granules 
caused by homozygous or compound heterozygous mutations in NBEAL2 which was initially 
identified by whole exome sequencing (WES) (Albers et al., 2011, Gunay-Aygun et al., 2011, 
Kahr et al., 2011). This defect causes platelets to be characteristically grey in colour on a blood 
smear. Platelets can vary in their ability to function however most sufferers have 
thrombocytopenia due to decreased platelet survival times. Other disorders that affect  
α-granules include Jacobsen Syndrome and its associated syndrome, Paris-Trousseau 
thrombocytopenia, and Quebec platelet disorder in which urokinase plasminogen activator 
(uPA) in α-granules produces profibrinolytic platelets (Pecci and Balduini, 2014, Hayward and 
Rivard, 2011). For this disorder, individuals present with delayed-onset bleeding following 
trauma. 
Dense granule disorders such as Chediak-Higashi and Hermansky-Pudlak syndrome (HPS) both 
lead to a dense granule deficiency (Nurden and Nurden, 2011). Chediak-Higashi is recognised 
as a separate disorder due to the severity of the immune defects resulting from mutations in 
the protein LYST, while HPS has been shown to be due to defects in ten genes in humans, 
although fifteen causative genes have been identified in mice (Di Pietro and Dell'Angelica, 
2005, Maaloul et al., 2016). The bleeding diathesis in affected individuals is caused by overall 
impaired aggregation due to lack of dense granule secretion. Other disorders that affect dense 
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granules include Jacobsen Syndrome and its associated syndrome, Paris-Trousseau 
thrombocytopenia caused by deletion of a region on chromosome 11, del11q23 which 
contains the gene that encodes FLI1 (White, 2007, Raslova et al., 2004). Paris-Trousseau 
thrombocytopenia has now been described without the 11q deletion caused only by genetic 
variants in FLI1 (Stockley et al., 2013, Stevenson et al., 2015).  
1.4.4. Disorders of megakaryopoiesis, proplatelet formation and release 
The production of platelets from megakaryocytes and primarily HCSs is a highly controlled 
process and there are a multitude of disorders that are associated with megakaryopoiesis 
defects, disruption in proplatelet formation and release. These can range from altered 
transcriptional control to disruption in signalling pathways associated with the differentiation 
process. As a result, platelet numbers and function are often reduced (Johnson et al., 2016a).  
Genetic variants in the gene which encodes the thrombopoietin receptor, c-Mpl, have been 
described to cause congenital amegakaryocytic thrombocytopenia (CAMT) which results in a 
severe pancytopenia due to bone marrow failure (Stoddart et al., 2013). The only feasible 
treatment for this rare condition is stem cell transplant from matched related or unrelated 
donors (Frangoul et al., 2010). The transcription factor GATA1 is involved in the cell lineage 
progression of HSCs to MEPs therefore dysfunctional GATA1 can affect thrombopoiesis and 
erythropoiesis. Genetic variants that affect the ability of GATA1 to bind to its cofactor FOG1 
cause X-linked thrombocytopenia whereas variants that affect GATA1’s ability to bind to DNA 
cause X-linked thrombocytopenia and thalassemia (Nichols et al., 2000). These platelets are 
typically abnormal in number, size and shape (Nichols et al., 2000). Furthermore, variants in 
the transcription factor RUNX1 give rise to an autosomal dominant disorder characterised by 
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quantitative and qualitative disorders of platelets along with a predisposition to 
myelodysplasia or leukaemia (Schlegelberger and Heller, 2017). 
During proplatelet formation and release, the control of the cytoskeletal rearrangement 
process during thrombopoiesis is also highly regulated in order to produce healthy, 
functioning platelets. Wiskott-Aldrich syndrome arises from mutations in the WAS gene which 
encodes the WAS protein (WASP) (Pecci and Balduini, 2014). WASP is known to affect platelets 
during megakaryopoiesis where it plays a key role in actin cytoskeletal regulation and typically 
results in microthrombocytopenia, therefore leading to the mild bleeding phenotype, in 
addition to other symptoms such as immunodeficiency which are often associated with this 
X-linked recessive disorder (Balduini and Savoia, 2012, Pecci and Balduini, 2014, Bolton-Maggs 
et al., 2006).  
Genetic variants in TUBB1 encode dysfunctional β1-tubulin. This leads to the expressed 
protein being unstable and unable to interact normally with other microtubules (Kunishima et 
al., 2014). The reduced number of proplatelets that are formed have a marked reduction in 
the number of tip swellings and these are more variable in size causing few platelets to be 
released into the circulation of varying sizes. Individuals with variants in the ACTN1 gene are 
affected in a similar way. α-actinin is an actin binding protein also involved in cytoskeletal 
remodelling during proplatelet formation (Kunishima et al., 2013). Megakaryocytes in 
individuals with these variants possess disorganised actin cytoskeletons resulting in 
abnormally large proplatelet tips which are reduced in number (Kunishima et al., 2013).  
There are many more known disorders of megakaryopoiesis, platelet production and platelet 
release and the study of these disorders has provided insights into the mechanisms of action 
of the now well-known transcription factors and megakaryocyte and platelet biology.  
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1.4.5. Disorders of platelet clearance, other and unknown disorders 
There are a number of genes affected by detrimental genetic variants which cause platelets 
to be cleared prematurely from the circulation. This includes variants in the gene encoding 
metalloproteinase ADAMTS13 resulting in Upshaw-Schulman syndrome (Levy et al., 2001). 
Affected individuals with this rare syndromic disorder have inactive ADAMTS13 leading to an 
increase and hence accumulation of vWF multimers. These large multimers, therefore begin 
to interact with circulating platelets causing them to aggregate. This inappropriate pre-
activation of the platelets causes them to be removed from the circulation leading to 
continually low platelet counts and characteristic of the disease phenotype (Levy et al., 2001). 
vWD Tybe 2B, described previously, manifests in a similar way however platelets also fail to 
aggregate. In both disease states, the vWF complexes are removed by macrophage action in 
the liver and spleen. 
Variants in the gene GNE cause a secondary symptom of thrombocytopenia due to excessive 
platelet clearance. The bifunctional enzyme the gene encodes, UDP-N-acetylglucosamine 2-
epimerase (GNE), initiates the synthesis of a precursor to sialic acid (Favier and Raslova, 2015). 
The affected individuals have reduced GNE activity and sialic acid biosynthesis failure, 
therefore sialic acid residues on the platelets’ surface are decreased (Futterer et al., 2018, 
Revel-Vilk et al., 2018). This causes increased platelet clearance from the liver hence 
thrombocytopenia. This disease requires further investigation as some affected individuals 




1.5. Non-platelet bleeding disorders 
There are numerous other causes of inherited bleeding that are not related to platelet 
dysfunction. Excluding the more common and regularly screened von Willebrand disease and 
haemophilia A and B, much less is known about these other bleeding disorders due to their 
rarity and difficulty in clinical diagnosis. For example, fibrinogen abnormalities are rare and 
are not as well characterised as some of the platelet function disorders (Acharya and 
Dimichele, 2008). 
1.5.1. Inherited fibrinogen disorders 
Inherited fibrinogen disorders can, like platelet function disorders, be due to quantitative 
defects (afibrinogenemia and hypofibrinogenemia) or qualitative defects (dysfibrinogenemia) 
(Acharya and Dimichele, 2008). Fibrinogen is a 340kDa glycoprotein synthesised in the liver 
encoded by genes: FGA, FGB and FGG, and as it is a precursor of fibrin, plays an essential role 
in the formation of the vascular plug (Tiscia and Margaglione, 2018). Variants in these genes 
lead to abnormal polymerisation of the protein, defective cross-linking and defective 
fibrinolysis. Fibrinogen is a multifaceted molecule and hence disease causing variants within 
the aforementioned genes can result in both bleeding and thrombotic phenotypes (Acharya 
et al., 2004).There are over 70 causative mutations identified in the fibrinogen genes with the 
majority being in FGA (Neerman-Arbez and de Moerloose, 2007, Tiscia and Margaglione, 
2018).  A valuable tool for investigating human fibrinogen variants can be found in the 




1.5.2. Coagulation factor deficiencies 
Coagulation factor deficiencies also cause varying severities of bleeding most of which are 
routinely screened at Haemophilia Comprehensive Care Centres across the UK (Mannucci et 
al., 2004). These include prothrombin (FII) deficiency, FV deficiency, FVII deficiency,  
FX deficiency, FXI deficiency, FXIII deficiency and combined FV and FVIII deficiency. Most 
patients with these deficiencies require replacement therapy regularly, usually with fresh-
frozen plasma which contains all the necessary coagulation factors (Mannucci et al., 2004). 
The treatment options are improving now with the availability of single coagulation factors 
for replacement therapy, however neither of the therapies are straightforward and 
haemostatic levels need to be constantly monitored (Mannucci et al., 2004).  
Other proteins implicated in bleeding include protein C which is a vitamin K-dependant serine 
protease and when activated acts as an anticoagulant (Danese et al., 2010). Variants within 
the gene PROC that encodes protein C, could hypothetically, lead to gain of function by 
increasingly inactivating cofactors of the coagulation cascade and hence reduce clotting 
(Danese et al., 2010). Protein S, encoded by genes PROS1 and PROSP, is also a vitamin  
K-dependent anticoagulant glycoprotein and acts as a cofactor to activated protein C  
(Lind-Hallden et al., 2012). Again, a genetic variant within these genes could affect 
haemostasis. Finally, genetic variants in THBD, which encodes the glycoprotein 
thrombomodulin, have been shown to cause a bleeding phenotype in affected individuals 
(Langdown et al., 2014, Dargaud et al., 2015). Thrombomodulin is expressed on the surface of 
endothelial cells and normally serves as a cofactor for thrombin, however, when its function 
is impaired the coagulation cascade is disrupted (Weiler and Isermann, 2003). 
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1.6. Genetics and genomics 
Genomics is defined as the study of the genetic material of an organism and its associated 
functions (World Health Organization, 2002). Genomics therefore aims to address all genes 
and their interrelationships in order to study and identify their combined influence on growth 
and development; this is in comparison to genetics which mainly scrutinises the function of a 
single gene (World Health Organization, 2002). In our now ‘post-genomic era’, massive 
advancements in genomic technology have been achieved.  
The Human Genome project (HGP) began in the mid-1980s and was an international, 
collaborative project with the goal to completely map and improve the understanding of an 
individual’s entire nucleic material known collectively as our genome (Venter et al., 2001, 
Sachidanandam et al., 2001). The initial sequence data was first published in the journal 
Nature in February 2001 when it was 90% complete, and was finally proclaimed 99% complete 
in 2003 (Lander et al., 2001, Collins et al., 2003). This project required and will continue to 
require new technologies to refine the draft and carry on research with regard to the complete 
human genome.  
Following the HGP, the 1000 Genomes Project was the first of its kind to sequence the 
genomes of a large group of individuals in order to provide a valuable resource to the scientific 
community on human genetic variation. The primary goal was to elucidate the genetic variants 
that have frequencies of at least 1% in the populations studied. The main drawback of the 
1000 Genomes Project was that the samples were anonymous and therefore no phenotype 
data was available. However, the 1000 Genomes data can be combined with genome-wide 
association studies (GWAS) for additional variants beyond those already genotyped and allow 
for disease-associated genes, regions, and variants to be researched in more depth.  
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GWAS focus on the associations between single nucleotide polymorphisms (SNPs) and the 
varying phenotypes of a specific syndrome or disease which are typically seen in inherited 
platelet disorders (Bunimov et al., 2013). Family-based designs for GWAS are particularly 
beneficial as they enrich for genetic defects and have more power than unrelated individuals 
to detect genetic defects (Ott et al., 2011). Family-based designs often include parent-
offspring trios, sibling pairs, consanguineous families and large extended families with 
multiple affected family members (Ott et al., 2011). The statistical principals underlying these 
designs such as the McNemar-type statistic are often complicated and will not be described 
here in detail (Ott, 1989, Terwilliger and Ott, 1992, Knapp et al., 1993).  
Platelet genetics is a challenging area of research due to the absence of a nucleus. Platelets 
do have residual levels of megakaryocyte-derived RNA, and have been shown to make low 
amounts of proteins most notably interleukin 1 (Macaulay et al., 2005, Booyse and Rafelson, 
1968, Loppnow et al., 1998). The platelet genome is yet to be fully defined but data 
enlightening on how genetic variation, at the level of gene transcription and translation, 
perturbs platelet function has been highly beneficial (Macaulay et al., 2005). This has led to 
further analysis in recent years with the birth of more specialised techniques within genomics 
and more manageable costs of genomic investigation.  
1.6.1. Next-generation sequencing  
DNA sequencing has been revolutionising medical research since the invention of Sanger 
sequencing by Sanger et al. and the polymerase chain reaction (PCR) by Mullis et al. (Mullis, 
1986, Sanger et al., 1977). These traditional methods have been replaced with next-
generation sequencing technologies and led to an exponential reduction in the costs involved 
in sequencing whole genomes/exomes (Rabbani et al., 2014). Whole genome sequencing 
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(WGS) and whole exome sequencing (WES) are used to identify genetic factors causing human 
diseases; some of which were previously undetectable. These high-throughput experimental 
approaches are now more widely available than ever and have been adopted in both research 
and clinical settings in relation to patients with platelet and bleeding disorders (Singleton, 
2011).  
It is well known that approximately 1.5% of the human genome contains protein-coding 
sequences (exons), within which 85% of alleles that underlie Mendelian disorders, that disrupt 
protein-coding sequences, reside (Rabbani et al., 2014). Therefore, exome sequencing alone 
is sufficint to harbour enough data to uncover most rare and potential genetic disorders and 
predisposing genetic variants (Majewski et al., 2011, Rabbani et al., 2014). The first report of 
selectively sequencing all exomes successfully was published by Ng et al. (Ng et al., 2009). 
There are several slightly different methods which all follow the same principle for the rapid 
identification of protein-coding variants; mutations include: missense and nonsense to small 
insertion/deletion mutations and splice site mutations (Teer and Mullikin, 2010, Singleton, 
2011). WES can also be used to identify the genetic causes of multifactorial disorders that can 
be more common in bleeding disorders (Leinoe et al., 2017).  
1.6.2. Limitations and challenges of NGS 
There are some fundamental limitations of WES, the most obvious being that WES does not 
assess the impact of non-coding regions, since it is only limited to coding and splice site 
variants (Rabbani et al., 2014). A further limitation is that the method is still time consuming 
and the coverage of regions of interest is not always complete. This aspect of WES has 
improved since the first experiments where 8% of regions of interest were not captured by 
the enrichment strategy, but it is not expected that 100% coverage will ever be reached 
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(Singleton, 2011, Ng et al., 2009). WES is often less cost effective than a large targeted panel 
and still has difficulty in identifying repeat mutations and copy number variants, often leading 
to false positives (Singleton, 2011). Confirmation and validation of possible disease causing 
variants by Sanger sequencing is nearly always required following WES as it has a very high 
level of coverage and the possibility of false-positive calls is little to none.  
Challenges also arise with the lack of development of bioinformatic analysis tools that are 
already lagging behind the advances in the substantial amount of data generated by NGS. This 
often leads to the analysis of bioinformatic data post NGS being the rate limiting step in the 
process of gene identification. Therefore, the second challenge faced within platelet genomics 
is the identification of the causal gene and variant among multiple possible variants and their 
link to disease and function (Majewski et al., 2011). This is often equivocal, and several 
candidates remain. Presently, sequence variant analysis is imperfect and a tremendous 
amount of work is needed to introduce a large-scale statistical automated framework for the 
calling of variants (Richards et al., 2015, MacArthur et al., 2014). There have been standards 
and guidelines published for the interpretation of sequence variants, as recommended by the 
American College of Medical Genetics and Genomics (ACMG) and the Association for 
Molecular Pathology which will be discussed in Methods section 2.14.2 (Richards et al., 2015). 
Another potential challenge arises with the inevitable discovery of genetic variants not related 
to the disease state in question, so called incidental or secondary findings (Wolf et al., 2008). 
This is a complex issue with many confounding factors involving ethics. The issue faced by 
clinicians is, should they disclose secondary findings with potential clinical relevance to their 
patients and if so, when and how? The interpretation of the information delivered would 
require adequate education of the patient and family, and with some inherited bleeding 
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disorders, possible genetic counselling. The ACMG have published a policy statement 
concerning NGS with emphasis on incidental findings in clinical pretesting, genetic testing and 
the reporting of results (ACMG Board of Directors, 2012). The recommendations of the ACMG 
Working Group on Incidental Findings in Clinical Exome and Genome Sequencing have also 
been published and outline a list of conditions, genes and variants they recommend for return 
of incidental findings in clinical sequencing (Green et al., 2013). This is deemed by many to go 
beyond targeted sequencing and true incidental findings to suggest automatic screening for 
genetic conditions in all patients undergoing WES/WGS (Allyse and Michie, 2013). It is a 
controversial area of interest that requires further social and professional debate both of 
which should proceed with ethical caution and concern (Allyse and Michie, 2013). 
1.6.3. Advancements of genomic technologies in discovering genetic variants 
in platelet disorders 
One of the main applications and challenges of NGS is proving that a certain genetic variant 
or variants are responsible for the clinical presentation of patients. In the case of bleeding and 
inherited platelet disorders, the phenotypes can vary greatly from one individual to another 
even with the same genotype. This makes it very difficult to generate genotype-phenotype 
correlations and elucidate a disease causing mechanism within these individuals.  
The first use of NGS in a platelet function defect identified NBEAL2 as the causative gene for 
grey platelet syndrome (GPS) (Albers et al., 2011). Many causative mutations within the gene 
which encodes a BEACH domain protein cause differential bleeding severities in the 
individuals with GPS (Gunay-Aygun et al., 2011). In the past few years however, several 
research groups and their collaborators have employed NGS to discover the causes of 
unexplained bleeding. We now have knowledge of platelet genes that are known or predicted 
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to have a role in regulation of platelets along with platelet physiological processes and we are 
therefore able to diagnose patients with specific platelet defects as a result (Leo et al., 2015). 
It is important to emphasise the need for cell biology to explore novel unclassified variants in 
order to investigate expression analysis and protein function to ensure a variant is well 
characterised  and proven to be functionally disrupting (Watson et al., 2013). As more data is 
accumulated about the genetics of bleeding and platelet disorders, the list of candidate 
variants will decrease. Therefore, the likelihood of finding a disease causing mutation will 
increase. A table of genes involved in bleeding disorders discovered by NGS can be seen in 













Table 1.2. Novel genomic variants reported in genes discovered in patients with an inherited bleeding disorder following next-generation 
sequencing. Gene and phenotypes associated with variants are shown. Heterozygous nucleotide changes (unless indicated) present in patients 
with inherited bleeding and their predicted effects on the resulting RNA or protein are also shown. Genomic variations are numbered according 
to positions in the publication of the reference indicated. dbSNP ID is given for each variant if known or is a novel variant not reported in the 
available databases (Bhagwat, 2010). 
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Genomic variation Protein effect Variation type dbSNP ID Reference 
SRC 
Thrombocytopenia, 
sometimes large platelets, 
lack of  α-granules. 
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c.222 C>GHom p.Ile74MetHom Missense rs724159972 (Manchev et al., 2014) 
RBM8A 
Thrombocytopenia, 
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1.7. Genetic studies of bleeding and platelet disorders 
There are a number of genetic studies for the investigation of potential bleeding and platelet 
disorders. These all use different approaches with the aim to find a causative genetic variant, 
determine the effect(s) of the variant and then link it to the disease phenotype. Research 
groups in the U.K., Italy, Spain, Denmark as well as the USA are progressing in the field by 
incorporating NGS to their investigation of unknown bleeding diatheses (Leinoe et al., 2017, 
Sanchez-Guiu et al., 2014, Bastida et al., 2018, Johnson et al., 2018).  
1.7.1. BRIDGE-Bleeding and Platelet Disorders 
The BRIDGE consortium was introduced as the NIHR BioResource funded body for projects 
involving NGS related to rare disease causing variants. The BRIDGE-Bleeding and Platelet 
Disorders (BDPs) study (B20) takes an alternative approach to the discovery of novel and 
known variants by high throughput sequencing (HTS) of a large patient cohort (> 1000 donors) 
and annotation with adapted Human Phenotype Ontology (HPO) terms 
(https://bridgestudy.medschl.cam.ac.uk/bpd.shtml) (Westbury et al., 2015). Their aim is to 
characterise cases with similar HPO terms and variants in the same gene to aid in gene 
discovery (Westbury et al., 2015).  
The BRIDGE-BPD study used their novel approach to gene discovery using HPO-encoded 
phenotype data for novel variants in ACTN1 along with other genes that have been implicated 
with bleeding including MYH9 (Kunishima et al., 2013, Westbury et al., 2015). A gain-of-
function mutation in SRC was also found to cause bleeding and other bone pathologies 
following WGS and HPO patient coding within the BRIDGE-BDP study as well as a gain-of-
function variant in DIAPH1 (Turro et al., 2016, Stritt et al., 2016). In order to ensure accurate 
annotation of the particular phenotypes, the study added 80 terms and associated symptoms 
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to HPO in parallel with the development of the software hpoPlot that summarises the HPO 
codes of the cases (Kohler et al., 2014). It was hypothesised that individuals with rare coding 
variants in the disease gene would cluster on the basis of the HPO-encoded phenotypes they 
were given upon recruitment to the study (Westbury et al., 2015). The data that was 
generated suggested that despite minor anomalies, bleeding disorders caused by common 
genetic backgrounds would tend to cluster on the basis of their HPO terms  
(Westbury et al., 2015). This approach to gene discovery was pioneered in bleeding and 
platelet disorders but is applicable to other rare diseases. The HPO data can be linked to large 
online databases such as Online Mendelian Inheritance in Man (OMIM) which can be used to 
prioritise disease gene candidates based on comparison to other ontological phenotype terms 
from scientific literature (Westbury et al., 2015).  
1.7.2. ThromboGenomics Platform 
The ThromboGenomics platform has also been implementing NGS with regard to bleeding, 
thrombotic and platelet disorders (http://www.thrombogenomics.org.uk). They have 
developed a targeted gene capture platform which encompasses approximately 70 candidate 
genes with the aim to provide a multi-gene high-throughput sequencing platform to obtain 
diagnoses for patients with suspected bleeding or platelet disorders (Simeoni et al., 2016). 
Again the use of HPO term based coding of patient phenotypes is being utilised in order to 
elucidate genotype-phenotype correlations (Simeoni et al., 2016). The ThromboGenomics 
platform has used WGS data and is critically dependent on the recruitment of patients with 
strong, clinically well characterised phenotypes. WES has been carried out on the genes 
ITGA2B and ITGB3 with input from ThromboGenomics in order to identify novel variants 
within these genes and predict whether the said variants are likely to cause Glanzmann 
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Thrombasthenia (Buitrago et al., 2015). ThromboGenomics has multiple national and 
international collaborators that are involved at various levels to continue the development of 
the platform. 
1.7.3. The Genotyping and Phenotyping of Platelets study 
The Genotyping and Phenotyping of Platelets (GAPP) study run from the University of 
Birmingham has recruited approximately 1000 participants with bleeding disorders of 
unknown cause from over twenty five collaborating Haemophilia Comprehensive Care Centres 
across the UK and involves collaborations with the Universities of Bristol, Nottingham and 
Sheffield (Figure 1.4) (http://www.birmingham.ac.uk/research/activity/cardiovascular-
sciences/research/platelet-group/platelet-gapp/index.aspx) (Watson et al., 2013).  
The GAPP study team use a combination of platelet phenotyping by LTA and WES in a different 
approach to variant discovery within platelet genomics with the aim to identify the likely 
causative gene(s) within each recruited individual (Watson et al., 2013, Jones et al., 2012). 
Blood from individuals suspected to have a platelet function disorder is subjected to LTA which 
is extensively used as the gold standard for platelet function testing with a streamlined panel 
of agonists (Dawood et al., 2007, Dawood et al., 2012). This has shown that most platelet 
function disorders can be reliably diagnosed using key platelet agonists at specified 
concentrations (Dawood et al., 2012). In some cases, additional phenotyping is performed 
including flow cytometry and the measurement of cyclic adenosine monophosphate (cAMP) 
to gain further information. The study emphasises the importance of the genotype-phenotype 
correlation to improve the classification and diagnosis of patients with unclassifiable, novel or 
unknown platelet and bleeding disorders (Watson et al., 2013). The GAPP study workflow can 











Figure 1.4. Map of the GAPP study network. Orange pins show all Haemophilia Comprehensive 
Care Centres from which patients are referred to the main laboratory at the University of 




The GAPP study 
workflow 









MEA T-TAS Platelet spreading 
Whole exome sequencing  
Classification and confirmation 
Figure 1.5. The GAPP study normal workflow. Patients suitable for the study are recruited. Blood 
is then taken and analysed using the Sysmex. Depending on the platelet count lumi-aggregometry 
or flow cytometry is carried out. If diagnosis is still not possible, DNA is selected to go forward for 
WES. Genetic variants are then confirmed by Sanger sequencing and functional work may need 
to be carried out.  
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The GAPP study workflow has allowed for the diagnosis of hundreds of patients since its 
inception through either phenotyping, genotyping or both (Jones et al., 2012, Johnson et al., 
2018). Patients with novel SLFN14 variants as well as those with RUNX1 and FLI1 variants 
implicated in bleeding were discovered through the GAPP study methodology of employing 
NGS, showing effective proof of principle for this approach (Fletcher et al., 2015, Stockley et 
al., 2013). The SLFN14 variants were narrowed down from eight potential disease causing 
single nucleotide variants (SNVs) shared by the three patients of the same family in the initial 
investigation. The affected individuals presented with thrombocytopenia and excessive 
bleeding disproportionate to their platelet counts (Fletcher et al., 2015). The platelets also 
have a reduced number of dense granules and therefore ADP secretion is also reduced 
(Fletcher et al., 2015).  
This study is not exempt from challenges and over the years, the GAPP study team have 
identified a large group of individuals in which no platelet defect was identified despite there 
being extensive bleeding histories (Figure 1.6).  It is this cohort of patients that require further 
investigation by WES in order to elucidate their causes of disease. Recently, a novel variant in 
GNE was found by WES to be the causative of a family’s thrombocytopenia and bleeding 
(Futterer et al., 2018). The GAPP study continues to investigate this ‘no defect’ group in 





Figure 1.6. The main findings and classification of defects from the GAPP study after Lumi-
aggregometry. Following lumi-aggregometry, the platelet defects were classified. The most 
common platelet defect was found to be secretion defects followed by Gi signalling pathway 
defects. In the largest group however, there were found to be no identifiable platelet 
defects. This illustrates the limit of particular assays to detect platelet function disorders and 
how they fail to address other possible causes of patients’ bleeding.  
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1.8. Thesis hypothesis and aims 
We propose that a significant proportion of patients (≈60%) with no obvious platelet defect 
despite having extensive bleeding history, have defective genes/mutations in other genes 
involved in haemostasis. We believe that some of these give rise to impaired platelet function 
but are not readily picked up in available tests. We will investigate this hypothesis using next 
generation sequencing approaches to identify the underlying gene mutations in a cohort of 
patients with no apparent laboratory platelet defect despite having an extensive bleeding 
history. Furthermore, we will explore the use of a platelet spreading assay in detecting platelet 
defects that may not otherwise be detected. 
The overarching aim is to elucidate disease mechanisms in novel inherited bleeding disorders. 
The objectives are as follows:  
1. To use a forward genetic approach to identify genes and pathways in patients with 
inherited bleeding disorders that are characteristic of a defect in platelet function but 
where laboratory testing has not identified a defect in platelet function. 
2. To determine whether an assay to test the ability of activated platelets to spread is a 
useful to investigate suspected platelet function defects. 
3. To determine how a proportion of these novel disease-causing mutations impair 






















Materials and Methods 
51 
 
2. Materials and Methods 
2.1. Materials 
All agonists, antibodies, software, and databases used in this thesis are listed in Tables 2.1, 
2.2, 2.3 and 2.4 respectively. If unstated, reagents used in this thesis are from Sigma-Aldrich™, 
UK and all plastics were purchased from StarLab, UK.   
2.2. Study approval 
The Genotyping and Phenotyping of Platelets (GAPP) study was approved by the UK National 
Research Ethics Service by the Research Ethics Committee of West-England (REC reference: 
06/MRE07/36) and participants gave full, written, informed consent in accordance with the 
Declaration of Helsinki. The GAPP study is included in the National Institute of Health Research 
Non-Malignant Haematology study portfolio (ID9858). This study is also registered at ISRCTN 











Table 2.1. Platelet agonists for light transmission aggregometry 
 
Agonist Concentrations used Source 
ADP 3, 10, 30 and 100 μM Sigma-Aldrich™, UK, #A2754 
Adrenaline 3, 10 and 30 μM Sigma-Aldrich™, UK, #E4375 
Arachidonic acid 0.5, 1 and 1.5 mM Cayman Chemical Company, USA, 
#10006607 
Collagen 1, 3 and 10 μg/ml Takeda, Japan, #1130630 
Collagen-related 
peptide, cross-linked 
1 and 3 μg/ml Provided by Dr Richard Farndale, 
University of Cambridge, #CRP-XL 
PAR-1 peptide 30 and 100 μM Severn Biotech, UK, custom product 
Ristocetin 1.5 and 2 mg/ml Sigma-Aldrich™, UK, #R7752 














Table 2.2. Antibodies 
 





Abcam, UK, #ab9485 WB: 1/5,000 
Anti-PolyG Rabbit Gifted from Koji Ikegami, 




Anti-TTLL10 1 Guinea Pig Gifted from Koji Ikegami, 
Hamamatsu School of 
Medicine, Japan 
WB:1/5,000-10,000 





Anti-TTLL10 3 Rabbit 
polyclonal 
Thermo Fisher Scientific, 
USA, #PA5-31631  
WB: 1/1000 















































































AGGRO/LINK® Interface  Chrono-Log, USA 
Chromas Technelysium, Australia 
ExonPrimer Helmholtz Center Munich, Germany 
GeneSnap Syngene, USA 
Ilastik Heidelberg Collaboratory for Image Processing- 
University of Heidelberg, Germany 
ImageJ Optical and Computational Instrumentation- University 
of Wisconsin-Madison, USA 
KNIME KNIME, Switzerland 
Mutation Surveyor® Softgenetics®, USA 
Mutation Taster Charité, Germany 
Novoalign Novocraft Technologies, Malaysia 
Polymorphism Phenotyping v2 BWH- Harvard Medical School, USA 
Primer3 Whitehead Institute for Biomedical Research, USA  
Protein Variation effect 
analyser 
J. Craig Venter Institute, USA 
SAMtools Wellcome Trust Sanger Institute, Cambridge 
SoftMax® Pro Molecular Devices, USA 
Sorting Intolerant from 
Tolerant 
J. Craig Venter Institute, USA 
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BDGP http://www.fruitfly.org/  21 Sep. 19 
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Progenitors 
https://blueprint.haem.cam.ac.uk/admin/query_genes  21 Sep. 19 
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dbSNP135 https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.c
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Ensembl https://www.ensembl.org/index.html  21 Sep. 19 
EVS http://evs.gs.washington.edu/EVS/  21 Sep. 19 
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2.3. Patient recruitment 
Patients have been recruited to the GAPP study since the study first opened to patients, in 
2006. Since then, nearly 1000 patients have been successfully recruited from multiple 
collaborating Haemophilia Centres across the UK and Ireland. Recruitment of patients to the 
study is based on a diagnosis of bleeding or thrombocytopenia of unknown cause as defined 
by the International Society of Thrombosis and Haemostasis (ISTH) Bleeding Assessment Tool 
(BAT) by a specialist Haematologist. Patients were deemed thrombocytopenic if their platelet 
count was < 150 x109/l in whole blood. Owing to the likely inheritance patterns of such 
bleeding disorders and thrombocytopenias, if the recruits had potentially affected family 
members, the relatives were also recruited and where appropriate, genetic pedigrees were 
taken.  
Selection for recruitment to the GAPP study required the patients to meet certain inclusion 
criteria. Patients who fulfilled all criteria and who were consented in writing by signing the 
consent form (Appendix, Figure B), were invited to participate. Any patients who fulfilled one 
or more of the exclusion criteria were not invited to participate in the study.  
Inclusion criteria: 
a. Aged 0-85 years 
b. Bleeding episodes in line with a platelet function disorder 
c. Normal coagulation factor screen results 





Exclusion criteria:  
a. Recently undergone major surgery 
b. Suffer from chronic renal failure requiring dialysis 
c. Severely anaemic (Hgb <8 g/dl) 
d. Recently received any blood products 
e. Receiving any known platelet function affecting drugs 
Patients were also excluded if they had a known cause of their bleeding or thrombocytopenia. 
Routine clinical screening tests from each referring centre differed; however, usually consisted 
of full blood cell count, peripheral blood smear, prothrombin time (PT) and activated partial 
thromboplastic time (APPT). From these tests, the most common causes of bleeding were 
excluded. Peripheral blood smears allowed platelets to be visualised. Large platelets with 
leukocyte inclusions (indicative of MYH9-related disorder) or grey platelets (Gray Platelet 
Syndrome) often lead to definitive diagnoses that were followed up with genetic tests if 
offered. Non-platelet bleeding based disorders including coagulation factor deficiencies and 
von Willebrand’s Disease were also diagnosed and these patients were not invited to 
participate in the study. Furthermore, patients were excluded if they were suspected to have 
idiopathic thrombocytopenic purpura (ITP) due to an autoimmune cause of disease. 
2.4. Healthy controls 
Healthy donor volunteers were required to be over the age of 18 years and physically well in 
the run up to and time of donation. The healthy donor volunteers should not take any known 
platelet disrupting drugs e.g. aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) 
in the two weeks before donation. Donors were unable to give blood to the NHSBT Blood 
Donation service up to two weeks before taking part in the study.   
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2.5. Sample collection 
Peripheral blood was collected simultaneously from patient and healthy donor volunteers 
where possible. If this was not possible, control blood from a healthy donor volunteer was 
collected at the site of blood analysis within similar time points as the patient blood collection. 
The blood was transported by courier at room temperature from the referring centre to the 
site of analysis in Birmingham. Previous investigations into the blood transport by members 
of the GAPP Study found that results from blood samples transported in this way were highly 
comparable to blood samples collected locally (Dawood et al., 2007).  
For adult patients, approximately 40 ml blood was collected in 3.2% trisodium citrate by 
venepuncture. For paediatric patients (<18 years) up to 20 ml blood was taken, depending on 
the age and weight of the patient, into 3.2% trisodium citrate by venepuncture. Blood was 
usually collected into BD Vacutainer® 2.7 ml citrate blood collection tubes (BD, UK, #363083) 
but collection varied occasionally due to different protocols within the referring centres. 
Control samples taken at the site of analysis were collected by venepuncture into 4% citrate 
concentrated solution (Sigma-Aldrich™, UK, #S5770) at a ratio of 1:9 (v:v), citrate to blood 
volume. A further 4 ml of ethylenediaminetetraacetic acid (EDTA) anticoagulated blood was 
taken from both patients and healthy donor volunteers for whole blood cell counts. Blood was 
collected into BD Vacutainer® blood collection tubes, coated in spray dried K2EDTA (BD, UK, 
#367835), by venepuncture.  
2.6. Platelet counts in EDTA-anticoagulated blood 
Whole blood cell counts were obtained from analysing EDTA anticoagulated blood on the 
Sysmex XN-1000™ Haematology analyser (Sysmex, UK). The XN-Series offers high diagnostic 
capabilities by using fluorescent flow cytometry to determine highly accurate whole blood cell 
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counts. The instrument has five core channels that provide readings of almost all components 
of the blood including white blood cells, basophils, nucleated red blood cells and haemoglobin. 
The most important channel for this project was the PLT channel that solely measured 
different platelet parameters. Within this channel there are three methods of obtaining 
platelet counts: platelet fluorescence (PLT-F), platelet impedance (PLT-I) and platelet optical 
(PLT-O). The PLT-F method required the fluorescent RNA staining dye, oxazine, which 
improved current methods due to its increased ability to differentiate between platelets and 
apoptotic white cells that other analysers were unable to do previously. Platelet counts were 
checked against the PLT-I and the PLT-O results and the data was collated to provide the 
overall platelet count. Mean platelet volume (MPV) and immature platelet fraction (IPF), a 
measure of platelet production, were also recorded within the PLT channel. A normal range 
record was determined by a study of analysis of blood from 40 healthy control volunteers in 
collaboration with Sysmex. Blood from both patients and controls recruited to the GAPP study 
was analysed in this way. Daily quality control was carried out with control blood (XN-CHECK 
[Sysmex, UK]) to ensure instrument performance throughout the study.  An example of the 







Figure 2.1. Full blood count using the Sysmex XN-1000™ Haematology analyser. This 
analysis shows that all components are within the normal ranges however; this read is for 
research purposes only. The parameters highlighted in red are of most interest when 
receiving new patient GAPP samples in order to process and filter the samples correctly. 
PLT, platelet count; MPV, mean platelet volume; IPF, immature platelet fraction. 
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2.7. Preparation of whole citrated blood 
 
Platelet rich plasma (PRP) was prepared for platelet function testing by LTA and lumi-
aggregometry. PRP was obtained by slow centrifugation of whole blood at 200 g for 20 
minutes at room temperature using the Heraeus™ Megafuge™ 16R centrifuge (Thermo Fisher 
Scientific™, USA). If a patient was suspected to have macrothrombocytopenia (MPV > 13 fl), 
PRP was prepared by centrifugation at 100 g for 30 minutes to retain the large platelets within 
the PRP layer. The PRP was removed and added to labelled 15 ml Falcon™ tubes.  Platelets 
were then counted; 5 µl of PRP was added to 10 ml COULTER® ISOTON® II Diluent (VWR, USA, 
#8448011) and the platelets counted three times using the Z™2 Series COULTER COUNTER® 
(Beckman Coulter®, USA) and the counts averaged. The remaining blood was centrifuged 
again at 1000 g for 10 minutes to obtain platelet poor plasma (PPP) for use as a reference and 
to set the aggregation scale during LTA and lumi-aggregometry. The PPP was removed and 
added to labelled 15 ml Falcon™ tubes. 
2.8. Preparation of washed platelets 
Washed platelets were prepared for platelet spreading assays in this thesis. 50 ml Tyrode’s 
buffer (134 mM NaCl, 2.9 mM KCl, 10 mM HEPES, 12 mM NaHCO3, 0.34 mM NA2HPO4,  
1 mM MgCl2, [all reagents available from Sigma-Aldrich™, UK]) was warmed in a 37 °C water 
bath along with 10 ml acid-citrate-dextrose (ACD) (39mM citric acid, 75 mM sodium citrate, 
135 mM dextrose [all reagents available from Sigma-Aldrich™, UK]). 45 mg of glucose was 
added to make modified Tyrode’s buffer and the pH was adjusted to 7.3. Blood was taken into 
sterile 4% citrate concentrated solution (Sigma-Aldrich™, UK, #S5770) as an anticoagulant at 
10% of the desired blood volume. 10% of the blood volume in ACD was added to the  
blood-anticoagulant mixture and transferred to polypropylene tubes. The anticoagulated 
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blood was then centrifuged at 200 g for 20 minutes at room temperature using the Heraeus™ 
Megafuge™ 16R centrifuge (Thermo Fisher Scientific™, USA). Platelet rich plasma (PRP) was 
pipetted off and added to a 50 ml Falcon™ tube. 10 µl prostaglandin I2 (PGI2) (10 µl of stock 
solution at 1 mg/ml [Cayman Chemical Company, USA, #18220]) per 10ml PRP was added and 
the tube gently inverted to mix before centrifuging at 1000 g for 10 minutes. The supernatant 
was removed and discarded and the pellet was resuspended in 1 ml warmed modified 
Tyrode’s buffer. Another 24 ml of modified Tyrode’s buffer and PGI2 were added and the tube 
was centrifuged at 1000g for 10 minutes to wash and pellet the platelets. This process was 
repeated once more. The supernatant was then removed, discarded and the platelet pellet 
gently resuspended in 1 ml modified Tyrode’s buffer before a further 4 ml was added.  
In order to count the platelets, 5 µl of washed platelets was added to 10 ml COULTER® 
ISOTON® II Diluent (VWR, USA, #8448011) and the platelets counted three times using the 
Z™2 Series COULTER COUNTER® (Beckman Coulter®, USA) and an average value calculated. 
The platelet solution was diluted to a final concentration of 2x107 /ml with modified Tyrode’s 
buffer and allowed to rest for 20-30 minutes before spreading. 
2.9. Platelet function testing- LTA with lumi-aggregometry 
LTA with lumi-aggregometry was carried out on all patients and controls with a platelet count 
of > 1 x108/ml in PRP as described and published previously by members of the GAPP study 
(Dawood et al., 2012, Dawood et al., 2007). LTA for the GAPP study was firstly performed by 
Dr Gill Lowe and Miss Sian Drake but was later performed by Dr Rashid Al Ghaithi.  
Patient and control PRP were processed using the same method and agonist conditions; LTA 
was carried out within 6 hours of the PRP preparation. All aggregations were preformed using 
a dual channel Chrono-log 460 VS Lumi-Aggregometer (Chrono-Log, USA). Briefly, this 
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technique, first described by Born, measures light transmission through the PRP platelet 
suspension before and after the addition of different agonists (Born, 1962). These agonists 
cause platelet aggregation therefore permitting greater light transmission through the 
solution that is detected by a photocell and recorded as a function of time. LTA now has the 
capacity to simultaneously measure ATP secretion from platelet dense granules using the 
luciferase assay (Holmsen et al., 1972).  
400 μl of the PRP samples was added to siliconized mini glass cuvettes and incubated at 37 °C 
for 2 minutes. This was followed by a further 1 minute under stirring conditions (1200 rpm) to 
set the baseline; the PPP was also used to set the aggregation scale. The platelets were then 
stimulated with a range of concentrations of different agonists ( 
Table 2.1. Platelet agonists for light transmission aggregometry). Platelet aggregation was 
measured for 5 minutes after the addition of the agonists and the maximal percentage of 
aggregation was recorded using the AGGRO/LINK® Interface (Chrono-Log, USA). Utilisation of 
the full panel of agonists depended on the individual patient responses. If the aggregation 
traces were abnormal, stimulation of PRP to that concentration of agonist was repeated. 
Furthermore, if responses to ADP or arachidonic acid were abnormal, further aggregation 
experiments were carried out in response to varying concentrations of U46619, the synthetic 
thromboxane A2 receptor agonist.  
 Dense granule release was measured by detecting ATP secretion by lumi-aggregometry. 30 μl 
of Chronolume® (Chrono-Log, USA, #395) containing D-luciferin was added to PRP samples 
during the 37 °C incubation stage for 1 minute. Platelets were then stimulated with the 
agonists and aggregation measured for 5 minutes, as previously mentioned. At the start of the 
experiment, an internal calibration was carried out to allow quantification of ATP secretion by 
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the addition of a 2 nM ATP standard (Chrono-Log, USA) for each channel. The AGGRO/LINK® 
Interface (Chrono-Log, USA) calculated total ATP released automatically.  
2.10. Sample storage- protein and buffy coat 
Any patient PRP remaining after lumi-aggregometry was saved and processed for storage of 
platelet protein. Depending on the platelet count of the patient and control samples, the 
volumes of PRP containing 3 ×108 platelets were removed from the samples. These were then 
added to separate, labelled 1.5 ml Eppendorf tubes. 1 μl of PGI2 (1 mg/ml [Cayman Chemical 
Company, USA, #18220]) was added to the PRP samples and inverted gently to mix. The 
samples were immediately centrifuged at 1000g for 10 minutes in the Heraeus™ Pico™ 21 
centrifuge (Thermo Fisher Scientific™, USA). The supernatants were carefully removed by 
aspiration to avoid disruption of the platelet pellets. The pellets were then resuspended in 1 
ml of phosphate buffered saline (PBS, [Sigma-Aldrich™, UK, #P4417]). 1 μl of PGI2 was added 
to the tubes, inverted gently to mix, and centrifuged at 13000 rpm for 2 minutes. The 
supernatant was removed and the remaining cell pellets were resuspended in 600 ml of 1 x 
sample buffer (60 mM Tris-HCl pH 6.8 [Sigma-Aldrich™, UK, #T6455] , 2% sodium dodecyl 
sulphate [SDS, Sigma-Aldrich™, UK, #L3771], 10% glycerol [Sigma-Aldrich™, UK, #G5516], 
0.002% Bromophenol Blue, 5% β-mercaptoethanol [Sigma-Aldrich™, UK, #M6250]). Samples 
were stored at -80 °C until needed. 
After the PPP was removed from the blood, the visible white layer separating the red cell layer, 
known as the buffy coat, was also removed by pipetting and transferred to 1.5 ml, labelled 
Eppendorf tubes. The buffy coat contains white blood cells that can be used in subsequent 




2.11. Preparation of platelet lysates from washed platelets 
Platelet lysates were made from particular samples for platelet protein analysis. 10 ml of 
extraction buffer was prepared from 2 x lysis buffer (300 mM NaCl, 20 mM Tris, 2 mM EDTA, 
2 mM EGTA and 1% Nonidet p-40 [NP-40, Sigma-Aldrich™, UK, #I8896]). Protease inhibitors, 
all on ice, were then added (250 μl sodium orthovanadate [Sigma-Aldrich™, UK, #450243],  
100 μl leupeptin [Enzo Life Sciences, USA, #260-009-M100], 10 μl aprotinin [Sigma-Aldrich™, 
UK, #A1153], 4 μl pepstatin [Sigma-Aldrich™, UK, #P5318] and 100 μl AEBSF [Calbiochem, UK, 
#101500]). An equal volume of extraction buffer was added to platelets and was incubated on 
ice for 40 minutes, vortexing every 10 minutes to aid lysis. Tubes containing buffer and lysed 
platelets were then centrifuged at 13,000 rpm for 20 minutes at 4 °C using the Refrigerated 
Microcentrifuge Model 5417R (Eppendorf®, USA). The supernatant containing the protein was 
removed and transferred to new, labelled tubes. 
2.12. DNA extraction from buffy coat and whole blood 
DNA was extracted from buffy coats or whole blood using the Gentra Puregene Blood DNA 
Extraction Kit (Qiagen, UK, #158389) according to the standard protocol. Blood was added 1:3 
(v:v) to RBC Lysis Solution and incubated for 10 minutes, inverted once during incubation. This 
was then centrifuged at 2000g for 10 minutes using the Heraeus™ Megafuge™ 16R centrifuge 
(Thermo Fisher Scientific™, USA). The supernatant was removed and discarded and tube 
vortexed at high speed to resuspend pellet in residual liquid. 3 ml Cell Lysis Solution was added 
to the resuspended pellet and tube inverted to aid lysis. The solution was incubated overnight 
at 37 °C if cell clumps were still visible. When the solution was homogenous, 15 µl RNase A 




The sample was cooled to room temperature and 3 ml Protein Precipitation Solution was 
added. This was vortexed at high speed for 20 seconds and centrifuged at 2000 g for 10 
minutes to pellet the precipitated protein. 
The supernatant containing the DNA was transferred into a clean, labelled 15 ml Falcon™ tube. 
3 ml 100% isopropanol (Fisher Scientific, USA, #389710025) was added and sample mixed by 
inverting then centrifuged at 2000 g for 3 minutes. The supernatant was removed and 
discarded and 3 ml 70% ethanol (EtOH) (VWR, USA, #20821.33) added to wash DNA pellet. 
The tube was inverted and centrifuged at 2000 g for 1 minute to re-pellet the DNA. Again, the 
EtOH was poured off and pellet left to air dry with tube inverted on paper towel. Once dry, 
100–250 µl DNA Hydration Solution was added depending on the size of the DNA pellet and 
hence quantity of DNA present. The mixture was vortexed for 10 seconds and solution 
incubated overnight at 55 °C to dissolve the DNA pellet.  
DNA was stored at -80 °C until needed. To avoid excess freeze thawing, DNA samples used 
regularly were aliquoted.  
2.13. DNA quantification 
The concentration of DNA for whole exome sequencing was determined using the Qubit® 3.0 
Fluorometer (Life Technologies™, USA) following the standard protocols and using the Qubit® 
reagents. The Qubit® dsDNA Broad Range (BR) Assay kit (Thermo Fisher Scientific, UK, 
#Q32850) was used to make up the Qubit® working solution. Either the standards (10 µl) or 
samples (3 µl) were added to the working solution to give a total volume of 200 µl in 500 µl 
thin-walled polypropylene Qubit® Assay Tubes (Invitrogen, UK, #Q32856). The mixes were 
briefly vortexed and incubated at room temperature for 2 minutes before being centrifuged 
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to collect the contents. The standards for the dsDNA BR Assay were run before samples were 
read and the DNA concentrations recorded.  
DNA for any other use was quantified using the NanoPhotometer® P360 (IMPLEN, Germany). 
The NanoPhotometer® P-Class Submicrolitre Cell was loaded into the cell holder. The well was 
blanked with 1 µl of water before samples were measured. Samples were vortexed and 1 µl 
was loaded into the well to be tested; the well was cleaned, and this was repeated three times. 
The average DNA concentration was calculated, and 260/280 ratio was recorded as an 
indicator of the sample quality.   
2.14. Whole exome sequencing  
Whole exome sequencing is a commonly used technique and classed as next generation 
sequencing technology. The exome (the protein coding regions of the genome) makes up 
approximately 1.5% of the human genome but contains around 85% of known disease-related 
variants. WES employed by the GAPP study is therefore a more cost-effective and rapid 
alternative to whole genome sequencing. Confirmatory Sanger sequencing is usually carried 
out post-WES.  
The whole exome sequencing for the GAPP study was carried out externally by a collaborating 
group headed by Professor Michael Simpson from King’s College, London, until 2016. After 
this time, the whole exome sequencing for the GAPP study was carried out by collaboration 
with Dr Yvonne Wallis from the West Midlands Regional Genetics service at Birmingham 
Women’s Hospital.   
A minimum of 1µg of DNA was required per patient for successful WES. The DNA was 
transported to the sequencing centre in sealed 1.5 ml Eppendorf tubes at room temperature. 
Enrichment of the coding regions and intron/exon boundaries was then completed with the 
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SureSelect Human All Exon kit (Agilent Technologies, USA) according to the manufacturer’s 
instructions. Following this, WES was carried out using the HiSeq® 2500 Sequencing System 
(illumina®, USA) with 100 bp paired-end reads. Sequencing reads were then aligned to the 
human reference genome (hg19) by applying the Needleman-Wunsch algorithm using 
NovoAlign (Novocraft Technologies, Malaysia). Duplicate reads and reads that mapped to 
multiple regions of the exome were excluded from the bioinformatic analysis. Small insertions, 
deletions, and single nucleotide variants were identified and filtered for quality by the 
SAMtools software (Wellcome Trust Sanger Institute, Cambridge) (Li et al., 2009). 
Furthermore, any calls with a read coverage of < 4 were again excluded from downstream 
bioinformatic analysis. 
The remaining variants were then filtered for novelty by comparison to known variants 
present in a number of databases including: dbSNP139 that now contains over 40 million 
validated human reference single nucleotide polymorphism clusters, the 1000 Genomes 
Project, Exon Variant Server (EVS) and the variants from the GAPP database of over 800 whole 
exome sequences.  
Post alignment and variant called sequencing bioinformatics was approached in a manner 
unique to the GAPP study and will be discussed in Chapter 4. 
2.14.1. Pathogenicity prediction and conservation  
The potential pathogenicity of each variant was analysed using five main pathogenicity 
prediction tools that use different methods to assess whether a variant will affect the protein’s 
functionality. The prediction tools are as follows: 
1. MutationTaster2 assesses the results of WES by a Naive Bayes classifier to predict the 
disease potential of a variant by deciding whether the effect might be deleterious. 
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MutationTaster2 can predict the effects of frameshift and non-frameshift insertions 
and deletions, SNPs and splice-site changes. Data of common polymorphisms and 
known disease causing mutations are included and if these variants are present, they 
are described automatically (Schwarz et al., 2014).  
2. Polymorphism Phenotyping version 2 (PolyPhen-2) calculates the probability of an 
amino acid substitution being damaging to the protein structure therefore affecting its 
function. This prediction is dependent on the sequence, the phylogenetic and 
structural information of the substitution. PolyPhen-2 will extract the above features 
of the substitution location and compute them to a probabilistic classifier  
(Adzhubei et al., 2013). For this study, the HumVar model was used, which consists of 
all human disease causing mutations from UniProtKB along with common SNPs not 
involved in disease.  
3. Sorting Intolerant From Tolerant (SIFT) is based on the degree of conservation within 
the amino acid residues under question in sequence alignments derived from  
closely-related sequences. SIFT assumes that important positions are highly conserved 
in a protein sequence throughout evolution and therefore substitutions within these 
regions may affect protein function (Kumar et al., 2009). This allows a prediction of 
whether an amino acid substitution will be tolerated or whether it will be deleterious 
to the protein function based on the sequence homology.  
4. Protein Variant Effect Analyser (PROVEAN) predicts the functional effect of non-
synonymous amino acid substitutions as well as insertions and deletions by using an 
alignment-based score. The change between the variant sequence and the reference 
sequence homology is measured and those variants scoring below the neutral 
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threshold (-2.5) are deemed deleterious, any scoring above the threshold are deemed 
neutral therefore, have no effect (Choi et al., 2012).  
5. Splice site variants were analysed using the Berkeley Drosophila Genome Project that 
works to predict whether donor or acceptor splice sites are altered by such variants.  
The levels of mRNA expression of each of the candidate genes in the different haematopoietic 
cells was also noted using the Blueprint Progenitors database along with RNA-seq data from 
the human and mouse platelet transcriptomes study (Rowley et al., 2011).  
Conservation at the site of the variant in query is determined by PhastCons and PhyloP- both 
available from MutationTaster (Pollard et al., 2010). MutationTaster uses precomputed values 
produced by UCSC. PhastCons values range between 0 and 1 to reflect the probability of a 
nucleotide belonging to a conserved region, based on the multiply aligned sequences of over 
46 species. The closer the value is to 1, the more likely the variant is conserved. PhyloP in 
contrast to phastCons, measures conservation without considering the effects of 
neighbouring nucleotides. PhyloP values range between -14 and 6, positive scores were 
assigned to sites predicted to be conserved while negative scores were assigned to sites 
predicted to be fast evolving.   
2.14.2. Variant classification 
Recently, there have been standards and guidelines published for the interpretation of 
sequence variants as recommended from the American College of Medical Genetics and 
Genomics (ACMG) and the Association for Molecular Pathology (AMP) (Richards et al., 2015). 
The genetic variants from WES of the GAPP study patients were classified in this way. 
Dominant inheritance was assumed for all patients unless the family histories obtained from 
the patients suggested otherwise. The report recommends the use of specific consensus 
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terminology – ‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, ‘likely benign’ and 
‘benign’ to describe variants. Candidate variants identified in possible disease causing genes 
were classified based on evidence for a set of criteria and the strength of the criteria (Richards 
et al., 2015). The classification of each variant was applied when predicting the pathogenicity 
of each variant. 
2.15. Polymerase chain reaction 
All PCRs were performed according to a standardised laboratory protocol. Each reaction 
consisted of  a total 25 µl containing: 12.5 µl REDTaq® ReadyMix™ PCR Reaction Mix (DNA 
polymerase) (Sigma-Aldrich®, UK, #R2523), 0.5 µl of forward primer, 0.5 µl of reverse primer 
both at a concentration of 10 µM in ddH2O, 6.5 µl ddH2O (Sigma-Aldrich®, UK, #R2523) and  
5 µl DNA at 20  ng/µl. All the primer pairs were designed using ExonPrimer and purchased 
from Sigma-Aldrich®, UK. 
The universal cycling conditions of denaturation, annealing and elongation were conducted 
under the following conditions in the DNA Engine Tetrad® 2, Peltier Thermal Cycler (Bio-Rad, 
USA): 
• 94 °C for 3 minutes 
o 94 °C for 1 minute 
o 60 °C for 1 minute 
o 72 °C for 1 minute 
• 72 °C for 5 minutes 
Results from the PCR were visualised using agarose gel electrophoresis. The gel was 0.0001% 
ethidium bromide (Sigma-Aldrich®, UK, #E8751-1G) stained in 1.5% Ultrapure™ Agarose 
x 30 cycles 
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(Invitrogen™, UK, #16500-500) and TAE (40 mM Tris, 20mM acetic acid and 1 mM EDTA). All 
gels were loaded with 10 µl of 1 Kb DNA ladder (Invitrogen, UK, #1078-018) and run at 120 V 
using a suitable power pack for 20-60 minutes. The gel was imaged with an ultraviolet 
transilluminator (Syngene, Gene Genius Bio Imaging System) and GeneSnap software version 
6.03.00 (Synoptics, UK). 
2.16. Sanger sequencing 
DNA sequencing has been revolutionising medical research since the invention of Sanger 
sequencing by Sanger et al. in 1977 and was the most used sequencing method for 40 years 
(Sanger et al., 1977). Sanger sequencing was used to verify WES candidate variants identified. 
The PCR products were cleaned before Sanger sequencing was carried out. 2.4 µl of PCR 
product, both for forward and reverse reads, were transferred to a clean plate. 2.4 µl of 
microCLEAN solution (Microzone, UK, #2MCL) was added to each well using the Multipette® 
Stream multi-pipette (Eppendorf, Germany). The plate was centrifuged at 4,000 rpm for 40 
minutes in the Universal 320R centrifuge (Hettich®, Germany). The plate was then turned 
upside down and centrifuged at 500 rpm for 30 seconds. 
Sequence amplification occurred on the dry pellet present in each well following the 
microclean step. Each reaction consisted of a total of 10 µl containing: 0.5 µl BigDye™ Ready 
Reaction Mix, 2 µl BigDye® Terminator 5x Sequencing Buffer (BigDye™ Terminator v3.1 Cycle 
Sequencing Kit, Applied Biosystems™, USA, #4337455), 0.4 µl forward or reverse primer both 
at 10 µM and 7.1 µl ddH2O. The plate was vortexed and briefly centrifuged. The universal 
cycling sequencing conditions of denaturation, annealing and elongation were conducted 




• 96 °C for 30 seconds 
o 96 °C for 30 seconds 
o 50 °C for 15 seconds 
o 60 °C for 4 minutes 
• 4 °C for ∞ 
The sequencing reactions were cleaned-up using 2x EtOH washes. Firstly, 2 µl 0.125 M EDTA 
(Sigma-Aldrich™, UK, #E7889) and 30 µl 100% EtOH (VWR, USA, #208121.33) were added to 
each reaction well. The plate was covered and centrifuged at 2,000 rpm for 20 minutes then 
turned upside down and centrifuged at 500 rpm for 30 seconds. 90 µl of freshly made 70% 
EtOH diluted in dH2O were added to each reaction well. The plate was then centrifuged at 
2000 rpm for 10 minutes and again turned upside down and centrifuged at 500 rpm for 30 
seconds. The pellets were left to air dry until no EtOH was visible in the wells. 
10 µl of Hi-Di™ Formamide (Thermo Fisher Scientific™, USA, #4311320) was added to each 
well and pipette mixed to ensure the DNA pellet was resuspended. A new adhesive film sealed 
the plate and the plate was placed in DNA Engine Tetrad® 2, Peltier Thermal Cycler (Bio-Rad, 
USA) at 94 °C for 2 minutes to denature the samples. Immediately after finishing, the plate 
was placed on ice to snap chill in order to stop single stranded DNA from re-annealing. 
The plate was then sequenced by fragment separation by capillary electrophoresis using the 
ABI 3730XL Automated Sequencer (Applied Biosystems™, USA) at the Core Sequencing 
Facility, Functional Genomics at the School of Biosciences, University of Birmingham.  
The sequences were analysed by Mutation Surveyor® (Softgenetics®, USA) that aligned the 
sequences against reference sequences. Chromas Version 2.4 (Technelysium, Australia) 
sequence chromatogram view was also used. Sequencing traces with high levels of 
x 30 cycles 
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background signal required repeat sequencing. Furthermore, unsuccessful Sanger sequencing 
usually required repeat sequencing, repeat amplification and sequencing or complete 
redesign of sequence primers and repetition of the whole process.  
2.17. Preparation of lysate from cell culture and lysates from tissues 
 
Cell lysates were prepared from cell culture for western blot analysis to detect specific 
proteins in the samples. Adherent cells were washed with sterile PBS (Gibco™, UK, 
#12549079). The PBS was then aspirated and ice cold lysis buffer (300 mM NaCl, 20 mM Tris, 
2 mM EDTA, 2 mM EGTA and 1% Nonidet p-40 [NP-40, Sigma-Aldrich™, UK, #I8896]) with 
protease inhibitors (250 μl sodium orthovanadate [Sigma-Aldrich™, UK, #450243], 100 μl 
leupeptin [Enzo Life Sciences, USA, #260-009-M100], 10 μl aprotinin [Sigma-Aldrich™, UK, 
#A1153], 4 μl pepstatin [Sigma-Aldrich™, UK, #P5318] and 100 μl AEBSF [Calbiochem, UK, 
#101500]) was added to the cell flask. The cells were then scraped using a plastic cell scraper. 
The cell suspension was transferred to a 15 ml Falcon™ tube and incubated on ice for  
30 minutes vortexing every 10 minutes to increase cell lysis. The cell suspension was then 
centrifuged at 4 °C using the Heraeus™ Megafuge™ 16R centrifuge (Thermo Fisher Scientific™, 
USA) at 12000 rpm for 20 minutes. The supernatant was removed and placed in a new 15 ml 
Falcon™ tube and kept on ice.  
Preparation of lysates from tissues was carried out in largely the same manner. The tissue of 
interest was dissected from wild-type mice by Dr Sian Lax and placed on ice to avoid tissue 
degradation by proteases. For a 5 mg piece of tissue 300 μl of ice-cold lysis buffer was added 
to the 1.5 ml Eppendorf tube containing the tissue. The tissue was homogenised either by an 
electric homogeniser or by sonication using the Ultrasonic processor, Vibra-Cell™ (Sonics and 
Materials, USA). For sonication, the probe was first rinsed in lysis buffer and the power was 
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set to 180 W. Sonication was carried out in rounds of 10 seconds with 10 second breaks to 
avoid sample warming and continued until the tissue was no longer visible. The sample was 
then incubated on ice for 30 minutes vortexing every 10 minutes to increase cell lysis.  
The tissue lysate was then centrifuged at 13,000 rpm for 20 minutes at 4 °C using the 
Refrigerated Microcentrifuge Model 5417R (Eppendorf®, USA). The supernatant containing 
the protein was removed and transferred to new, labelled tubes kept on ice. 
A Bradford assay was carried out on all cell and tissue lysates before western blotting; this is 
a colourimetric assay used to measure the concentration of protein in the solution.  
The DC Protein Assay kit (Bio-Rad, USA, #5000111) was used for all Bradford assays and carried 
out according to the manufacturer’s instructions. This assay was carried out in 96 well, flat-
bottom plate and absorbances were read at 750 nm using the VersaMax Microplate Reader 
(Molecular Devices, USA). The results were collected by SoftMax® Pro software, version 6.3 
(Molecular Devices, USA). The concentration of the protein was determined by the generation 
of a standard curve using Microsoft® Excel. The proteins were adjusted and the appropriate 
amount of sample buffer (60 mM Tris-HCl pH 6.8 [Sigma-Aldrich™, UK, #T6455] , 2% sodium 
dodecyl sulphate [SDS, Sigma-Aldrich™, UK, #L3771], 10% glycerol [Sigma-Aldrich™, UK, 
#G5516], 0.002% Bromophenol Blue , 5% β-mercaptoethanol [Sigma-Aldrich™, UK, #M6250]) 
was added to the sample. Samples were stored at -80 °C until needed.  
2.18. Western blot analysis 
Western blot is a widely used technique that aims to resolve and detect specific proteins in a 
sample of interest. The samples used for western blots in this thesis include cell lysates, tissue 
lysates, and stored platelet protein or platelet lysates depending on availability.   
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Before use, samples are boiled at 105 °C for five minutes to be denatured. Precast 
polyacrylamide 10 and 12 well Bolt™ Bis-Tris Plus gels (Invitrogen, UK, #NW04120BOX and 
#NW04122BOX) were loaded into Bolt™ Mini Gel Tanks (Invitrogen, UK, no longer in 
production). 20X Bolt™ MES SDS Running Buffer (Thermo Fisher Scientific, USA, #B000202) 
diluted to 1x in dH2O was added to the gel tank up to the fill line. 5 µl of Colour Prestained 
Protein Standard, Broad Range (11-245 KDa) (New England BioLabs, USA, #P7712) was added 
to the first well of the Bolt™ Bis-Tris Plus gel in order to observe protein separation, verify 
transfer and approximate protein size. 20 µl of denatured sample were then added to the 
remaining wells. The Bolt™ Mini Gel Tanks were attached to a suitable power pack and run at 
60 V for 10 minutes followed by 120 V for 1–2 hours depending on the size of the protein of 
interest.  
The protein bands were transferred from the polyacrylamide gels to low fluorescence 
polyvinylidene difluoride (LV PVDF) membranes using the Trans-Blot® Turbo™ Transfer System 
(Bio-Rad, UK). PVDF membranes from the Trans-Blot® Turbo™ RTA Transfer Kit (BioRad, UK, 
#1704274) were activated by immersion in methanol (VWR, USA, #20847.307) for 2 minutes. 
Blot absorbent filter paper was pre-soaked in 1 x Trans-Blot® Turbo™ Transfer Buffer (BioRad, 
UK, #10026938) prior to transfer. Filter paper, PVDF membrane, and polyacrylamide gel were 
stacked and rolled to expel air bubbles and topped with a final layer of filter paper.  
The stack was loaded into the Trans-Blot® Turbo™ Transfer System Cassette (Bio-Rad, UK) and 
run at 1.5 V for 10 minutes.  
Membranes were blocked with 4% bovine serum albumin (BSA) (First Link UK Ltd., UK, #41-
00-450) and 0.1% sodium azide (Sigma-Aldrich®, UK, #S2002) in tris-buffered saline with 
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Tween® (TBS-T, [200 nM Trizma base, 1.37 M NaCl, 0.1% Tween-20]) for 1 hour at room 
temperature. 
Membranes were then incubated overnight in primary antibody solution diluted in 4% BSA 
and 0.1% sodium azide in TBS-T solution at 4 °C on a tube roller. Western blots were probed 
with anti-GAPDH (Abcam, UK, #ab9485) or anti--tubulin (Sigma-Aldrich®, UK, #T6199) 
antibodies for loading control validation. After primary antibody incubation, membranes were 
washed 3 x for 5 minutes in TBS-T. 
Horseradish peroxidase-conjugated secondary antibodies were added to TBS-T. Membranes 
were then incubated with secondary antibodies diluted in TBS-T for one hour at room 
temperature on a tube roller.  
After secondary antibody incubation, membranes were washed 5 x in TBS-T before being 
developed. Proteins on the membranes were stained using an enhanced chemiluminescence 
system with the Pierce™ ECL Western Blotting Substrate Kit (Fisher Scientific, UK, #32106).  
1 ml Detection Reagent 1 Peroxide Solution was added to 1 ml Detection Reagent 2 Luminol 
Enhancer Solution and mixed. Membranes were placed protein-side-down in the solution for 
5 minutes. Membranes were blotted dry and mounted into a film cassette.  
The chemiluminescence was visualised by exposure of the membrane to Amersham Hyperfilm 
ECL (Fisher Scientific, UK, #GZ28906837) and developed in the dark room using the XOGRAPH 
Compact X4 Film Processor (Xograph, UK,). 
Bound antibodies were stripped from the membrane by incubating in stripping buffer (TBS-T 
containing 2% SDS) and 1% β-mercaptoethanol (Sigma-Aldrich™, UK, #M6250) for 20 minutes 
at 80 °C. Membranes were stripped again in stripping buffer without β-mercaptoethanol for 
20 minutes at 80 °C. Membranes were then blocked again in 4% BSA (First Link UK Ltd., UK, 
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#41-00-450) and 0.1% sodium azide (Sigma-Aldrich®, UK, #S2002) in TBS-T for 1 hour at room 
temperature and primary antibodies were added as previously mentioned.  
2.19. Platelet spreading 
Coverslips (VWR, USA, #631-0150) were prepared in advance of the experiment. Coverslips 
were washed in 100% EtOH (VWR, USA, #208121.33) and rinsed with 1 x PBS, (Sigma-Aldrich™, 
UK, #P4417) prior to coating in fibrinogen. 400 µl of fibrinogen (Enzyme Research 
Laboratories, UK, #FIB3) at 100 µg/ml was added to wells and incubated overnight at 4 °C. The 
fibrinogen solution was removed and replaced with 300 µl 5 mg/ml denatured BSA (First Link 
UK Ltd., UK, #41-00-450) in PBS and incubated for 1 hour at room temperature. Coverslips 
were washed 3 x in PBS. 
The washed platelet solution was diluted to 2 ×107 /ml with modified Tyrode’s buffer and left 
to rest for 20–30 minutes before spreading. 300 µl of washed platelets at 2 ×107 /ml were 
added to the coverslips and allowed to spread for 45 minutes in a 37 °C incubator. The platelet 
solution was then removed, and coverslips washed 1 x in PBS. The platelets were fixed in  
500 µl 10% Formalin (Sigma-Aldrich®, UK, #HT5012-1CS) for 10 minutes then washed 3 x in 
PBS. 
2.19.1. Immunofluorescence 
The coverslips were incubated for 5 minutes with 0.1% triton x 100 (Sigma-Aldrich®, UK, 
#9002-93-1) and washed 3 x with PBS. Coverslips were then incubated for 20–30 minutes in 
blocking buffer (1% BSA [First Link UK Ltd., UK, #41-00-450], 5% goat serum [Gibco™, USA, 
#11530526] in PBS). -tubulin fibres were stained with primary antibody, Monoclonal Anti-α-
Tubulin DM1A (Sigma-Aldrich®, UK, #T6199), which was added (1:200) to blocking buffer and 
coverslips placed platelet-side down on para-film in 50 µl of mix for 1 hour; other antibodies 
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were also used. Coverslips were washed 3 x in PBS and secondary antibodies Alexa Fluor® 647 
goat anti-mouse IgG (1:250) (Thermo Fisher Scientific™, USA, #A21235) and Alexa Fluor® 488- 
conjugated Phalloidin (1:300) (Thermo Fisher Scientific™, USA, #A12379) to stain actin fibres, 
were added to blocking buffer and coverslips were incubated in 50 µl in the dark, on para-film 
for 1 hour. Coverslips were then washed with PBS, dipped in H2O, blotted dry and mounted 
on glass microscope slides (Fisher Scientific, USA, #7101) with Hydromount (Scientific 
Laboratory Supplies Ltd., UK, #NAT1324). Before imaging, the slides were left to dry overnight 
in the dark at 4 °C. 
2.19.2. Confocal microscopy 
All images were taken using a DM IRE2 Leica Inverted microscope, SP2 confocal system 
running Leica Confocal Software Version 2.61 Build 1537. Spread platelet confocal imaging 
was performed using the 488 nm line of an Argon-Ion laser 457-514 nM (to image Alexa Fluor® 
488) and the 633 nm line of an Helium-Neon-Ion laser (to image Alexa Fluor® 647) with an HCX 
Plan Apo lbd.BL 63x NA 1.4, Leica objective. Z-stacks were taken and the average intensity 
projection of 10 fields of view per control or patient were analysed. The detection parameters 
(gain and offset settings) were kept the same each time to enable comparisons from multiple 
patients who attended clinic on different days. Images were analysed and quantified using 
ImageJ and other image analysis sotfware and will be discussed in Chapter 3.  
2.20. Transfection of Human umbilical vein endothelial cells 
Human umbilical vein endothelial cells (HUVECs) were plated on 0.1% gelatine coated, 6 cm 
plates at a density of 360,000 cells per plate. 1M HCl acid washed coverslips (VWR, USA, #631-
0150) were added to plates in which the cells were being used for immunofluorescence.  
The cells were then kept in a 37 °C incubator for 24 hours prior to transfection. M199 media 
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with the following supplements was used for HUVEC culture: 2.2 g/l NaHCO3, 0.1 g/l L-
Glutamine, 90 mg/l heparin, 10% (v:v) Foetal Calf Serum (FCS) (Sigma-Aldrich®, UK, C8056) 
and 0.1% (v:v) Bovine Brain Extract as per Maciag et al. (Sigma-Aldrich®, UK, B3635-1G) 
(Maciag et al., 1979). As the HUVECs were being used for siRNA-mediated knockdown of 
genes, they were cultured in media without antibiotics. All cell culture work was carried out 
in a laminar flow cell culture hood.  
Silencer® Select siRNAs (Thermo Fisher Scientific™, USA, #4427037) were made up to 20 μM 
using H2O. The Gibco™ Opti-MEM™ reduced serum media (Thermo Fisher Scientific™, USA, 
#31985070) was filtered before use using a sterile 50 ml syringe and Ministart filter (Sigma-
Aldrich®, UK, 16534K). 3.6 μl of each siRNA was mixed with 241.4 μl Opti-MEM™ and 
incubated at room temperature for 10 minutes. The Lipofectamine™ mix was then made with 
4.3 μl Lipofectamine™ RNAiMAX Transfection Reagent (Thermo Fisher Scientific™, USA, 
#13778075) and 38.7 μl Opti-MEM™ and incubated at room temperature for 10 minutes.  
43 μl of the Lipofectamine™ mix was then added to the siRNA mix and incubated at room 
temperature for 20 minutes. Before the transfection, the cells were removed from the 
incubator and the media was aspirated. The cells were washed 2x with 5 ml sterile PBS (Sigma-
Aldrich™, UK, 806552-500ML). 1152 μl Opti-MEM™ was added to each plate being transfected 
along with 288 μl of the siRNA mix added dropwise around the plate. The plates were gently 
rocked and incubated at 37 °C for 4 hours to allow transfection. After 4 hours, the plates were 
removed from the incubator and the Opti-MEM™ and siRNA mix was aspirated from the plates 
and replaced with 4 ml pre-warmed M199 media. The cells were then left in 37 °C incubator 
for 48 hours before harvesting.  
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To harvest the cells, plates were removed from the incubator and washed 2x in 5 ml sterile 
PBS. A further 1 ml PBS was then added to the plate to aid the scraping. Cells were forcefully 
scraped from the plate surface using a cell scraper and removed to a 1.5 ml Eppendorf.  
The cells were then centrifuged at 5,000 rpm for 3 minutes. If the cells were being used for 
RNA extraction, the pellets were frozen at -80 °C; if the cells were being used for protein 
assays, 40 μl of ice-cold lysis buffer was added and a Bradford assay was carried out as 
previously described. 
2.21. RNA extraction from cultured cells 
RNA was extracted from harvested HUVECs according to the Macherey-Nagel NucleoSpin® 
RNA kit and protocol (Macherey-Nagel, Germany, 740955.50). After cells were collected by 
centrifugation, they were lysed by the addition of 350 μl Buffer RA1 and 3.5 μl β-
mercaptoethanol (Sigma-Aldrich™, UK, #M6250) and vortexed vigorously. The lysate was then 
filtered through the NucleoSpin® Filter in a collection tube and centrifuged for 1 minute at 
11,000 g. The NucleoSpin® Filters were discarded and 350 μl of 70% ethanol was added to the 
lysate and mixed by pipetting up and down. The lysate was then added to a NucleoSpin® RNA 
Column in a collection tube and centrifuged for 30 seconds at 11,000 g. The Column was then 
placed into a new collection tube. 350 μl Membrane Desalting Buffer was added to the column 
and centrifuged for 1 minute at 11,000 g to dry the membrane. The DNA was then digested 
by addition of 95 μl rDNase reaction mixture to the centre of the membrane and incubated at 
RT for 15 minutes. The DNase reaction mixture was made from 10 μl reconstituted rDNase to 




3x washes were then carried out on the column membrane. 200 μl Buffer RAW2 was added 
to the column and centrifuged for 3 seconds at 11,000 g; the column was then added to a new 
collection tube. 600 μl Buffer RA3 was then added to the column and centrifuged for 30 
seconds at 11,000 g. The flow-through was discarded and the column was placed back into 
the collection tube. 250 μl Buffer RA3 was added to the Column and centrifuged for 2 minutes 
at 11,000 g to dry the membrane. The column was then placed into a 1.5 ml nuclease-free 
collection tube. The RNA was eluted by the addition of 60 μl RNase-free H2O and centrifuged 
for 1 minute at 11,000 g.  
To check the RNA had not degraded, 5 μl RNA was mixed with 1 μl Gel Loading Dye (New 
England BioLabs, USA, B7024S). This was run on a 1% Ultrapure™ Agarose gel (Invitrogen™, 
UK, #16500-500) in TAE (40 mM Tris, 20mM acetic acid and 1 mM EDTA) for 20 minutes at  
120 V. Intact RNA showed 2 bands representing the 28S and 18S ribosomal subunits.  
RNA Quantification was carried out using the Qubit® 3.0 Fluorometer (Life Technologies™, 
USA) following the standard protocols and using the Qubit® reagents using the same method 
as outlined in Section 2.13. The Qubit® RNA (HS) Assay kit (Thermo Fisher Scientific, UK, 

























Patient platelet phenotyping 




3. Patient platelet phenotyping using a platelet spreading assay   
3.1. Summary of background to this results chapter 
Understanding a patient’s phenotype is the first crucial step to the correct diagnosis of any 
disorder including inherited bleeding disorders.  
The GAPP study started recruiting patients in 2008, aiming to completely categorise a patient’s 
disease with extensive phenotyping by platelet function testing and other functional assays 
along with genotyping by using next-generation sequencing technologies. Recruitment to the 
study is based on a diagnosis of clinical bleeding using the International Society of Thrombosis 
and Haemostasis (ISTH) bleeding assessment tool (BAT) (not used in assessing children) by a 
consultant haematologist following normal coagulation factor tests and the absence of any 
evidence that suggests an acquired platelet disorder. The study has recruited over 1000 
patients in 10 years from multiple collaborating haematology referral centres across the UK 
and Ireland. As a multicentre study, this incorporates 28 centres across the countries 
accounting for over two-thirds of the total number of Haemophilia Comprehensive care 
centres within the UK and Ireland. Given the likely genetic component of such disorders, the 
recruited patients have potentially affected family members, so relatives are also recruited 
where possible.  
There is still a lack of a single and robust platelet function test, therefore diagnosis can be 
difficult in this patient group. To add to the difficulty, the phenotypes of patients with 
inherited bleeding disorders can be very heterogeneous despite similar genetic aetiologies. 
This variable phenotypic presentation suggests that patients should be individually considered 
instead of carrying out one particular method of diagnosis for all.  
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Over 10 years of research by the GAPP study has identified that a large proportion of patients 
(≈ 60%) who are still classified as having ‘no identifiable platelet defect’ despite the extensive 
phenotyping carried out and the patients’ lifelong bleeding histories. This illustrates the limit 
of particular assays to detect some platelet function disorders and fails to address those 
individuals who may have other causes for their unexplained bleeding. Therefore, in this 
thesis, an alternative platelet phenotyping assay was selected and tested on a selection of 
patients to address those patients who required further investigation into their bleeding 
disorder. The platelet spreading assay is a well-known assay carried out in a research setting, 
however its clinical application and full utility for a complete diagnosis is currently unknown.  
3.2. Aims of this chapter  
This chapter aims to build upon previous work carried out in the GAPP study to completely 
categorise the patients’ bleeding phenotype. The overarching aim is to combine platelet 
spreading with other methods of platelet function testing to try and elucidate platelet function 
disorders that are not identified by other methods of testing.  
3.3. GAPP Study workflow and platelet spreading assay 
The GAPP study workflow for patients is followed as outlined in Chapter 1, Figure 1.5. Patients 
were successfully recruited and blood was sent to the GAPP study laboratory team in the 
Birmingham Platelet Group. A full blood count was initially carried out followed by platelet 
function analysis. For patients with a platelet count in PRP above 1x108 /ml, lumi-
aggregometry was carried out as the standard platelet function test. The GAPP study has 
previously trialled different methods for phenotyping including Multiplate® multiple electrode 
aggregometry and the Total Thrombus-Formation Analysis System. In addition, platelet 
spreading was recently introduced (for the work of this thesis) as a method of phenotyping. 
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These further assays were carried out alongside the gold-standard method of platelet function 
testing- lumi-aggregometry. Following phenotyping, in selected cases, genotyping was carried 
out by WES. All genetic variants were then classified and confirmed by PCR amplification 
followed by Sanger sequencing.  
Over the last 15 years, investigation into platelets’ adhesion and activation mechanisms has 
been carried out by many research groups. However, it was over 40 years ago that the reports 
of activated platelet conformational change was recorded cinematographically (Allen et al., 
1979). Allen et al. recorded the conformational change of platelets from disks to spheres with 
the extension and retraction of ‘pseudopodia’ using a sensitive differential interference 
contrast (DIC) microscope (Allen et al., 1979). Furthermore, Savage et al. showed that the 
mechanisms of platelet adhesion with agonists fibrinogen and vWF are complementary to 
achieve stable adhesion (Savage et al., 1996). Later on, it was shown that there are a multitude 
of molecules all acting in synergy to facilitate platelet adhesion spreading upon activation 
(Obergfell et al., 2002, Wonerow et al., 2003, Inoue et al., 2006). Along with these 
investigations it was also shown that deficiencies in platelet membrane glycoproteins can 
cause defects in platelet spreading (Nieuwenhuis et al., 1986). Platelet spreading assays have 
the ability to highlight platelet structural defects that may not be picked up by other assays. 
This could include defects of the platelet cytoskeleton which may be detrimental to the 
function of platelets, reducing their ability to spread and hence cause prolonged bleeding 
times in affected individuals.  
Since work on this thesis began, patients from the GAPP study cohort have been included in 
further phenotyping in the form of a platelet spreading assay. The normal GAPP study 
workflow was followed along with the standard laboratory procedures for these patients. The 
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platelet spreading assay works to activate platelets with variable activators e.g. fibrinogen, 
which are coated on glass coverslips. When washed platelets are added to the coverslips, they 
transform from their resting state to an activated state, stimulating the formation of extended 
filopodia and lamellipodia resulting in an increase in the platelets’ surface area (Aslan et al., 
2012). The morphology of the platelets can then be studied using fluorescence microscopy to 
identify possible platelet abnormalities (the full method is outlined in Chapter 2, Section 
2.19.).  
3.4. Patient cohort demographics studied in this thesis 
To date, 71 patients from the GAPP study cohort have been included for phenotyping using 
the platelet spreading assay. This number includes patients from paediatric and adult referral 
centres, therefore there is a considerable age range between the patients in the cohort. 
Patient ages were available for 64 individuals in this study. The average age of the 64 
individuals was 32 years, ranging from the youngest at 2 years to the oldest at 80 years (Figure 
3.1.). 32 healthy volunteer controls were also included in the platelet spreading assay 
however, ages were not available for this anonymised control group.  
The gender of the patients was known for all 71 individuals. The cohort consisted of 77% 
female (n = 55) and 23% male (n = 16) participants (Figure 3.1.). Again, the genders of the 
control group of healthy volunteers was not made available.  
The ethnicities of the patients in this cohort were not provided by the referring clinicians. 
The patient group included 7 families with more than one affected family member (n = 22) 
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Figure 3.1. Basic patient demographics. (A) Age distribution showing the median and 
interquartile range of 64 individuals for which this data was available. (B) Gender 
distribution for 71 patients (16 males and 55 females).  
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3.5. Patient bleeding symptoms 
Patient bleeding histories were taken by the referring clinician during the initial examination 
and the BAT score questionnaire was carried out in most cases (The ISTH-BAT questionnaire 
can be found in the Appendix, Figure A). BAT score data was available for 48 of 71 patients (40 
female and 8 male). The BAT scores differed between female and male patients which can be 
seen in Figure 3.2. The median BAT score for the group was 10; the median for female 
participants was 11 whereas the median for male participants was 5. This reflects the 
difference in haemostatic challenges faced between females and males. The BAT score uses 
questions about the different patients’ bleeding symptoms. The patients mostly suffered from 
minor bleeding symptoms including but not limited to epistaxis, cutaneous bleeding and 
bleeding following surgery. Some patients also suffered from more severe bleeding symptoms 
including post-partum haemorrhage and gastrointestinal bleeding. Bleeding symptoms and 
clinical findings of the participants can be seen in Table 3.1.  
Bleeding symptom data was only available for 60 patients. The most common bleeding 
symptoms were related to cutaneous bleeding with 65% (39 of 60) stating that they had 
previously suffered from the symptom. Bleeding from minor wounds and oral cavity bleeding 
were the next most common symptoms, present in 58% (35 of 60) and 51% (31 of 60) of 
patients respectively. Of the 48 female patients with known symptoms, 75% (36 of 48) had 
suffered from menorrhagia. Several female patients had also suffered from post-partum 
haemorrhage following childbirth, 27% (13 of 48), however this number does not reflect the 
number of women who have undergone pregnancy. In most cases this bleeding was resolved 

































Figure 3.2: BAT score values in patients who were included in the platelet spreading 
assay. The values for the total cohort (48 patients) as well as separate plots for females   
(n = 40) and males (n = 8) is included. The boxes show the median, 25% percentile and 






Table 3.1. Phenotypes of all patients recruited to the GAPP study that were included in platelet spreading investigations. F, Female; M, 
Male; MPV, Mean Platelet Volume; BAT Score, Bleeding Assessment Tool; n/a, not applicable e.g. for children.  
Code of bleeding:  
1 – Epistaxis, 2 – Cutaneous bleeding, 3 – Petechiae, 4 – Oral cavity bleeding, 5 – Bleeding from minor wounds, 6 – bleeding after tooth 
extraction, 7- Bleeding after surgery, 8 – Hematuria, 9 – GI bleeding, 10 – Ovulation bleeding, 11 – Menorrhagia, 12 – Post-partum 
haemorrhage, 13 – Muscle haematomas.   
Individual/ 
Family 
Age Gender Platelet 
count (x109/l) 
MPV (fL) secretion (nmol 
ATP/1x108 platelets) 




1 72 F 270 10.1 0.57 Mild secretion defect 13 1, 2, 6, 11 
2 32 F 74 14.3 0.89 Thrombocytopenia/delayed 
secretion 
17 1, 2, 4, 5, 6, 10, 
11, 12 
3 80 F 204 11.6 0.74 No defect 9 1, 2, 4, 5 
4 ― F 281 10.5 1.06 No defect 10 2, 4, 5, 6, 11 
5 ― F 265 10.7 1.25 No defect 13 1, 2, 4, 6, 8, 11, 
12 
6 ― F 371 10.5 0.86 No defect 5 4, 5, 10, 11 
7 ― F 281 11.3 1.04 No defect 12 2, 4, 5, 6, 8, 11 
8 38 F 273 9.8 0.99 No defect 13 1, 2, 4, 5, 11, 12 
9 58 F 286 10.4 2.46 No defect 9 2, 4, 5, 11, 12 
10 54 F 238 10.9 0.92 No defect 7 2, 4, 5, 11, 12 
11 ― F 270 12 1.11 Medication - Clopidogrel 7 2, 4, 8, 9, 11 
12 ― F 352 10.5 1.27 No defect 15 4, 5, 7, 9, 11 
13 38 F 101 12.1 ― Thrombocytopenia ― 1, 2 
14 32 F 292 9.7 0.61 COX defect ― 1, 2, 3, 7, 8, 12 
15 40 F 232 10.2 0.77 No defect 6 2, 7, 11 
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16 I 39 F 221 13.9 ― ITP/Thrombocytopenia/ no 
defect 
― ― 
16 II 54 M 107 ― ― ITP/very weak evidence of 
secondary defect 
― ― 
16 III 28 M 85 ― ― Thrombocytopenia/ 
secondary defect 
― ― 
17 54 F 239 11.9 0.74 No defect 16 2, 7, 8, 10, 11 
18 49 F 289 11.5 1.3 No defect 6 4, 5, 11 
19 77 F 417 10.1 1.72 No defect 23 1, 2, 4, 6, 8, 11, 
12 
20 45 F 375 10 1.22 Gi defect 8 4, 5, 6, 7 
21 20 F 182 12.5 2.35 Gi defect 5 4, 5, 11 
22 72 M 113 10.2 1.05 Thrombocytopenia/signalling 
defect 
13 1, 7, 8, 9 
23 32 F 122 ― 1.47 Thrombocytopenia/Gi defect 10 2, 4, 11, 12 
24 49 F 195 10.4 0.63 No defect 14 2, 4, 5, 7, 11, 12 
25 52 F ― ― 1.49 No defect 16 1, 4, 5, 11, 12 
26 20 F ― ― ― No defect ― 2, 5, 9 
27 I 79 F 105 14.5 0.73 Thrombocytopenia/mild 
qualitative defect 
9 1, 2, 7 
27 II 53 F 172 13.9 1.03 Thrombocytopenia 7 11, 12 
27 III 35 F 107 15.1 0.26 Thrombocytopenia/Gq 
signalling defect 
4 1, 9, 
28 36 F 221 11.7 1.13 No defect 13 1, 2, 4, 11, 12 
29 57 F 261 9.3 0.82 COX defect 12 1, 5, 6, 11 
30 22 F 291 11 1.03 No defect 13 2, 4, 8, 11 
31 I 30 M 59 13 ― Thrombocytopenia/ 
secondary defect 
8 1, 4, 5, 7 
31 II 52 M 183 12 0.66 No defect 2 5, 7 
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32 6 M 140 10.1 0.53 Thrombocytopenia/mild 
secretion defect 
n/a 2, 3 
33 12 F 355 8.3 0.75 No defect n/a ― 
34 68 F 43 ― 0.34 Congenital 
thrombocytopenia 
― ― 
35 ― F 241 9 0.11 Secretion defect 14 1, 4, 5, 6, 11 
36 43 F 331 10 0.56 Gi Defect 14 1, 2, 4, 5, 11, 12 
37 29 F 225 12.1 0.55 No Defect 10 2, 4, 5, 11, 12 
38 76 M 120 14.6 0.97 Thrombocytopenia with COX 
defect 
3 ― 
39 I 23 M 428 9.1 0.39 Secretion Defect 10 1, 4, 5, 7, 9 
39 II 20 F 345 10.2 0.59 COX Defect 12 2, 4, 5, 6, 11 
39 III 17 M 329 10.9 0.25 Secretion defect 3 2, 5 
40 6 F 230 10.3 0.39 Secretion defect n/a 1, 2 
41 18 F 235 11 0.97 No defect 11 1, 2, 4, 5, 10, 11 
42 53 F 298 11.1 0.72 No defect 13 2, 4, 7, 9, 11 
43 78 M 91 ― 0.45 Thrombocytopenia 2 2, 4 
44 I 7 F 287 8.8 1.01 No defect n/a ― 
44 II 73 F 150 10.5 0.5 Secretion defect ― ― 
45 6 M 104 8.9 0.87 Thrombocytopenia n/a 2, 3 
46 7 F 170 10.5 0.55 Secretion defect n/a ― 
47 27 F 256 11.1 0.75 No defect 9 1, 2, 5, 6, 7, 11 
48 60 F 184 12.2 0.46 COX defect 21 1, 2, 4, 5, 7, 9, 10, 
11, 13 
49 23 F 204 12.4 0.59 Secretion defect 8 1, 2, 5, 10, 11 
50 22 F 323 11.5 0.66 No defect 3 1, 5, 6 
51 19 F 269 11.9 0.73 No defect 16 1, 2, 4, 5, 7, 9, 11 
52 26 F 295 10.8 0.89 No defect 3 1, 5 





54 50 M 270 11.4 1.39 Gi Defect ― 1 
55 I 9 F 329 12.1 ― No defect n/a 1, 2, 5, 7 
55 II 10 F 246 11.3 ― No defect n/a 2, 5 
55 III 30 F 259 11.7 ― No defect ― 11 
55 IV 33 M 196 12.6 ― No defect 0 n/a 
56 I ― F 93 12.8 2.14 No defect 0 n/a 
56 II 8 M 126 11 1.68 No defect n/a 1 
56 III 2 M 217 8.8 0.91 No defect n/a 1 
56 IV 10 M 196 9.4 1.81 No defect n/a 1 
56 V 12 F 185 10.8 1.38 No defect n/a 1, 2, 5, 10, 11 
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3.6. Platelet counts and morphology 
Platelet counts and mean platelet volumes were measured using the Sysmex XN-1000™ as 
outlined in Chapter 2, Section 2.6. The platelet counts were available for 69 of the 71 patients 
and are shown in Table 3.1. Platelet counts were also determined for the control group of 32 
individuals and shown in Table 3.2.  
The platelet counts for both groups were compared and analysed (Figure 3.3.). The overall 
platelet counts in the patient group ranged from 43–428 ×109 /l. The average platelet count in 
this group of individuals was 225 ×109/l (n = 67). 17 patients had a platelet count of  
<150 ×109/l which is below the normal range and therefore labelled as thrombocytopenia. The 
overall platelet counts in the control group ranged from 67–420 ×109/l. The average platelet 
count in this group was 217 ×109/l (n = 32). After carrying out an unpaired t test to compare 
both groups, the data was not found to be significantly different.  
The mean platelet volume (MPV) was measured for 64 patients (Figure 3.3.). The normal range 
is between 9.2–12.9 fL. The MPV in the patient group ranged from 8.3–15.1 fL. The average 
MPV for the patient group was 11.17 fL. The MPV for the control group was measured in 31 
individuals and it ranged from 8.9–13.4 fL. The average measurement was 11.54 fL. Again, an 
unpaired t test was carried out to compare the two groups. The data was not found to be 






Table 3.2. Platelet counts, MPVs and platelet secretion values for health volunteer control 
group. 
Individual Platelet count (x109 /l) MPV (fL) Secretion (nmol ATP /1x108 platelets) 
1 258 11.7 1.47 
2 67 12.1 0.6 
3 288 12.2 1.29 
4 285 12.4 1.24 
5 234 12.3 1.06 
6 281 12.2 1.77 
7 175 12.5 ― 
8 187 10.1 1.04 
9 72 10.1 ― 
10 235 12.5 1.24 
11 246 11.9 1.68 
12 218 12.7 1.6 
13 233 12.3 1.29 
14 ― ― 1.31 
15 260 11.5 1.64 
16 259 12 1.76 
17 227 12.6 1.37 
18 165 12.1 1.03 
19 194 12.5 1.11 
20 204 10.6 0.46 
21 205 10.7 0.57 
22 202 13.4 0.62 
23 247 11.9 0.64 
24 277 10.5 0.55 
25 126 11.1 1.45 
26 322 8.9 0.99 
27 185 10.7 0.93 
28 187 11.9 0.76 
29 297 10.3 0.74 
30 248 10.7 1.21 
31 420 9.6 ― 



































































Figure 3.3. Platelet parameters for Patient and Control groups. (A) Platelet counts in whole 
blood showing the median and interquartile range for 31 control individuals and 67 patients 
for which this data was available. (B) MPV measurements are also shown as the median and 
interquartile range for 31 control individuals and 64 patients.  
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3.7. Platelet function testing 
Platelet function testing by lumi-aggregometry was carried out on all 71 patients as per the 
standard GAPP study workflow.  
3.7.1. Light transmission aggregometry 
LTA remains the reference method for the investigation of platelet function. This has been the 
main method for over 50 years as the core principles of the original method have not changed 
(Born, 1962). Platelets’ aggregation responses to agonists which target different receptors and 
signalling pathways are measured. By interpreting the aggregation traces, certain disorders of 
specific pathways can be identified.  
The main findings of the 71 patients’ LTA can be seen in Figure 3.4. The largest group with 54% 
(38/71) of the patients had no platelet defect identified by LTA. This further reiterated the 
need for other, perhaps more specialised, platelet function tests and this is where the platelet 
spreading assay comes into play. The second largest group, with 16% (11 of 71) of patients, 
was the group where more than one platelet defect was identified in the patients. This mostly 
included patients with thrombocytopenia as well as a secondary defect for example, secretion 
or signalling defects. Platelet secretion defects were the third largest group with 10% (7 of 71) 
of patients affected. These are patients with secretion values below the cut-off value of 0.65 
nmol ATP/1x108 platelets. Secretion data for the control group was also measured. The 
patients’ median secretion value was 0.87 nmol ATP/1x108 platelets. For the controls, the 
median secretion was 1.2 nmol ATP/1x108 platelets. An unpaired t test suggested that the 
values between the control group and the patient group were in fact, statistically significant 























7 Secretion defect (10%)
5 Thrombocytopenia (7.14%)
4 COX defect (5.71%)
4 Gi defect (5.71%)
1 Medication (1.43%)
11 Multiple defects (15.71%)
38 No defect (54.29%)
Figure 3.4. Main findings of 71 patients recruited to the GAPP study following 
phenotyping by Lumi-aggregometry. The largest group of patients were classified as ‘no 
defect’ due to normal platelet aggregation and secretion.  
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groups as all the patients have a history of bleeding symptoms. Furthermore, 10% of the 
patient group were diagnosed with secretion disorders alone. A graph showing the patient 
and control secretion values can be seen in Figure 3.5.  
A few examples of representative patient aggregation traces are displayed in Figure 3.6. 
Patient 39.1 was diagnosed with a secretion defect due to abnormal aggregation in response 
to all doses of ADP and low doses of collagen and PAR-1 peptide along with a secretion value 
that was markedly reduced (0.39 nmol ATP/ 1 × 109). Patient 39.2 was diagnosed with a COX 
pathway defect due to abnormal aggregation responses to all concentrations of arachidonic 
acid and collagen but normal responses to U46619 and collagen-related peptide. However, 
aspirin intake can replicate the same defective responses observed. Therefore, it is necessary 
to proceed with caution and perhaps repeat this patient’s aggregometry and explain the 
important of refraining from taking any NSAIDs up to 10 days prior to the blood test 
appointment.   
In addition, it was established after the blood was taken that Patient 11 was taking clopidogrel 
at the time of testing which therefore meant that the results of her LTA phenotyping could 
not be analysed. Clopidogrel usually mimics a platelet function defect (P2Y12 receptor defect) 
when the patient’s blood is tested by LTA. In order to repeat the test, she would need to stop 
























Figure 3.5. Platelet secretion for Patient and Control groups. Platelet secretion was 
measured in both groups in PRP during lumi-aggregometry with PRP. The median and 
interquartile ranges for 29 control individuals and 61 patients are shown for which this 
data was available. A value of p = 0.049 after an unpaired t test indicated that the 




















Figure 3.6. Representative lumi-aggregometry traces from patients recruited to the 
GAPP study who were also included in the trialling of the platelet spreading assay. (A) 
Patient 39.1 (represented by the blue line) shows reversed aggregation in response to ADP 
10 µM, reduced aggregation and secretion (black line) to collagen 3 µg/ml and absent 
aggregation in response to 30 µM PAR-1 peptide however full aggregation in response to 
100 µM PAR-1 peptide. These results might indicate a secretion defect. (B) Patient 39.2 
(represented by the blue line) showed absent aggregation in response to high 
concentrations of arachidonic acid with no secretion (black line) and reduced aggregation 
and secretion in response to collagen. However, normal responses to U46619 and 
collagen-related peptide were observed. These findings suggest a defect in the 
cyclooxygenase pathway or aspirin intake.  
 
ADP 10 µM Collagen 3 µg/ml PAR-1 Peptide 100 µM 
A 
B 
AA 1.5 mM Collagen 10 µg/ml 
 





The Total Thrombus-formation Analysis System (T-TAS) is an automated system that measures 
thrombus formation using microchip flow chambers. The flow chambers are pre-coated with 
specific agonists to mimic in vivo conditions; in addition, the flow pressure and conditions can 
be altered to mimic the different, variable flows within a vessel. T-TAS analysis was only 
carried out in a small number of patients in this study due to this being a trial of the T-TAS 
assay. Representative T-TAS graphs, showing normal platelet thrombus formation are shown 
in Figure 3.7. 
The T-TAS is advantageous for use in this platelet testing setting as only small volumes of blood 
are required for the assay to be carried out successfully. Furthermore, the assay is relatively 
quick, easy to carry out, and can yield results approximately 10 minutes after the assay was 
started. The patient blood tested using the T-TAS provided useful insights into the possible 
future uses for the assay (Al Ghaithi et al., 2019). Analysis by T-TAS carried out in the 
laboratory demonstrated good agreement with LTA when the techniques were carried out in 
parallel (Al Ghaithi et al., 2019). This suggests that from our work, the T-TAS assay could be 
useful to screen patients with potential platelet function defects (Al Ghaithi et al., 2019). This 
could save time to diagnosis and would not require a skilled worker to perform, unlike LTA. It 
was also concluded that the T-TAS could be valuable for patients who are prescribed 
antithrombotic therapies and require regular monitoring. In addition to this, we showed the 
utility of the T-TAS in animal models of disease. The properties of the assay make it very 
suitable for quickly testing animal blood and has the potential to reduce the numbers of 






Figure 3.7. Measurements of thrombus formation using the T-TAS PL- chip with whole 
blood samples from patients. Thrombus formation in this assay was measured under low 
shear rates (1000 s-1) to generate representative flow pressure curves. The time taken for the 
growing thrombus to fully occlude channels within the chip was measured. This process 
involved platelet adhesion, aggregation and granule secretion and hence thrombus growth. 
(A and B) show normal flow pressure curves and the time taken to reach full occlusion. The 
green lines show the actual reading of flow pressure, the red lines show the calculated mean 
measurement of the flow pressure. 





























3.8. Platelet spreading  
During the process of platelet activation, platelets extend filopodia and develop lamellipodia. 
This cytoskeletal reorganisation results in a dramatic increase in the platelet size; platelets 
transition to a spherical shape to adhere to exposed or damaged subendothelial matrix of the 
blood vessels (Cuenca-Zamora et al., 2019). Here, they can become fully spread and aggregate 
to promote the cessation of unwanted blood flow. These platelet morphological changes can 
be affected if the individual has abnormal platelet function or is prescribed medication which 
can alter this. Furthermore, defects in components of the platelet cytoskeleton are not 
routinely screened following the diagnosis of a suspected platelet function defect. However, 
platelet spreading in vitro is a widely used laboratory technique to assess platelets and platelet 
proteins using blood from animal models and specific antibodies.  
During this workflow, platelets were spread on fibrinogen for 45 minutes as described in 
Chapter 2, Section 2.19. The platelets could then be stained with fluorescent antibodies to 
actin and tubulin. The platelets can then be visualised using confocal microscopy and images 
can be acquired for later analysis. 
3.8.1. Healthy donor volunteer spreading 
Healthy donor volunteer spreading was also analysed in order to provide values for 
comparison with the patients’ platelet spreading values. Confocal microscopy derived images 



























Figure 3.8. Wide field images of healthy volunteer control platelets after spreading on 
fibrinogen for 45 minutes. (A) Actin fluorescence. (B) Tubulin fluorescence. (C) Merged 
actin (green) and tubulin (blue) fluorescence. (D) Reflectance image. Scale bar, 10 µm.  
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3.8.2. Patient spreading 
Example confocal microscopy derived images of a selection of patient platelet spreading can 
be seen in Figure 3.9. In these images, platelets were spread on fibrinogen for 45 minutes. 
Images were acquired at 63× magnification and at 2× and 8× zoom from the wide field image 
in order to view the actin and tubulin staining clearly. The patient platelets imaged, suffered 
from bleeding symptoms from an early age and currently have no diagnosis as the results from 














Figure 3.9. Confocal microscopy images of spread platelets after spreading on fibrinogen 
for 45 minutes from patient 55.1. Left column shows a 2× zoom and the right column shows 
a 8× zoom of a different field of view. (A) Actin fluorescence. (B) Tubulin fluorescence. (C) 
Merged actin (green) and tubulin (red) fluorescence. (D) Reflectance image.  







3.9. Methods of image analysis 
The field of image analysis in science is evolving rapidly and there are now many methods of 
analysis employed by different groups. There are also a multitude of software and 
programming techniques available in order to analyse the highly detailed and complex images 
we are able to acquire using microscopy techniques.  
3.9.1. ImageJ 
ImageJ is a Java-based image processing and analysis program. ImageJ was originally 
developed by Wayne Rasband at the National Institute of Health and the Laboratory for 
Optical and Computational Instrumentation (LOCI, University of Wisconsin-Madison); it was 
first released in 1997. ImageJ was designed with an open architecture intended to make 
adding, upgrading or exchanging components easy. This provides ImageJ with extensibility 
therefore allowing custom plugins to be used or developed to deliver solutions to the image 
processing and analysis challenges that are routinely encountered by biologists.  
ImageJ can calculate area and pixel value statistics of user-defined regions and create 
intensity-thresholded areas. In addition, the software can measure microscopic distances, and 
angles between points in an image. The image processing functions include, but are not 
limited to: convolution, sharpening, smoothing, and standard geometric transformations. In 
this thesis, ImageJ was used to create average intensity projection images from Z-stacks or 
multiple images taken at different focal distances in a user-defined field of view. This provided 
a composite image with a greater depth of field useful for analysing 3D cells such as platelets. 
ImageJ is an invaluable tool for the scientific community, and with the powerful tools it 
employs, users can develop and share reproducible analysis workflows.  
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3.9.2. KNIME and Ilastik 
KNIME, the Konstanz Information Miner, is a free and open-source data platform that was 
created in 2004. The first version of KNIME was released in 2006 and was used by several 
pharmaceutical companies. By 2012, KNIME was being used by thousands of operators across 
sectors not only within life sciences but by banks, publishers, manufacturers and other 
industries. KNIME’s popularity grew as the platform allows users to create bespoke data flows, 
selectively perform some or all chosen analysis steps and then later, view the results, models 
and interactive views. KNIME allows for the processing of large data volumes that are only 
limited by the available hard disk space. The results of the KNIME workflows can then be used 
to create report templates and can be exported to document formats. Furthermore, KNIME’s 
additional plugins allow for the integration of methods for text mining and more importantly, 
image mining. The KNIME Image Processing Plugin allows for many methods of analysis to be 
run on images. Feature vectors identified can then be used to apply machine learning methods 
in order to train and apply a classifier.  
This method of image analysis for this thesis was performed using a custom segmentation 
algorithm developed by Jeremy Pike at the University of Birmingham using the software, 
Ilastik. Ilastik is an open source software for image classification and segmentation. Ilastik 
allows users to annotate images with set classes using a mouse interface. This can be done to 
a number of images in order to train the machine learning component. Overall, this improves 
accuracy of the segmentation when the classifier is applied to further images or large sets of 
images as in this case. Commercial and open source platforms mentioned, focus on the ease-
of-use value and broad coverage of image processing tasks.  
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3.10. High-throughput platelet spreading analysis 
The large-scale platelet spreading data set for this high-throughput analysis was generated by 
taking images from 10 representative fields of view from each slide of patients’ or healthy 
volunteer controls’ spread platelets. The spread platelet samples were stained with phalloidin 
conjugated to a fluorophore to detect actin filaments in the cells. Probing for this cytoskeletal 
component allows for the accurate delineation of platelet morphology within the high 
signal/noise ratio that is required for successful image capture and robust high-throughput 
analysis.  
In order to isolate fluorophore signal from the background signal, a pixel classifier within Ilastik 
was trained on a smaller subset of the images (Sommer et al., 2011). Once the training set was 
defined, this was run on the whole dataset within KNIME to produce binary images; any gaps 
smaller than 10 µm2 within the binary images were automatically filled (Berthold et al., 2009). 
Inevitably, within the images, some platelets were overlapping or touching; as such, these 
cells were separated by manually placing identifying points within the centre of each one using 
the interactive annotator node within the KNIME workflow (Khan et al., 2019a). Following this, 
the previously identified points were used as seeds for a watershed transformation of the 
binary images, subsequently producing a labelled segmentation of individual platelets within 
the image (Khan et al., 2019a). Any image artefacts smaller than 1 µm2 were removed from 
the image.  
Once all the images had been analysed by the semi-automated workflow, the labelled 
segments within each image and for each patient could be processed by the programs. 
Measurements for each platelet were collected, which included, the area covered by the 
platelet (A), the perimeter of the spread platelet (P), platelet circularity (C) and mean 
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fluorescent intensity. Circularity is defined as the equation below and has a maximum value 






3.10.1. High-throughput platelet spreading analysis results  
Platelet area and circularity data measurements are displayed in Figure 3.10. This data was 
plotted using with the median of the data set generated for each patient or control and 
visualised using PlotsOfData which is a freely available, open-source, web app (Postma and 
Goedhart, 2019).  
Firstly, it was necessary to calculate a normal range for spread platelet area and circularity as 
this is a novel assay and normal range values for these measurements had not been 
established. Control data set was used to establish the normal range from the healthy 
volunteer control samples that were treated identically, which included travelling with the 
patient blood from the referring centre to the laboratory in Birmingham where the assay took 
place. To create the normal range, the median value of the data set for each control was 
calculated; the 95% confidence interval (CI) was also calculated. The normal range was 
calculated by adding or subtracting the CI from the median value. The normal range for spread 
area and circularity were calculated. Platelet data which lay outside of the normal range were 
flagged as outliers which potentially have a function defect or a defect affecting the platelets’ 























Figure 3.10. Area and circularity data generated from automated image analysis were 
classified according to the control range established by spreading data from healthy 
control volunteers (n = 5). Patient samples with medians and confidence intervals outside 
of the control range, shown by the red box, were classified as positive hits (blue boxes) for 
either a defect in platelet area or circularity, while samples which fall outside both normal 
ranges were classified as double positives (orange boxes). 
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Overall, platelet spreading abnormalities were counted in 58% (32 of 55) of the patients tested 
(Khan et al., 2019a). This consisted of patient platelets displaying defects in area only  
(n = 6), circularity only (n = 13), defects in both platelet area and circularity (n = 13) and no 
platelet defects observed (n = 23). The defect distribution of patients double positive for area 
and circularity abnormalities is displayed in Figure 3.11. Abnormal platelet area and circularity 
are synonymous with small, round and unspread platelets and consequently, these ‘double 
hits’ (defects in both area and circularity) were considered a strong indication of 
morphological spreading defects. Representative platelet spreading immunofluorescent and 
segmentation images of selected patients with clear defects in platelet area or circularity can 
be seen in Figure 3.12. 
This data was then correlated with the results of the other platelet function tests that were 
also carried out on the patient blood as part of the normal GAPP study workflow, namely lumi-
aggregometry. Spreading defects were found in 9 patients where we also found defects in 
platelet aggregation (Gi defects, n = 3; secretion defects, n = 5; COX defect, n = 1). 
Interestingly, 50% (16 of 32) of the patients who were positive for a spreading defect, did not 
demonstrate a platelet function defect during testing by lumi-aggregometry. This suggests 
that platelet defects have been identified by the platelet spreading assay that would not have 
been identified by lumi-aggregometry. In addition, these 16 patients all presented with high 
ISTH-BAT scores, with a median score of 11. 63% (10 of 16) patients had double positive hits 
for defects in platelet area and circularity. This data confirms that a platelet spreading assay 
could supplement the results obtained from lumi-aggregometry by confirming aggregation 
defects as well as highlighting platelet morphological abnormalities that would not be 












Figure 3.11. Pie chart indicating the defect distribution of patients double positive for 














Figure 3.12. Representative platelet spreading immunofluorescent and segmentation 
images of selected patients with clear defects in platelet area or circularity. The top 
panels show a representative healthy volunteer control. Lower panels show patient 
images; patients 21 and 3 were found to have a platelet area spreading defect only, 
patients 13 and 31.1 had a platelet spreading circularity defect only, and patients 16.1 and 






















From the work in this results chapter, high-throughput platelet spreading analysis was 
systematically correlated with clinical and lumi-aggregometry data to determine its utility and 
usability in the investigation of suspected platelet function disorders. The data showed that 
patients positive for both area and circularity abnormalities, as well as abnormal morphology 
are both positive and negative for defects in aggregation. Furthermore, 80% of patients with 
a spreading defect, but negative for an aggregometry defect presented with a high ISTH-BAT 
bleeding score. This is of particular interest as a large number of patients positive for a platelet 
spreading defect, and with a history of excessive bleeding, are negative for an aggregation 
defect. This all suggests that applying platelet spreading as part of a platelet testing panel can 
reveal problematic platelet morphological defects that might otherwise be missed by lumi-
aggregometry alone.  
As with all studies, this study is not without some limitations. The high-throughput method of 
analysis is indeed a rapid technique to analyse a large number of images in a standardised 
manner. However, it is the method of spreading, staining and image acquisition that are the 
rate limiting steps of this assay. This brings into question whether this assay could be used in 
a routine clinical testing laboratory or whether it is to be used more as a specialised research 
tool. The spreading step requires the coating of coverslips ahead of time as well as platelet 
resting steps and spreading steps. To get to this stage can take over 2 hours of relatively hands-
on time. The staining steps again take longer than 2 hours. Lastly, the platelet image 
acquisition for this chapter was carried out by confocal microscopy. Not all centres especially 
Comprehensive Haemophilia Care Centres have confocal microscopes available with workers 
who are trained to carry out imaging on a regular basis; in addition, imaging to gain a set 
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number of representative fields of view also takes a long time. These are all limitations of this 
assay. The assay could be streamlined in order to speed up the process and it would benefit 
from set methods and standardised concentrations and values. An alternate method of 
imaging would also be beneficial to this assay for example, an EVOS® cell imaging system that 
could carry out the imaging independently. If we could then apply the images to the high-
throughput workflow again mostly automatically, this would speed up the process of 
obtaining results and would require fewer hours of work by an individual in the laboratory and 
which might not have to be limited to a specialist site.  
Another major drawback of this assay is that it cannot diagnose specific disorders in isolation. 
This is because there are many platelet or bleeding disorders that could present with 
abnormalities in platelet spreading. If we could use patient blood from a group of patients 
who had already been diagnosed with a specific platelet function/bleeding disorder affecting 
platelet structure, it would be interesting to carry out the platelet spreading assay with their 
blood to observe if the area and/or circularity values would vary from a group of patients 
previously diagnosed with a different platelet disorder that affects platelet structure. If the 
values were to vary, it would be interesting to try to diagnose patients using these values. 
Furthermore, the diagnosis could be validated with genetic testing; this would allow for the 
assay to become more standardized and the normal range values to be improved.  
A major advantage is that the platelet spreading assay is not dependent on platelet count 
unlike the aggregation-based platelet function tests (Dawood et al., 2007, Dawood et al., 
2012). The spreading assay could therefore be a useful tool to test for platelet function defects 
in patients with thrombocytopenia as only a small number of platelets are required.   
120 
 
All that being said, this assay is a useful screen for patients with a strong bleeding history from 
which conventional assays have not been able to diagnose the disorder. The potential utility 
of this assay in a patient population is only just being explored but the platelet spreading assay 
approach described in this chapter validates the use of high-throughput platelet spreading 
analysis as an analytical tool to improve and enhance existing platelet function testing. As high 
content imaging approaches become increasingly accessible and commonplace, applying 
high-throughput platelet spreading strategies is likely to be an invaluable addition to the 
current range of platelet function tests.  
3.12. Future work 
Platelet counts, platelet parameters, and platelet sizes vary within an individual and there are 
many methods available to calculate all of these measures in patient blood samples. However, 
we do not currently have a robust assay that assesses activated platelet morphology. It would 
be interesting to combine other platelet parameters with the findings from the platelet 
spreading assay across a larger cohort of patients. If there were any correlations between 
platelet data and spreading data, we could characterise these disorders to hopefully provide 
the patients with a diagnosis for their previously undiagnosed platelet or bleeding disorder. In 
addition, it can be difficult to determine potential secondary defects in patients who are 
affected by bleeding symptoms. For example, if a patient was suspected to have a secondary 
qualitative defect, transmission electron microscopy could be carried out to confirm the 
presence or absence of alpha or dense granule deficiencies.  
If the platelet spreading assay was to become more common place as a research tool or in 
specialist laboratories, a wider range of specialist antibodies could be investigated for use 
during the platelet staining stage. This would allow for an increased number of platelet 
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cytoskeletal components to be investigated during platelet activation and spreading. The 
semi-automated workflow could be altered for the analysis of these platelets, but the images 
could highlight aberrant proteins in patients with bleeding symptoms. 
Whilst we are making advances in the field of platelet biology and our knowledge of platelet 
function has improved dramatically in recent years, there are still patients in this cohort 
without a clinical diagnosis despite having a clinically meaningful bleeding diathesis. In order 
to fully understand and hopefully find a diagnosis for these patients, a combination of 
phenotyping and genotyping is required, especially as these patients are suspected to harbour 
















4.  Patient genotyping by whole exome sequencing 
4.1. Summary of background to this research 
The investigation into an individual’s genome and their genetics is now commonplace in 
hospitals and research centres across the world. Genetic testing has the ability to identify 
defects in chromosomes, genes or proteins. The results of a genetic test can either confirm or 
exclude a suspected genetic cause of disease, as well as helping to determine an individual’s 
chance of developing or passing on a particular condition caused by a genetic change. Genetic 
testing is always voluntary due to the sometimes complex and life changing nature of the 
results. However, positive results can lead to disease prevention, disease monitoring and 
personalised treatment options.   
Molecular genetic tests and the technology involved has rapidly progressed since the 
invention of Sanger sequencing over 40 years ago (Sanger et al., 1977). Today, a more 
contemporary version of Sanger sequencing using fluorescence and capillary array 
electrophoresis is widely used across all genetic diagnostic services. Following the 
development of next-generation sequencing technologies, there has been a shift in the usage 
of small-scale genetic sequencing applications, to larger scale studies involving whole exome 
and whole genome sequencing. This relatively new technology has led to the rapid and 
accurate ability to sequence large amounts of genetic material successfully (Ng et al., 2009, 
Ng et al., 2010, Bamshad et al., 2011).   
The increase in clinical usage of next-generation sequencing is firstly due to dramatic 
improvements in the methods. This has allowed the sequencing to be performed more quickly 
but also allowed for specialised bioinformatic analysis tools to be created and utilised. This 
has decreased the clinical time frame overall for producing high quality and quality-controlled 
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results for patients. Secondly, the costs of next-generation sequencing have decreased. The 
total cost of sequencing the first human genome by the Human Genome Project was 
estimated to be approximately $3 billion. However, the cost of sequencing a whole genome is 
now approximately $1000 (Warr et al., 2015). This cost is set to decrease even further with 
many biotechnology companies competing to improve and refine their sequencing methods 
and products for clinical and research settings.  
Such improvements have impacted the field of gene discovery in inherited bleeding and 
platelet disorders. NGS has aided in the discovery of novel, disease causing genetic variants as 
well as elucidated the genetic aetiology behind many previously known disorders (Albers et 
al., 2011, Kunishima et al., 2013, Maclachlan et al., 2017b). However, the use of genetic 
investigation is still mainly used for known diseases and well-classified disorders to confirm a 
diagnosis. The question is then whether the disease subset such as rare bleeding disorders in 
families with multiple affected family members, as well as single isolated cases would benefit 
from NGS by WES. WES and WGS could prove vital for discovering novel genetic causes of 
bleeding and in genes not previously implicated in bleeding.   
Due to limitations of platelet function testing as discussed in Chapter 3, patient genotyping is 
an ideal approach to elucidate the cause of disease in patients with clinical bleeding of 
unknown aetiology. WES and Sanger sequencing were carried out on selected patients 
previously recruited to the GAPP study. The patients were included in this group if, following 
extensive platelet function testing and a normal platelet count, the overall laboratory 
phenotype results were normal despite the patient having an extensive bleeding history.  
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4.2. Aims of this chapter 
This results chapter will aim to genotype individuals from 10 multiplex families within the 
GAPP study with bleeding of unknown cause. All individuals presented with normal platelet 
counts and normal platelet function but suffered from regular bleeding episodes. Up to two 
patients per family were sequenced by WES, to try to determine the genetic variant(s) likely 
to be causative of their disorder. The results will potentially lead to an overall diagnosis helping 
with treatment and management of the patients along with providing novel insights into 
bleeding physiology and potential novel genetic variants, with which to carry out further 
functional investigation and characterisation. 
4.3. Patient characteristics  
During the course of the research for this thesis, 18 patients with normal platelets but 
extensive bleeding histories were included in the WES cohort. This included 10 families with 
multiple affected members. Patients were consented to take part in the GAPP study that 
included consent regarding genetic research (Consent form, appendices Figure B).  
The patients’ ages were available for 16 of 18 patients, which included both paediatric and 
adult patients. The average age of the patients was 27 years, ranging from the youngest at 7 
years to the oldest at 60 years (Figure 4.1). Gender information was available for all patients. 
The cohort consisted of 72% (n = 13) females and 28% (n = 5) males (Figure 4.1). The ethnicities 
























Figure 4.1. Demographics of GAPP study patients who underwent WES. (A) Ages of 
patients shown with median (27 years) and interquartile range. (B) Percentages of 
male and female participants.  
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The clinical findings and bleeding symptoms for all 18 patients can be seen in Table 4.1. 
Platelet count data from whole blood was only available for 5 of 18 patients as some patients 
were recruited before the acquisition of the Sysmex™ Haematology Analyser. Before this, 
platelet counts were measured in PRP. The platelet counts for all patients, regardless of the 
method of measurement, were within the normal range (150–400 × 109/l).  MPV values were 
measured to examine platelet size and were available for 16 of 18 patients. MPV values ranged 
from 8 fL to 12.4 fL; the median value for the group was 9.8 fL. In addition, platelet secretion 
was measured by lumi-aggregometry (as described in Chapter 2, Section 2.9) and is available 
for 11 of 18 patients, the values are displayed in Table 4.1 where available.  
The bleeding symptoms of the patients was provided by the referring clinicians for 17 of 18 
patients. The patients all reported suffering from similar ‘minor’ bleeding symptoms. These 
were classed as minor, which can still have a big impact on the patients’ lives, especially for 
the paediatric cases. The most common bleeding symptom reported was easy cutaneous 
bleeding with 71% (12 of 17) of patients reporting this occurring on a regular basis. Secondly, 
47% (8 of 17) of patients reported suffering from frequent epistaxis (> 5 /year lasting more 
than 10 minutes); the third most common symptom reported was excessive bleeding from 
minor wounds with 41% (7 of 17) of patients reported regularly suffering from this. 
Furthermore, 58% (7 of 12) of females reported from suffering from menorrhagia often 
requiring time off work/school and requiring treatment by antifibrinolytics, hormonal therapy 





Table 4.1. Phenotypes of all patients recruited to the GAPP study that were included in 
WES investigations. The normal ranges for platelet count, MPV and secretion are shown in 
square brackets. F, Female; M, Male; MPV, Mean Platelet Volume  
Code of bleeding phenotype:  
1 – Epistaxis, 2 – Cutaneous bleeding, 3 – Petechiae, 4 – Oral cavity bleeding, 5 – Bleeding 
from minor wounds, 6 – bleeding after tooth extraction, 7 – Bleeding after surgery, 8 – 
Hematuria, 9 – GI bleeding, 10 – Ovulation bleeding, 11 – Menorrhagia, 12 – Post-partum 


























No defect 6, 7, 11 




No defect 2, 9, 13 






Family 3 II:3 9 F 329 12.1 3.88 No defect 1, 2, 5, 7 
Family 3 II:2 10 F 246 11.3 2.4 No defect 2, 5 




No defect 2, 11 




No defect 2, 4, 6, 11 
Family 5 I:1 54 M 
   
No defect 6, 7 
Family 5 II:1 12 M 
   
No defect 1, 2, 5, 13 
Family 6 II:1 10 M 
 
8.1 2.5 No defect 3 
Family 6 II:2 14 F 
 
7.8 2.01 No defect 1, 7 
Family 7 I:2 
 
F 284 12.1 0.72 No defect 1, 2, 4, 5, 
11 
Family 7 II:1 
 
F 191 12.3 0.98 No defect 1, 2, 4, 5, 
11,12 
Family 8 II:1 12 F 221 12.4 2.74 No defect 1, 2, 5 
Family 9 II:2 38 F 
 
9.2 1.8 No defect 2, 4, 6, 11, 
12 
Family 10 II:2 9 M 
 
8.9 1.59 No defect 1, 2 
Family 10 II:3 7 F 
 
8.8 1.91 No defect 1, 5 
Family 10 II:1 17 F 
 
8.9 1.96 No defect 2, 6, 7, 11 
129 
 
4.4. Whole exome sequencing overview 
Whole exome sequencing was performed on 18 individuals following the GAPP phenotyping 
and platelet function testing workflow, as detailed in Chapter 1 and outlined in Figure 1.5. This 
included lumi-aggregometry in response to a panel of platelet agonists at multiple 
concentrations that are summarised in Chapter 2, Table 2.1. 
4.4.1.  Development of a bioinformatic pipeline 
A bioinformatic pipeline was developed by the GAPP study team in order to determine 
plausible candidate variants from the WES data (Figure 4.2). Sequence alignment, annotation 
and variant calling were carried out by collaborators in London/Birmingham in addition to 
describing variant novelty and frequency of the variants in multiple populations. Bioinformatic 
analysis was then carried out on the variant called files (VCFs) for each individual.  
Bioinformatic analysis was carried out by two different criteria (arms) performed in parallel. 
One arm compared variants to a gene panel created for this patient group which included 
genes implicated in platelet formation, count and function in addition to all genes implicated 
in blood coagulation, fibrinolysis and endothelial cell function. The second arm was used to 
analyse novel variants only.  
Firstly, variants were compared to the gene panel of 856 known platelet, bleeding, coagulation 
and endothelial genes, a list developed by me and mentioned below. These variants were then 
filtered on the basis of exclusion criteria created by the GAPP study. A rare variant cut off value 
was used of 0.01 or 1% of the population as variants with a minor allele frequency (MAF) of < 
0.01 were given priority when being analysed. Synonymous changes, not modifying the amino 
acid sequence, were excluded. Splice site variants occurring > 4 base pairs away from the exon 
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boundary were also filtered out. Where more than one affected family member was analysed 






Whole Exome Sequencing 
Filtered against database of 856 genes known or 
predicted to be associated with platelet count/ 
function, coagulation or endothelial cell function 
  
  
Alignment to hg19 
Novelty determined by comparison of variants against 
EVS 
1000 genomes 
GAPP database of over 800 whole exomes 
dbSNP135 
Exome aggregation consortium dataset of 61,486 unrelated individuals 
Exclude variants with: 
MAF≥ 0.01, 
≥1% frequency in GAPP database  
Synonymous changes 
Splice site variants occurring > 4 base pairs away from the exon 
Not shared in additional affected family members 
  
Remove all non-novel variants 
  
  
Predict pathogenicity using: 
PolyPhen2, Provean, SIFT, Mutation Taster, mRNA expression levels 
Candidate gene defects 
Removal of variants with non-significant changes; 
Synonymous changes 
Splice site variants > 4 base pairs away from the exon 
  
Compare to whole exomes from other affected 
family members. 
Exclude all non-shared variants 
Variant classification 
  
Figure 4.2. Bioinformatic pipeline for the analysis of WES data.  
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The second arm of analysis excluded all non-novel variants. Novelty was determined by 
comparison of the variants against multiple databases including EVS (Exome Variant Server), 
1000 Genomes database, dbSNP135 (Single Nucleotide Polymorphism database) and ExAC 
(Exome Aggregation Consortium). Again, synonymous changes, not modifying the amino acid 
sequence, were also excluded. Splice site variants occurring > 4 base pairs away from the exon 
boundary were also filtered out. The remaining variants were compared to those from other 
affected family members and non-shared variants were excluded.  
The remaining variants from both arms of analysis in the bioinformatic pipeline were further 
analysed by the same method. In silico pathogenicity prediction tools and software were 
employed. Individual tools are outlined and described in Chapter 2, Section 2.14.1. Variants 
that were predicted to alter the coding sequence and hence alter the length of the sequence 
for example, insertions, deletions and nonsense variants were analysed by MutationTaster 
(Schwarz et al., 2014). Single nucleotide variants that lead to missense variants were analysed 
by PolyPhen-2, Provean, SIFT and MutationTaster. Due to differences within the prediction 
tools, the pathogenicity prediction of certain variants was not always in agreement across all 
the tools used. This added difficulty to the classification of variants in the bioinformatic 
pipeline but is in keeping with previous studies (Leo et al., 2015, Richards et al., 2015). If 2 or 
more of the pathogenicity prediction tools suggested that a variant be pathogenic, the variant 
was taken forward for further analysis. 
4.4.2. Development of inherited bleeding related gene panel 
In order to create the gene panel used in the bioinformatic pipeline, genes were collected 
from a number of different sources and collated. Genes were collected from other previously 
used panels in the GAPP study such as the genes implicated in thrombocytopenia (Johnson et 
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al., 2016b). All genes implicated in coagulation and fibrinolysis-related genes were identified 
through previously published literature and findings, animal models and experts in their field. 
An endothelial-related genes list was obtained from Professor Roy Bicknell (Institute of 
Cardiovascular Sciences, Birmingham) in addition to literature searches/publications on 
expression data. The final gene panel contained 856 genes; these can be seen in Table A of 
the Appendices.   
4.4.3. Analysis of candidate variants 
The candidate gene variants that resulted from the bioinformatic pipeline analysis were then 
classified (outlined in Chapter 2, Section 2.14.2). This is one of the most challenging and 
complex tasks in the genetics field as for most novel variants, the true pathogenicity is 
unknown. It is also difficult to classify variants that have limited evidence and likely with novel 
variants. The ACMG guidelines were followed as recommended which provided a framework 
for evidence assessment for variants and is the current gold standard of variant interpretation 
(Richards et al., 2015). The 28 criteria that assess evidence from population data, functional 
data and allelic data to computational predictions are strictly defined and all assigned a code. 
The codes are weighted (stand-alone, very strong, strong, moderate or supporting) and 
assigned significance (benign or pathogenic). These evidence codes can be combined to 
produce a classification (pathogenic, likely pathogenic, variant of uncertain significance, likely 
benign, or benign) of the variant in question. If a variant does not have enough evidence to 
produce a classification, or the lines of evidence are contradictory, then the variant is classified 
as a variant of ‘uncertain significance’. This is the most common classification amongst novel 
variants. Overall, the ACMG guidelines provided much needed consistency when classifying 
variant pathogenicity.  
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4.5. Results of WES in families with multiple affected individuals 
4.5.1.  Family 1 
A mother and son were recruited to the GAPP study with a lifelong bleeding tendency, 
including post traumatic bleeding, but presented with normal PRP counts (4.2 × 108 /ml and  
3 × 108 /ml respectively) and normal platelet function. The family pedigree displays an 
autosomal dominant inheritance for the bleeding phenotype (Figure 4.3). An extensive 
bleeding history throughout the pedigree was evident. The index case, a male III:2, suffered 
from haemarthroses, soft tissue, and muscle bleeding in childhood and a spontaneous rectal 
sheath hematoma in 2006. His mother, II:4, was admitted to hospital for 3 weeks after wisdom 
teeth extraction, suffered bleeding after tonsillectomy and menorrhagia requiring 
hysterectomy further complicated by bleeding. His grandmother, I:1, suffered from bleeding 
after dental extraction requiring transfusion, easy bruising, and postpartum haemorrhage. His 
maternal aunt, II:3, suffered from extensive bleeding which resorted in a nephrectomy 
following a road-traffic accident. His maternal uncle II:2, lost an eye as a result of traumatic 
bleeding as a child, as well as suffering from bleeding post dental extraction and soft tissue 
and muscle haematomas. To study these patients further, a forward genetic approach by WES 
was implemented to establish the disease aetiology where laboratory testing had not 
identified a defect in platelet function. 
The patients were evaluated and a clinical history was taken including bleeding scores using 
the International Society of Haemostasis and Thrombosis bleeding assessment tool (Lowe et 
al., 2013). Blood was taken from both patients, the PRP was isolated and platelet function was 
tested using lumi-aggregometry and a range of concentrations of agonists. Platelet ATP 
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secretion from dense granules was also measured using the luciferase assay (Dawood et al., 
2012).  
Patients’ platelet aggregation traces showed normal responses to all the concentrations of 
agonists that were tested (Figure 4.4). Normal platelet granule secretion values were also 
observed in both patients in response to all agonists. Therefore, no defect in platelet 
aggregation or secretion was detected in either patient. Factor IX genetics were also normal; 
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Figure 4.3. Family 1 Pedigree. This shows a dominant form of inherited bleeding. Pedigree 
shows affected individuals as shaded symbols and asterisks (*) indicate patients (II:4 and III:2) 



















Figure 4.4. Representative light transmission aggregometry traces in platelet-rich plasma. 
The level of aggregation in response to stimulation was assessed with ADP (10 µM), collagen 
(1 µg/ml), U46619 (1 µm) and PAR1 peptide (30 µM) along with a multitude of other agonists 
and concentrations as summarised and shown in Chapter 2, Table 2.1.  
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WES was performed and identified 26,125 variants in II:4 and 25,969 variants in III:2. The 
bioinformatic pipeline was used to narrow down the variants with a series of filtering steps 
displayed in Table 4.2. Following the alignment step and determining the novelty of the 
variants, they were filtered against a panel of 856 genes known or predicted to be associated 
with platelet count or function, coagulation, fibrinolysis or endothelial cell function.  
The remaining variants were then filtered by frequency; variants with a MAF of more than or 
equal to 0.01 were excluded as were any synonymous changes. Comparison of both patients 
with a MAF ≤ 0.01 reduced the number to a total of 17 sequence variants. Pathogenicity 
prediction tools (Mutation Taster, Phastcons, SIFT, Provean etc.) were then utilised and the 
variants were classified as outlined by the ACMG guidelines (Richards et al., 2015). Candidate 
sequence variants were selected and reduced based on a pathogenic prediction in at least 
three out of four of the prediction tools.  
This left remaining candidate variants in five genes: APC, PDE3A, ACE, OCLN, and THBD where 
pathogenicity prediction details are shown in Table 4.3. All previously mentioned variants 
were classified as being of ‘uncertain significance’ by the ACMG guidelines except for the 
variants in THBD which was classified as ‘pathogenic’. This classification led to further research 
into the function of the gene and the potential consequence of the THBD genetic variant. It 
was found to have been previously reported in the population, with two publications 
(Langdown et al., 2014, Dargaud et al., 2015). In both cases, the patients and their families 
suffered from similar bleeding histories as the patients in the GAPP study.  
Sanger sequencing was then performed to confirm the variants thereby ruling out the 
possibility of false-positive results of WES. Sanger sequencing confirmed that the genetic 
variant in THBD (c.1611C>A) was present in both patients (Figure 4.5.). 
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 II:4 III:2 
Total number of variants identified by WES 
 
26,125 25,969 
Total number of variants (excluding 
synonymous) with a MAF ≤ 0.01 
 
2,320 2,376 
Shared significant variants from the panel of 
platelet and endothelial cell genes with a 
MAF ≤ 0.01 
 
17 
Total number of novel variants 
 
181 152 
Total number of shared novel variants 
 
50 
Total number of shared panel genes 




(APC, PDE3A, ACE, OCLN and THBD) 
Table 4.2. Genetic variants filtered by bioinformatic pipeline. A series of filtering steps 
































































c.1611C>A p.C537* Nonsense Novel Disease 
causing 










Table 4.3. Table of candidate genes for Family 1 predicted to be pathogenic by pathogenicity prediction tools. The table shows genomic 
variation and the protein effect as well as the prevalence of the variant in the population. ACMG criteria were assigned as appropriate leading 









Figure 4.5. Sanger sequencing electropherograms confirming the c.1611 C>A change in 
(A) II:4 and (B) III:2. 
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The THBD sequence variant identified in this family encodes the protein thrombomodulin 
(c.1611C>A, p.Cys537Stop). Thrombomodulin, a glycoprotein, is expressed on the surface of 
endothelial cells and normally serves as a cofactor for thrombin (Weiler and Isermann, 2003). 
In a normal state, thrombomodulin forms a complex with thrombin reducing blood 
coagulation by the activation of protein C, therefore inactivating factors Va and VIIIa, cofactors 
highly involved in the coagulation cascade, and promoting fibrinolysis. However, the genetic 
variant in these patients leads to a stop codon in the sequence, resulting in premature 
termination of transcription and hence a truncated form of the protein. Due to the truncation, 
the protein is shed from the endothelial cell membrane into the blood plasma. The increase 
of soluble thrombomodulin promotes protein C activation and is also seen in several 
pathologic conditions associated with endothelial dysfunction (Dahlback and Villoutreix, 2005, 
Kurosawa et al., 2008). This therefore reduces thrombin generation within a potential 
thrombus, resulting in the phenotype of posttraumatic bleeding (Langdown et al., 2014). 
Furthermore, this concurs with the abnormal prothrombin consumption index observed when 
the patients were tested. This is a rare example of where a gain-of-function mutation in a 
procoagulant protein rather than platelet dysfunction, causes a bleeding disorder (Dargaud et 
al., 2015).  
The discovery of a variant in the gene encoding thrombomodulin demonstrates that the 
bioinformatic pipeline is working to be applied to other exomes in the same way. In other 
words, this is proof of principle for the method that has been developed as part of the GAPP 
study, especially in those patients with non-classic platelet disorders such as those included in 
this chapter of this thesis. As for the patients, appropriate monitoring and preventative 
measures can be taken in light of their genetic diagnosis and has already been used to cascade 
143 
 
genetic screening for further members of the extended family to aid clinical management of 
this relatively severe bleeding disorder. 
4.5.2. Family 2 
Two sisters were recruited to the GAPP study at the ages of 41 and 36 years. Both sisters 
suffered from bleeding episodes for the duration of their lifetimes. Both sisters had normal 
platelet counts in PRP (4 × 108/ml and 4.6 × 108/ml) and normal MPV values (9.2 fl and 9.9 fl). 
There is no known history of bleeding in other family members. The family pedigree can be 
seen in Figure 4.6. 
Platelet aggregation studies were performed using PRP against a wide range of agonists. All 
platelet responses were within the normal range. Platelet secretion was tested using lumi-
aggregometry that resulted in normal values for both patients. Overall, no defect in 
aggregation or secretion was detected in the two sisters however, their bleeding disorder still 
remained undiagnosed. WES was carried out with DNA from II:1 only, this was because the 
concentration of DNA from extracted from II:2 was too low to perform accurate WES despite 
efforts to concentrate the samples.  
WES followed by bioinformatic analysis revealed five potential disease-causing variants. These 
variants were in genes: EPHA4, PLA2G4C, PRKACA, PTPRF and SELPLG. The variants and their 
classifications can be seen in Table 4.4. The five variants were all classified as variants of 
‘uncertain significance’ due to the lack of evidence for both the novel and rare variants.  The 
variant in the gene SELPLG (c.245C>G, p.T82S) could be interpreted as the prime candidate for 
these patients due to its association as a ligand for P-selectin expressed on the surface of 
endothelial cells and activated platelets. However, the other variants cannot be ruled out by 
biases towards certain genes until the correct variant is proven to cause the disease.  
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Further work needs to be carried out to confirm this variant in this family however this work 























Figure 4.6. Family 2 Pedigree. Pedigree shows affected individuals as shaded symbols. Crosses 
(+) indicate patients recruited to the GAPP study and asterisks (*) indicate patients (II:1) whose 
whole exomes were sequenced.  
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Table 4.4. Table of candidate genes for Family 2 predicted to be pathogenic by pathogenicity prediction tools. The table shows genomic 
variation and the protein effect as well as the prevalence of the variant in the population. ACMG criteria were assigned as appropriate leading 















































































4.5.3. Family 3 
A young girl (index case II:3), aged four years at the time of recruitment, was referred to the 
GAPP study for further phenotyping of her undiagnosed bleeding disorder. She was referred 
due to a strong history of bleeding, highly unusual in young children. She suffered from 
frequent epistaxis, cutaneous bruising and prolonged bleeding times from minor wounds. 
However, the possibility of a bleeding disorder was raised after she bled excessively following 
an adenotonsilectomy to the extent of becoming haemodynamically unstable. She required 
further surgery, packing and received blood products and other clinical treatments.  
The index case has two sisters, one of whom was also recruited to the GAPP study (II:2) at the 
age of six years. She suffers from cutaneous bruising and prolonged bleeding times from minor 
wounds. There is no family history of bleeding apart from the mother who has always had 
heavy menstrual bleeding however never received any treatment for this. The family pedigree 
can be seen in Figure 4.7. 
The GAPP study investigative workflow was carried out on both patients (II:2 and II:3). Both 
patients had normal platelet counts (II:2, 246 × 108/l and II:3, 329 × 108/l) and normal mean 
platelet volumes (II:2, 11.3 fl and II:3, 12.1 fl). Lumi-aggregometry performed showed normal 
platelet aggregation and secretion results in both II:2 and II:3 (2.4 nmol ATP/1 × 108 platelets 
and 3.88 nmol ATP/1 × 108 platelets respectively). Normal coagulation factor screen results 
were also gathered by the referring hospital. There was no obvious platelet defect found to 
explain the participants’ bleeding history therefore WES was employed to further investigate 




























Figure 4.7. Family 3 Pedigree. Pedigree shows affected individuals as shaded symbols. Crosses 
(+) indicate patients recruited to the GAPP study and asterisks (*) indicate patients (II:2 and 




The genetic variants that resulted from sequencing and bioinformatic scrutiny were analysed. 
This resulted in nine potential disease causing genetic variants in genes: ACPT, CD109, GLIS2, 
MEAF6, PLA2G3, PPP1R14A, TARS2 classified as variants of ‘uncertain significance’, and two 
variants in TTLL10 classified as ‘likely pathogenic’. The TTLL10 variants are both frameshift 
variants (c.462delG and c.745_746insG). Table 4.5 shows the variants, their pathogenicity 
prediction results and classifications.  
The ‘likely pathogenic’ classification of the TTLL10 variants was due to the evidence collated 
for the variants. They are both frameshift variants therefore alter the length of the protein; 
they are also not present in population databases which together allows for two moderate 
evidences for pathogenicity criteria to be given. As there is more than one affected family 
member with the variants and because there is more than one line of computational evidence 
that supports a deleterious effect of the variants, two supporting lines of evidence for 
pathogenicity criteria are given. When these criteria are added together, the rules for 
combining criteria to classify sequence variants as ‘likely pathogenic’. This classification led to 
further investigations.  
Blood from the mother and father was obtained after consenting for genetic testing in order 
to strengthen the genetic analysis to show disease segregation with the genotyping. The use 
of true nuclear parent-offspring trios in genetics is highly valuable especially when assessing 
rare variants (Teo et al., 2009). DNA from I:1, I:2, II:2 and II:3 was used for Sanger sequencing 
to confirm the presence of the variants (Figure 4.8). Sanger sequencing confirmed both 
c.462delG, p.P154Rfs*38 and c.745_746insG, p.V249Gfs*57 variants were present in the 
index case, her sister (II:2) and their father (I:1). The mother was wild-type for both variants. 
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Table 4.5. Table of candidate genes for Family 3 predicted to be pathogenic by pathogenicity prediction tools. The table shows genomic 
variation and the protein effect as well as the prevalence of the variant in the population. ACMG criteria were assigned as appropriate leading 





























































































c.745_746insG p.V249Gfs*57 Frameshift 
insertion 
Not known Disease 
causing 


























Figure 4.8. Sanger sequencing electropherograms for each of the family members recruited. The 
mother (I:2) is WT. The father (I:1) and both children (II:2 and II:3) have both TTLL10 variants. c.462delG 





Ensuring a candidate genetic variant is well characterised and proven to be functionally 
disrupting is challenging. It is not yet known whether TTLL10 is the disease-causing gene in 
this family. It can be said that the variants are inherited in an autosomal dominant manner, 
but they may not necessarily be the cause of their bleeding. Furthermore, the mother does 
not have the TTLL10 variants as seen in the Sanger sequencing. This family will be discussed 
further in Chapter 5. 
4.5.4. Family 4 
A mother and her daughter were recruited to the GAPP study with a suspected bleeding 
disorder of unknown cause. The mother was 41 years old at the time of recruitment and her 
daughter was 19 years old. The mother had a lifelong history of bleeding episodes including 
heavy menstrual bleeding, epistaxis, cutaneous bruising and excessive bleeding following a 
tooth extraction. At first, a diagnosis of VWD was suspected but later this was shown to be 
incorrect. Her daughter also suffered from bleeding episodes and experienced heavy 
menstrual bleeding, bleeding after tooth extraction and excessive bleeding from wounds 
(bleeding for two days following a superficial dog bite). After examining the family history, it 
emerged that her maternal grandmother had also suffered from bleeding episodes. The family 
pedigree can be seen in Figure 4.9.   
Both mother and daughter had normal platelet counts in PRP (4.8 × 108/ml and 4.2 × 108/ml) 
and normal MPV values (8.6 fl and 9.4 fl). Platelet aggregation studies were carried out which 
showed responses within the normal range. Furthermore, secretion from dense granules was 
normal. Therefore, no defects in platelet aggregation or secretion were detected in the two 
patients. Unfortunately, the mother (II:2) died during the investigations of causes unrelated 



















Figure 4.9. Family 4 Pedigree. Pedigree shows affected individuals as shaded symbols. Crosses 
(+) indicate patients recruited to the GAPP study and asterisks (*) indicate patients (II:2 and 





WES was performed for these two patients due to the strong family history and unknown 
aetiology of their disease. WES and bioinformatic analysis led to the discovery of 11 possible 
causative variants. Variants in genes: ARRDC2, GRIN3B, GSN, ITFG1, PHF20, PIK3C2B, RAB40B, 
and ZNF749 were classified as variants of ‘unknown significance’. Variants in genes: ASTE1, 
STARD7 and TTLL10 were classified at ‘likely pathogenic’. Interestingly, we found the same 
frameshift insertion (c.745_746insG, p.V249Gfs*57) in the gene TTLL10 that was also found in 
members of Family 3. The full table of candidate variants can be seen in Table 4.6. 
4.5.5. TTLL10 variant in patients of Family 3 and 4 
TTLL10 encodes a protein, tubulin tyrosine-like ligase 10, which is able to add glycine side 
chains to tubulin as a method of post-translational modification therefore the enzyme is 
known as an elongase (Ikegami and Setou, 2009). Little is known about the physiological role 
of TTLL10 however, evidence suggests that the genetic variants my abrogate protein function. 
Investigation into whether these TTLL10 genetic variants are disease causing will be discussed 
in Chapter 5. 
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Table 4.6. Table of candidate genes for Family 4 predicted to be pathogenic by pathogenicity prediction tools. The table shows genomic 
variation and the protein effect as well as the prevalence of the variant in the population. ACMG criteria were assigned as appropriate leading 






























c.832A>T p.K278X Nonsense Novel Disease 
causing 

































































c.1066C>T p.R356* Nonsense Novel Disease 
causing 






















c.1836delT p.Y612* Nonsense 8.25 ×10-6 Disease 
causing 








4.5.6. Families 5-10 
Family 5 comprises a father and son kindred both of whom were affected by bleeding 
symptoms. The family pedigree is displayed in Figure 4.10. The father was recruited to the 
GAPP study at the age of 54 having suffered from heavy bleeding after teeth extraction, and 
rehospitalisation following both a tonsillectomy and appendectomy due to bleeding. His son, 
age 12 at the time of recruitment, suffers from bleeding episodes including: frequent 
cutaneous bleeding and epistaxis, prolonged bleeding from minor wounds and he suffers from 
haematomas in his calf muscles after trauma (playing football). As both patients had normal 
platelet function, their DNA was sent for WES. Following analysis of the variants, 14 candidate 
variants of ‘uncertain significance’ and 2 variants with the classification ‘likely pathogenic’ 
remained (Table 4.7.). One of the variants with a ‘likely pathogenic’ classification was in the 
gene ADAMTS13 which encodes a metalloproteinase enzyme that cleaves von Willebrand 
factor. However, patients previously reported with variants in ADAMTS13 usually have a 
reduced platelet count that is not seen in this family, the syndrome is also reported to be 
inherited in an autosomal recessive manner, which again is not the case for this family. This 
cause of disease has not been ruled out and further investigation is needed to find a cause of 
disease.  
Family 6 are a brother aged 10 (index case) and his older sister aged 14, who have both 
suffered from a number of bleeding symptoms since birth. The family pedigree is displayed in 
Figure 4.10. He (I:1) has suffered from petechiae and excessive bruising after vaccinations. She 
(II:2) has suffered from frequent epistaxis requiring nasal cautery and experienced bleeding 
after tonsillectomy requiring readmission to hospital. An additional older sister, not recruited 
to the GAPP study, is also affected by bleeding symptoms such as menorrhagia and 
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experienced bleeding post-surgery requiring re-suturing. Their mother and maternal 
grandmother both experienced severe menorrhagia and underwent hysterectomies aged 38 
and 33 respectively. This strong bleeding history and inheritance suggests an autosomal 
dominant disease. Both recruited individuals’ platelet function was normal therefore DNA 
from II:1 and II:2 was sent for WES. The bioinformatic analysis that followed resulted in 15 
candidate genetic variants classified as variants of ‘unknown significance’ (Table 4.7.). One of 
these variants was in the gene ACTN1 which has been shown to cause 
macrothrombocytopenia in patients with some variants however, the platelet counts and 
MPVs for these patients are within the normal ranges (Kunishima et al., 2013). Patients with 
variants in ACTN1 have also been reported without a thrombocytopenia (Gueguen et al., 
2013). This cause of bleeding cannot be confirmed at this stage and as there are 14 other 
candidate variants for this family, further investigation is needed. It would be interesting and 
beneficial to recruit their mother and older sister of the children and carry out Sanger 
sequencing to try to narrow down the list of candidate genetic variants.  
Family 7 included a mother and her daughter; the family pedigree is displayed in Figure 4.10. 
The mother (II:1) who’s age is unknown, has a strong history of bleeding including: epistaxis, 
cutaneous bleeding, bleeding from minor wounds and oral cavity bleeding. She required 
packing following the extraction of 2 teeth and blood transfusions after her 3 successful 
pregnancies. Her daughter (II:2) suffers from the same symptoms in addition to menorrhagia 
requiring antifibrinolytic therapy and also experienced post-partum haemorrhage after her 
only pregnancy. Both females’ platelets showed normal function with no explanation to their 
bleeding histories. DNA from both patients was sent for WES. 10 candidate genetic variants of 
‘uncertain significance’ remained following the bioinformatic pipeline and these can be seen 
in Table 4.7. 7 of 10 of these variants are novel, therefore the cause of disease in these patients 
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could be a novel genetic variant. This family requires further work to try to elucidate their 
cause of disease. To strengthen the genetic investigation, additional siblings/children could be 
recruited to the GAPP study.  
Family 8 comprises a family with 4 children born to a mother and father biologically related as 
first-degree cousins. The family pedigree is displayed in Figure 4.10. The eldest child, a female, 
was the only child whose whole exome was sequenced at the time of writing this thesis. The 
female (II:1), aged 12 at the time of recruitment to the GAPP study had a significant bleeding 
history including bruising, prolonged bleeding from cuts and grazes and recurrent nose bleeds. 
Her 3 brothers suffer from the same symptoms. Their father is also reported to suffer from 
bleeding episodes however; he was not available for recruitment to the GAPP study. When 
analysing the genetic variants for this female, special attention was given to any homozygous 
variants. This is because the phenomenon of consanguinity increases the level of homozygotes 
therefore 2 carriers of a recessive disorder can pass autosomal recessive disorders onto 
offspring. Heterozygous genetic variants were not excluded in the analysis of this family. 12 
variants of ‘uncertain significance’ remained after the bioinformatic pipeline and series of 
filtering steps were followed. These variants can be seen in Table 4.7. This family may have a 
novel genetic cause of their bleeding which will need further work to resolve. It is hoped that 
the DNA of the further 3 children will be investigated in the future.  
Family 9 were recruited to the GAPP study together as 2 sisters; the family pedigree is 
displayed in Figure 4.10. Patient II:1 was 44 at the age of recruitment at II:2 was 38. Both 
sisters have extensive bleeding histories including: easy bruising, excessive oral cavity 
bleeding, menorrhagia requiring hormonal and antifibrinolytic therapies and serious post-
partum haemorrhages, one of which lasted 8 weeks for II:2. Due to a lack of high quality, 
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extracted DNA from II:1, only DNA from individual II:2 was sent for WES. Following WES and 
the bioinformatic pipeline, 11 candidate genetic variants were classified as variants of 
‘unknown significance’ and can be seen in Table 4.7. Again, these individuals may have a novel 
genetic cause of their bleeding which requires further investigation. Sanger sequencing of the 
genetic variants in question for individual II:1 will help to decrease candidate variant numbers 
although WES would be ideal to strengthen the investigation.  
Family 10 are 3 siblings affected by bleeding episodes. The eldest, a female, was 17 at the age 
of recruitment to the GAPP study and her siblings were 9 (male) and 7 (female). The eldest 
sister is believed to have a different father to the younger children and is therefore biologically 
their half-sister. The family pedigree is displayed in Figure 4.10. The 17-year-old girl has 
suffered from bleeding episodes since birth inducing: easy bruising, menorrhagia treated by 
hormone therapy, tooth extractions requiring packing and at the age of 7 she suffered from 
prolonged postoperative bleeding following a tonsillectomy. Both younger children have 
suffered from easy bruising since birth and frequent epistaxis. WES was carried out on the 
DNA from all 3 children. The candidate genetic variants can be seen in Table 4.7. There are 
fewer genetic variants (4 of ‘uncertain significance’) for this family due to the filtering steps; 
only variants that are shared between all 3 individuals have been included. This family requires 
further investigation. The genetic variants may need to be re-analysed if the mother of the 
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Figure 4.10. Family pedigrees for families 5–10. (A) Pedigree for Family 5. (B) Pedigree for 
Family 6. (C) Pedigree for Family 7. (D) Pedigree for Family 8. (E) Pedigree for Family 9. (F) 
Pedigree for Family 10. +, denotes the individual has been recruited to the GAPP study; *, denotes 
that WES has been carried out; =, denotes a relationship of consanguinity.  
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Table 4.7. Tables of candidate genes for Families 5-10 predicted to be pathogenic by pathogenicity prediction tools. The table shows genomic 
variation and the protein effect as well as the prevalence of the variant in the population. ACMG criteria were assigned as appropriate leading 













PolyPhen-2 SIFT Provean ACMG criteria Classification 
ADAMTS13 
NM_139025 
c.1315G>T p.E439* Nonsense Novel Disease 
causing  






















c.18301C>T p.Q6101* Nonsense Novel Disease 
causing  
















c.407C>G p.S136* Nonsense 8.269 ×10-6 Disease 
causing  



















































































































PolyPhen-2 SIFT Provean ACMG criteria Classification 
ACTN1 
NM_001130005 
























c.485A>G p.Y162C Missense 8.276 ×10-6 Disease 
causing  












































































c.1544G>A p.G515D Missense 0.002285 Disease 
causing  





























PolyPhen-2 SIFT Provean ACMG criteria Classification 
BRD8 
NM_006696 































































































PolyPhen-2 SIFT Provean ACMG criteria Classification 
CER1 
NM_005454 
















c.4058C>G p.T1353S Missense 0.0005618 Disease 
causing  















































































































































































































PolyPhen-2 SIFT Provean ACMG criteria Classification 
MYO19 
NM_025109 





































Presented within this chapter is the identification of genetic variants in patients with inherited 
bleeding disorders and normal lumi-aggregometry by the application of WES and 
bioinformatic analysis.  
Overall, genetic variants within genes previously known to cause a bleeding phenotype were 
identified in one family (1 of 10). The majority of the other variants were missense and most 
of those were novel (not previously described in relevant databases). When considering 
pathogenicity, WES analysis revealed a positive prediction call (classification of ‘pathogenic’ 
or ‘likely pathogenic’) in 8.2% (8 of 98) of variants across all the families. 91.8% (90 of 98) of 
the variants were unknown and classified as variants of ‘uncertain significance’ due to a lack 
of evidence suggesting their pathogenicity. There were no variants where a negative 
pathogenic prediction classification was given. These figures reflect the sample of patients 
that were taken forward for WES as by only recruiting patients with an unknown aetiology of 
disease this excluded patients where a clinical diagnosis might be more obvious. This might be 
the case with, for example, the haemophilias where platelets on their own otherwise function 
normally in non-severe cases; or a thrombocytopenic cohort whereby the genetic causes are 
more well-known and therefore easier to target.  
The genetic cause of bleeding in two individuals from Family 1 recruited to the GAPP study 
has been elucidated as a genetic variant in the gene THBD using next-generation sequencing. 
The same genetic variant in THBD (c.1611C>A, p.C537*) has previously been shown to cause 
a bleeding phenotype within affected individuals. This can therefore explain the cause of 
bleeding in II:4 and III:2 and suggests that it may be a recurrent mutation in the population. In 
addition to the further reports by Dargaud et al. and Langdown et al., a recent finding has 
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shown the same mutation in an extended French pedigree and not thought to be related to 
the previous reports (personal communication, Dr Marie-Christine Alessi, Aix-Marseille 
University) (Langdown et al., 2014, Dargaud et al., 2015). Furthermore, this discovery 
highlights the importance of not restricting only platelet causes of bleeding to the 
investigation of bleeding related disorders. Here, is it shown that this is not a true platelet 
dysfunction however, a protein, thrombomodulin, involved in the coagulation cascade which 
indirectly effects thrombus formation; the mechanism of action of which can be seen in Figure 
4.11. The loss of thrombin generation is also assumed to reduce the number of activated 
platelets and the platelet-platelet positive feedback activation of surrounding platelets.  
WES in one member of Family 2 revealed multiple potential disease causing genetic variants. 
Currently, none of the variants have been proven to be the causative of the disease. Out of 
the five variants, they are all feasible candidates, but a mechanism of disease must be 
elucidated before any of them can be ruled out. EPHA4 (c.1105T>C, p.C369R) belongs to the 
ephrin receptor subfamily of the protein-tyrosine kinase family whereas PLA2G4C (c.889delC, 
p.P297Gfs*13) encodes a protein which is a member of the phospholipase A2 enzyme family 
producing precursors in the production of signalling molecules. PTPRF (c.4324C>T, p.R1442W) 
encodes a protein of the protein tyrosine phosphatase family, signalling molecules known to 
regulate a variety of cellular processes. PRKACA (c.304C>A, p.P102T) encodes one of the 
catalytic subunits of protein kinase A (PKA) that with other subunits, binds to cAMP; cAMP-
dependant phosphorylation of proteins by PKA is also important for many cellular processes 
(Turnham and Scott, 2016). Finally, SELPLG (c.245C>G, p.T82S) encodes a glycoprotein that 
functions as a high affinity counter-receptor for the cell adhesion molecules P-, E- and L-
selectin. None of the genes mentioned above have been associated with bleeding and they 
are all functionally very different. Further work must be carried out in order to narrow down 
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the variants even more. Functional work regarding novel variants can be challenging and may 
not provide the answers to the questions being asked.  
Family 3 presented with an interesting case. WES revealed variants in a number of genes 
including two frameshift variants in TTLL10 (c.462delG, p.P154Rfs*38; c.745_746insG, 
p.V249Gfs*57). Variants in other genes included: CD109 (c.763A>G, p.T255A) which encodes 
a glycosyl phophatidylinositol linked glycoprotein that localises on the surface of platelets 
activated T-cells and endothelial cells, PLA2G3 (c.592T>C, p.Y198H) which encodes a protein 
that belongs to the secreted phospholipase A2 family and PPP1R14A (c.256G>C, p.E86Q) 
which encodes a protein that belongs to the protein phosphatase 1 inhibitor family. These 
variants and the others not mentioned were all confirmed in both II:2 and II:3 by Sanger 
sequencing. The mother and father were recruited to the GAPP study and Sanger sequencing 
for the TTLL10 variants was carried out. This revealed that the mother was wild-type for both 
variants but the father as well as the two children possessed both frameshift variants. This 
added some questions as the father had not suffered from any bleeding symptoms. However, 
this is often common in males who have never been challenged with injury or surgery and 
they often present with symptoms later in life. With this family, WES sequencing could be 
carried out on the mother and father to make the genetic analysis more powerful as is known 
with parent-offspring trio investigations. There may also be more than one cause of bleeding 
within this family, the multifactorial nature of bleeding disorders is well known and other 





















Figure 4.11. A gain of function mutation in thrombomodulin causes a bleeding phenotype. 
The c.1611C>A, p.C537X variant causes thrombomodulin to be shed from the endothelial 
surface (shown by red line) leading to an increase of soluble thrombomodulin in the 
circulation. This promotes protein C activation therefore inactivating factors Va and VIIIa and 
reducing thrombin generation within a potential thrombus. A loss of thrombin formation is 




The candidate variants of Family 4 presented in a number of genes including the same 
frameshift deletion in TTLL10 (c.745_746insG, p.V249Gfs*57) as was found in Family 3. This 
was particularly interesting as both families suffered from similar bleeding symptoms, normal 
platelet counts and normal platelet function. Other genes in which variants were found were: 
GSN (c.322G>A, p.G108S) which encodes a protein that binds to the plus ends of actin 
monomers and filaments to prevent monomer exchange, PIK3C2B (c.3556G>T, p.V1186L) 
which encodes a protein that belongs to the phosphoinositide 3-kinase family involved in cell 
signalling pathways and STARD7 (c.1066C>T, p.R356X) which encodes a phospholipid transfer 
protein which promotes uptake of phosphatidylcholine by mitochondria (Yang et al., 2017, 
Kiuru et al., 2000). Variants in other genes were found and are not being excluded until a 
mechanism of disease is concluded. As the same variant was found in the same gene in two 
separate, unrelated families, further investigation into TTLL10 expression and function was 
carried out.  
The 5 further families again all present with interesting cases. Family 5, a father and son, both 
present with clinically relevant bleeding diathesis which is rarely seen in males due to the lack 
of haemostatic challenges. Family 6 present with a strong family history of bleeding going back 
3 generations with 5 affected family members. This mode of inheritance is thought to be 
autosomal dominant. Further study into this family could provide novel insights into ACTN1 
variants that here may present differently to previously reported cases (Westbury et al., 
2017). Both women of Family 7 have an extensive bleeding history that may be caused by a 
novel genetic variant. For this family, recruitment of additional unaffected family members 
would strengthen the investigation as variants not present in unaffected individuals could be 
excluded and therefore decrease the list of candidate genetic variants. Family 8, 5 children 
with bleeding episodes, also have a potential novel genetic cause of their disease. However, 
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the cause the disease could also be recessive. Children of consanguineous unions can be at 
increased risk of genetic disorders due to expression of autosomal recessive variants inherited 
from a common ancestor; first cousins share an average of 12.5% of their DNA (Wright, 1922). 
The DNA from the 4 boys will be investigated further by Sanger sequencing in this family in 
order to try to elucidate their cause of disease. Recruiting the father of the children to the 
GAPP study would also be beneficial if the confirmation of a recessively inherited disorder is 
needed.  
The women in Family 9 both suffered from life threatening post-partum haemorrhage 
however, a cause of disease has still not been established. This could be because WES was 
only completed for one of the sisters. In order to find the cause of disease, WES in the second 
sister would be ideal to study the genetics in this family. Family 10, 3 young girls are all affected 
by bleeding symptoms. WES was carried out for all the sisters, giving rise to only 4 candidate 
genetic variants. However, as the older sister is a half-sibling of the other two girls, she could 
have a different disorder to her siblings. This is unlikely but the possibility cannot be ruled out. 
Therefore, the genetic variants could be reanalysed in a way in which takes into account the 
differences in genetics. This could be achieved by keeping her genetic variants separate and 
only comparing the variants of her sisters. This would allow any variants which are not shared 
by her sisters to be identified. Further investigation is needed for all the families mentioned 
above. This is very important to provide the necessary care and preoperative preventative 
measures to benefit the health of the patients. All the families could present very interesting 
cases for the clinical and research community investigating bleeding disorders.  
Whole exome sequencing is of great value in this type of investigation but as with many 
methods, there are some drawbacks of using WES rather than WGS for this investigation. 
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Firstly, and most obviously, only the exons are sequenced which leaves intronic regions, where 
mutations can have pathogenic consequences and therefore would be unsequenced. This also 
affects possible splice site variants which may be missed or even regulatory variants deep 
within introns or promoter/enhancer regions of the genome. In addition to this, some exons 
are not detected including those buried in repeated regions towards the end of the 
chromosomes which are not normally part of exome sequencing chips. A few other genetic 
manifestations can also be missed, for example, copy number variants where they do not 
change the sequence but can increase the disease risk, and structural variants (translocations 
and inversions) where DNA can be dramatically altered. Furthermore, WES cannot assess 
neither epistatic interactions nor epigenetic changes as it only picks up DNA sequences rather 
than gene expression. These are all important considerations to remember when analysing 
genetic variants and when trying to link them to the disease state in question.  
The biggest challenge faced in this investigation is with potential non-platelet genes causing 
bleeding. These are much more difficult to investigate and often these are novel discoveries 
as with the SLFN14 variants (Fletcher et al., 2015). However, with the updated panel of non-
platelet and endothelial related genes, WES variants can now be readily screened against 
them all. As more data is accumulated about the genetics of bleeding disorders, the list of 
candidate variants for each patient will hopefully decrease. Therefore, the likelihood of finding 
a disease causing mutation will be improved with increased positive variant discovery rates 
even within this challenging area of genetic discovery. Powerful WGS will probably soon be 
used in place of WES across the field.  
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4.7. Future work 
Next generation sequencing is a very powerful tool for investigating the genetic causes of 
unexplained bleeding. It is all very well classifying potential variants and in the presence of 
well-known disease causing variants NGS and Sanger sequencing are enough to confirm the 
variant. However, when an individual has multiple possible disease causing novel variants 
these can remain ambiguous and uncertain and usually these require further investigation to 
confirm or exclude.  
As many of the genetic variants in question may have no previous associations to haemostasis 
and thrombosis, it can then be difficult to link the variant to the disease. Thus, functional work 
for each variant is challenging and time consuming often without in vitro or in vivo methods 
for investigation therefore requires work to develop, validate and improve with no reagents 
such as antibodies available. Often the best way to investigate this is overexpressing the 
dysfunctional gene in an immortalised cell line but as well as advantages, this comes with 
some disadvantages. Animal models of disease are also a strong method of investigation, but 
this is time consuming, expensive and comes with its own set of challenges namely regarding 
interspecies disparities.  
Work is still needed to functionally confirm all the variants within the 9 families investigated 
as without this, the mechanisms of their disease will remain unknown. If successful, this has 
the potential to develop our current knowledge of haemostasis mechanisms and creates 
scope for potential new therapeutics for thrombosis. Furthermore, it will allow the patients 
to have a categorised diagnosis, which is highly important for some individuals and for their 





























Determining the functional 
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5. Determining the functional effects of TTLL10 
5.1. Summary of background to this research 
Since next-generation sequencing became widely available, its usage has exponentially 
increased. Consequently, there are now growing numbers of genetic variants identified in 
individuals affected by all diseases and syndromes. Whether this is in a clinical or research 
setting, it brings with it a set of challenges. The biggest challenge researchers face in this field 
is the examination of candidate genetic variant lists in order to determine each variant’s 
functional effect, if it is unknown, and potential disease causing status.  
In the previous results chapter, Chapter 4, WES and a bleeding disorders specific bioinformatic 
pipeline identified a number of potential disease causing sequence variants in 10 unrelated 
pedigrees. These variants are potentially pathogenic and therefore causative of the bleeding 
phenotypes seen in the affected individuals. The classification of these variants has been 
based solely on computational analysis software and related algorithms and predictions. 
These software tools are highly valuable; however, the classification calls should be 
approached with caution.  Rarely, but of high importance within this field, variants have been 
incorrectly classified; this demonstrates that these programs should not be used in isolation 
(Tchernitchko et al., 2004). Misclassification of a variant could be detrimental to the health of 
the patients, cause problems from a genetic counselling perspective, as well as raising 
questions surrounding medical negligence. In clinical settings, this is an area where only highly 
trained scientists operate and where multiple clinical scientists check final results which would 
lead to a diagnosis by a practicing clinician. 
As many of the variants identified through this project, as well as similar projects, are 
potentially novel, further study of the variants is required to elucidate their functional 
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relevance and link the variation to a disease state. It has become well known that many 
disorders are not simple in their presentation. This is because there can sometimes be 
phenotypic variance in patients with the same disorder; for example, if two patients with the 
same disorder or even the same genetic variant present with very different phenotypes. It can 
be difficult to identify these from other disorders due to the differential presentation. 
However, genetic investigation, twinned with functional investigation, could provide the 
answers and hopefully link a genetic variant to a specific role. This also provides solid evidence 
for the investigation of future patients who may have slightly differing phenotypes of an 
already established disorder.  
Functional investigation can be approached using a multiplicity of techniques which all assess 
function by employing different methods. It is also important to investigate and have a sound 
understanding of the gene and protein expression in humans as well as animal models 
including mouse models, if applicable. The information gained from further investigations can 
be used to assess whether the genetic variant will detrimentally affect the protein in question 
and cause serious health problems for human patients. 
5.2. Aims of this chapter 
This chapter will follow on from work on previous results from Chapter 4 where variants from 
WES were analysed in a number of families with inherited bleeding. The aim of this chapter is 
to investigate novel genetic variants in the gene TTLL10, as a likely genetic candidate in two 
unrelated families with bleeding and to categorise the novel variants within TTLL10 focusing 
on the expression of TTLL10 protein.  
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5.3.  Patient characteristics  
Patients who are recruited to the GAPP study undergo phenotyping and genotyping with the 
aim to elucidate the cause of their previously undiagnosed cause of bleeding as outlined in 
Chapter 2, Section 2.9 and 2.14. 
5.3.1. Family 3 & 4 
A frameshift deletion (c.462delG, p.Pro155Argfs*38) and frameshift insertion (c.745_746insG, 
p.Val249Glyfs*57) were initially found in Family 3; the same frameshift insertion 
(c.745_746insG, p.Val249Glyfs*57) was found in unrelated Family 4 using WES analysis. Other 
candidate genetic variants were identified from WES in both families, though the TTLL10 
variants were the most plausible. All affected individuals had clinical bleeding symptoms of 
unknown cause after extensive phenotyping. Further members of Family 3 were recruited and 
lumi-aggregometry was carried out along with other phenotyping tests such as total 
thrombus-formation, platelet spreading and DNA was extracted for further genetic studies. 
The platelets aggregated normally in response to all agonists tested and the platelet secretion 
values were within the normal range. Sanger sequencing was carried out to verify the WES on 
all recruited family members, namely the mother, father and two of their three daughters. 
The Sanger sequencing results showed an autosomal dominant inheritance pattern. The 
mother was wild type for the TTLL10 variants; however, the father had both TTLL10 genetic 
variants (c.462delG, c.745_746insG). The two daughters recruited to the GAPP study also have 
both TTLL10 variants therefore both variants are paternally inherited and also on the same 
allele. The frequency of the variants in genetic databases is important to take into 
consideration. The frameshift deletion variant is novel, which means that is has never been 
reported before in any population. The frameshift insertion is not described as novel however, 
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it has not been found at a relatively low frequency in the Exome Aggregation Consortium 
(ExAC) database.   
5.3.2. Additional family 11 with a TTLL10 sequence variant 
Following this finding in Family 3 and 4, 95 patients previously recruited to the GAPP study, 
with normal platelet counts and with no obvious platelet dysfunction, were sequenced using 
specifically designed primers for PCR amplification of all exons of TTLL10 followed by Sanger 
sequencing.  
A missense variant was found in exon 11 of the TTLL10 gene in a female patient with a 
moderate bleeding history but normal platelet count; this was a heterozygous variant 
(c.1018C>T), resulting in an amino acid substitution (p.R340W) (Figure 5.1). This variant was 
found to be classified as a variant of ‘uncertain significance’ by the ACMG guidelines as there 
was not sufficient evidence to suggest pathogenicity, however, multiple lines of 
computational evidence suggested this prediction of pathogenicity.  
This female patient (age unknown), has suffered from lifelong bleeding tendencies. She has 
easy cutaneous bleeding, excessive bleeding from minor wounds, and suffers from 
menorrhagia. Following a tooth extraction, she bled for 7 days requiring packing and 
resuturing. She also suffered from post-partum haemorrhage following the births of both her 
children. It was noted by the referring clinician, that her grandfather also suffered from easy 
cutaneous bruising and excessive bleeding from minor wounds. The family pedigree is shown 
in Figure 5.2.  
During the investigations into her platelet function, the results from lumi-aggregometry with 
all agonists showed normal platelet responses. Platelet secretion values were also normal. 
Other investigations including a clotting factor screen as well as vWF and factor VIII genetic 
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Figure 5.1. Sanger sequencing electropherograms in Family 11. Upper panel shows the 
reference sequence and the lower panel shows the patient with a heterozygous variant, 




























Figure 5.3: Family 11 Pedigree. Pedigree shows affected individuals as shaded symbols 












5.4. TTLL10 background  
Tubulin tyrosine ligase like 10, TTLL10, had been hypothesised to be involved in the 
polyglycylation of microtubules formed from tubulin, a major component of the cytoskeleton 
in eukaryotic cells (Ikegami and Setou, 2009).  
Microtubules play an essential role in cells’ normal function, from maintenance of cell 
morphology, to cell motility and intracellular transport (Gadadhar et al., 2017a, Gadadhar et 
al., 2017b). As tubulin is present in almost all cell types, it has adapted to provide a wide 
variety of different cellular functions (Janke, 2014). Tubulin sequences are highly conserved 
across species and abnormalities in structure or function are not well tolerated and often lead 
to significant, detrimental consequences (Luduena, 2013). Tubulin heterogeneity is generated 
by the expression of different isoforms of the tubulin gene. There are nine isoforms of tubulin 
monomers in mammals; combinations of these monomers then join to form a functionally 
distinct microtubule; isoforms α- and β-tubulin are the most common (Ludueña, 1993).   
5.4.1. Microtubule post-translational modifications  
It is also known that tubulin isoforms undergo PTMs in order to interact with other 
microtubules, motor proteins and accessory proteins (Gadadhar et al., 2017a). There are many 
PTMs that occur as the general mechanism for the regulation of microtubule function 
(Gadadhar et al., 2017a, van Dijk et al., 2007, Yu et al., 2015). Classical methods of PMT include 
microtubule phosphorylation and acetylation; there are also others that have mostly been 
found to regulate tubulin monomers which include: tyrosination/detyrosination, 
polyglutamylation and polyglycylation (Janke, 2014, van Dijk et al., 2007).  
Phosphorylation of proteins is one of the most important and hence most studied form of 
PTM. Phosphorylation occurs by several kinases typically on serine 172 on β-tubulin which 
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allows for microtubules involved in the cell cycle to carry out their specialised function 
(Fourest-Lieuvin et al., 2006).  
Acetylation has been found to play a greater role in cell biology than just transcriptional 
regulation. It typically targets lysine 40 of α-tubulin which is mediated by tubulin acetyl 
transferase enzyme (αTAT1) (Friedmann et al., 2012). The acetylation can be reversed by 
either SIRT2 or a histone deacetylase (HDAC6) (Friedmann et al., 2012). Neuronal 
microtubules are highly acetylated which has been shown to be important in neuronal survival 
and maintenance of synaptic transmission; decreased levels of acetylation have been linked 
to diseases including Huntington’s disease and Charcot-Marie-Tooth syndrome (Magiera et 
al., 2018, Dompierre et al., 2007).  
Tyrosination and detyrosination occur on α-tubulin by the addition or removal of tyrosine 
which has been shown to be ATP-dependent and tubulin tyrosine ligase (TTL) mediated. 
During detyrosination, an exposed terminal glutamate residue is left, therefore altering the 
stability of the microtubule (Maruta et al., 1986). Additional amino acids can then be removed, 
altering the microtubule further. Detyrosination of microtubules is thought to be a 
consequence of stability as the exposed residues on the microtubules are targeted by certain 
motor proteins often allowing for specific cellular transport (Liao and Gundersen, 1998). These 
interactions are vital for neuronal development; as such, TTL knock-out mice die prematurely 
due to the disorganisation of neuronal networks (Erck et al., 2005). Furthermore, a loss of 
detyrosination can affect muscle tissue, in particular, the normal function of cardiomyocytes 
as the microtubule transportation can be reduced therefore affecting cardiomyocyte 
contraction (Chen et al., 2018).  
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All tubulin glutamylation and glycylation is catalysed by enzymes which form the tubulin 
tyrosine ligase-like (TTLL) family of enzymes; this is a large family of proteins all with a TTL 
homology domain (Janke et al., 2005). To date, 13 distinct types have been found in humans 
(Garnham and Roll-Mecak, 2012, Bosch Grau et al., 2017). TTLL3 and TTLL8 are initiating 
polyglycylases whereas TTLL10 is an elongating polyglycylase (Rogowski et al., 2009). 
Polyglutamylation results in the addition of glutamate residues and has been observed in 
axenomes, mitotic spindles, centrioles and neurons (Gadadhar et al., 2017a). Polyglycylation 
results in the addition of glycine residues and has also been observed in axenomes (Gadadhar 
et al., 2017a). As both of the PTMs mentioned above occur in axenomes, this suggests a role 
for these specific PTMs in regulating ciliary function (Gadadhar et al., 2017b). Ciliopathies can 
affect a wide range of biological processes which is shown by the number of diseases in which 
ciliopathies are implicated in  (Waters and Beales, 2011). 
The platelet cytoskeleton has been of great importance with regard to understanding platelet 
physiology and how it is impacted in disease states (Hartwig and DeSisto, 1991, Boyles et al., 
1985). Therefore, further investigation of TTLL10 and its involvement in the platelet 
cytoskeleton is warranted and especially in the context of the novel TTLL10 variants found in 
the GAPP patients mentioned earlier.  
5.4.2. Tubulin tyrosine ligase protein family 
The study of protein regulation by PTM led to the discovery of tubulin polyglutamylation and 
subsequent investigation of the tubulin tyrosine ligase (TTL) family of proteins (Janke et al., 
2008). The first polyglutamylase enzyme to be identified was polyglutamylase subunit 1 (PGs1) 
and further study identified another enzyme found to play a role in PTM, PGs3, which shared 
functionalities with the known protein TTL (Ersfeld et al., 1993, Janke et al., 2005). As such, 
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PGs3 is now called tubulin tyrosine ligase like-1 (TTLL1) and this finding discovered that 
polyglutamylase enzymes are members of the TTLL family (Janke et al., 2008). 
Following this finding, systematic study of the TTLL family by a number of research groups 
showed the presence of 13 TTLL proteins in mammals. These were identified from sequence 
searches based on common regions present in the proteins. All 13 proteins differ in structure 
and function, however, they were all characterised by the presence of an identical TTL core 
domain and ATP binding domain. A summary of the 13 TTLL proteins’ structure and function 
can be seen in Figure 5.3. TTLL1, 4–7, 9, 11 and 13 are glutamylases whereas, TTLL3, 8 and 10 
are glycylases (Yu et al., 2015). The TTLLs function to initiate the incorporation of a specific 
amino acid (glutamic acid or glycine) to tubulin, or to elongate the modification by adding 
further amino acids to ones already present. Lastly, the TTLL proteins have shown preferences 
as to which isoforms of tubulin they work to modify; different TTLL proteins target either α- 
or β-tubulin and some can even work to modify both isoforms (Yu et al., 2015). 
To date, despite significant progress in deciphering the tubulin code, it is not well known how 
tubulin PTMs are integrated into normal physiological processes (Yu et al., 2015). Further work 
is required to elucidate the mechanism of action of these PTMs as well as how they are 
regulated by differential expression and hence the localization of these enzymes in the human 







Enzyme Modification Tubulin type 
preference 
Initiase vs elongase 
activity 
TTL Tyrosination α Initiase 
TTLL1 Glutamylation α and β Initiase 
TTLL2 Glutamylation Unknown Unknown 
TTLL3 Glycylation α and β Initiase 
TTLL4 Glutamylation β Initiase 
TTLL5 Glutamylation α Initiase 
TTLL6 Glutamylation α Elongase 
TTLL7 Glutamylation β Initiase/Elongase 
TTLL8 Glycylation α and β Initiase 
TTLL9 Glutamylation α Elongase 
TTLL10 Glycylation α and β Elongase 
TTLL11 Glutamylation α Elongase 
TTLL12 Tyrosination Unknown Unknown 
TTLL13 Glutamylation α Elongase 
 
 
Figure 5.3. TTLL proteins (A) Schematic diagram to represent TTL and the 13 TTLL proteins. 
The core TTL domain is shared by TTL proteins (yellow rectangle) although TTL domain in 
TTLL12 is less conserved (striped yellow rectangle). It has also been shown that the ATP 
binding site (red bar) has high sequence homology between all TTLLs (van Dijk et al., 2007). 




5.4.3. Suspected function of TTLL10  
It is believed that the novel protein, polyglycylase TTLL10, could be involved in the affected 
patients’ bleeding disorder as described earlier in this thesis. As shown in Figure 5.4 A, the 
mechanism of action of the TTLL10 protein is to add glycine residues to the glycine chains 
already attached to tubulin, which is part of the PTM required for its normal function. The 
TTLL10 genetic variants reported in the 3 unrelated families could lead to a loss-of-function of 
the protein and therefore a possibility is that little to no polyglycylation would occur. This 
suggests a role for the TTLL10 gene, either in normal platelet function in a physiological 
setting, clot formation or thrombus stability.  
Previous research has shown that by introducing point mutations into the core TTL domain of 
TTLL10, this renders the protein inactive and is sufficient for the enzyme to completely lose all 
of its enzymatic activity (Rogowski et al., 2009). As 2 of the genetic variants in the patients are 
predicted to result in a truncated protein and the other results in a missense change, and 
occur before the TTL core domain, the domain essential for ATP binding and to the function 
of the protein, we can predict that function maybe affected, and hence the reasoning behind 
the possibility that these variants may cause the patients’ bleeding disorder. The positions of 
these variants are shown in Figure 5.4. B.  
However, in order to further investigate the functional consequence of the TTLL10 protein, an 
understanding of the protein expression in humans is necessary. Furthermore, to be able to 
report the effects of the PTM on tubulin microtubules, a biological model is necessary which 
takes into account the complex regulatory network of enzymes that lead to PTMs. This model 
is required to be species specific to avoid any differences in evolutionary divergent 

























Figure 5.4. Schematic diagrams showing (A) TTL proteins mechanism of action on α-
tubulin (B) the TTLL10 protein with annotated genetic variants. (A) The TTL family 
proteins catalyse adding or removing amino acids to and from tubulins; TTLL10 acts to 
elongate glycine sidechains, a polyglycylase and TTLL6 and TTLL9 act to elongate glutamic 
acid sidechains, polyglutamylases. (B) The TTLL10 protein is made up of 673 amino acids 
and contains a TTL core region from amino acid 334–513, which is highly conserved in the 
TTL protein family members. The red lines show the locations of the variants identified in 
patients of the GAPP study; the blue lines show variants that have been introduced in vitro 
and show that the enzyme activity was abrogated (Ikegami and Setou, 2009).  
E, glutamic acid; G, glycine; K, lysine; N, asparagine; R, arginine; S, serine; T, threonine; V, 




5.5. TTLL10 and other TTL family protein expression 
It is has been known since the 1960s that cells express different genes which allow them to 
develop into different cell types with specific physiological functions. It is also important to 
understand the level of protein expression within the different cell types. If protein expression 
is too high or too low for a specific cell type this can be detrimental to overall health and is a 
common cause of many disease states. In order to further understand the function of TTLL10, 
we investigated its expression within a number of tissue and cell types. To do this initially we 
used different online databases and tools. Most of these are freely available online and the 
valuable information they offer is frequently used by scientists. 
5.5.1. Open access protein expression databases for TTLL10 and other TTL 
family members 
The first version of the Human Protein Atlas (HPA) was released in 2005 when it covered 650 
protein-coding genes (Uhlen et al., 2010). Today, all of the approximately 20,000 human 
protein-coding genes have been analysed within over 40 tissue types and 60 cell lines (Uhlen 
et al., 2015). There is still some protein expression data missing and their aim is to “provide a 
finite list of human protein-coding genes and generate firm protein evidence and expression 
characteristics for all those genes” (Uhlen et al., 2015). The latest release of the HPA is 
complimented with RNA-data from the Functional Annotation of Mammalian Genomes 5 
(FANTOM5) project (http://fantom.gsc.riken.jp/). The HPA’s Tissue Atlas shows the expression 
and the localisation of proteins within tissues and organs. This is based on deep-sequencing 
of RNA (RNA-seq); there is also antibody-based protein data which provides cell-type 
specificity and the relevant abundance of the protein in the tissues. The expression of the TTL-
family of proteins in different tissues can be seen in Table 5.1. The Cell Atlas contains mRNA 
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expression profiles from a diverse set of human derived cell lines from different germ layers 
and tissues. This atlas also contains immunofluorescence images of cells detailing the 
subcellular distribution of the proteins in question. The expression of the TTL-family of 
proteins in different cell lines can be seen in Table 5.2.  
Using the data from the HPA, we were able to see which of the TTL-family of proteins was 
most highly expressed in certain tissues and cell lines. TTLL3, TTLL5 and TTLL12 were 
moderately expressed across most tissues (range 2.6–104 transcripts per million [TPM]). 
TTLL4, TTLL7 and TTLL11 were expressed at low levels across most tissues (range 0.3–46.8 
TPM). The most highly expressed protein was TTLL5 in testis tissue (104 TPM); the second 
most highly expressed protein was TTLL12 in oesophagus tissue (74.3 TPM). With regards to 
TTLL10 expression in tissues, it seems to be expressed at very low levels throughout a range 
of different tissues with its highest expression in the testis (27.9 TPM), fallopian tube (14.2 
TPM) and lung tissues (2.7 TPM). TTLL12 is highly expressed across all cell lines (range 108–
8.4 TPM) whereas TTLL3, TTLL4 and TTLL5 were lowly expressed across all cell lines (range 0.9–
35.2 TPM). TTLL10 expression was negligible in most cell lines but showed low levels of 
expression in HaCaT (human keratinocyte) cells (0.4 TPM), HEL (human erythrolukaemia) cells 
(0.4 TPM) and RPMI-8226 (human multiple myeloma) cells (0.2).  
We also used Haemosphere (https://www.haemosphere.org/) as a tool for investigating TTL 
family gene expression. Haemosphere is an online data portal where users can search for 
genes of interest, view their expression profiles within cell lines of the haematopoietic stem 
cell lineage, run differential expression analyses and handle multiple sets of genes (Choi et al., 
2019). Unlike the HPA, Haemosphere focusses only on key specific cells across normal 
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haematopoiesis; in addition, it has curated datasets which cover mouse expression 
information (de Graaf et al., 2016).    
Furthermore, the Blueprint project (http://www.blueprint-epigenome.eu/) which ran from 
October 2011 to September 2016, has provided data which has been utilised by many research 
groups across the world. This project aimed to further understand epigenetic and 
transcriptomic profiles of normal and malignant haematopoietic cells. The Blueprint 
Consortium sequenced RNA from human progenitor cell populations of the haematopoietic 
lineage (Chen et al., 2014). The expression of the TTL family of genes can be observed in Figure 
5.5. This shows that TTL, TTLL1, TTLL3, TTLL4, TTLL5, and TTLL12 are expressed in the main 
progenitor cell types of the haematopoietic cell lineage. TTLL10 is lowly expressed until the 
common lymphoid progenitor cell stage where expression increases. TTLL10 expression is also 
increased in the granulocyte-monocyte progenitor cell population; however, expression 
decreases when cells progress through to the megakaryocyte-erythroid progenitor population 
and is decreased again in megakaryocytes.  
Lastly, the human platelet proteomic database described by Burkhart et al. was scrutinised to 
assess the expression of the TTL proteins in platelets alone (Burkhart et al., 2012). The 
database showed low levels of TTLL12 protein expression in platelets. This fits with the data 
shown by the HPA as TTLL12 was the most expressed protein in both the tissue types and the 
cell lines. In addition, the TTLL12 platelet expression is also mirrored by the Blueprint data 
which shows TTLL12 expression all through the haematopoietic progenitor cells, down to 
megakaryocytes. This database aimed to provide a ‘starting point’ for platelet proteomics 
therefore not all proteins may be included; further studies have been initiated and the 
database will then be updated (Burkhart et al., 2012). 
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Table 5.1.  The Human Protein Atlas dataset showing TTL protein expression in tissue. RNA-seq tissue data is reported as mean TPM (transcripts 
per million) corresponding to mean values of different individual samples from each tissue. Colour coding is based on TPM values; white 























































Adipose tissue 1.1 3.5 0 15 4 5.2 0 4.6 0 0 1.3 4.5 11.3 
Bone marrow 1.2 1.5 0 19.7 3.6 7.4 0 0 0 0 0 0.8 16.6 
Breast 0.8 6.2 0 17 7.8 8.9 0 1.2 0 0.6 0.1 4.4 10.8 
Cerebral cortex 4.4 18.3 0 18.3 12.4 10.8 0.5 46.8 0 1.3 0 15.7 19.9 
Cervix 0.9 7.9 0 26 5 11.1 0 2.5 0 0.1 0.4 5.9 12.4 
Colon 0.7 3 0 11.2 5.4 5.7 2.8 1.9 0 0 0.1 4.2 34.9 
Oesophagus 1.3 4.5 0 11.8 7 8.7 0 3.5 0 0 0.1 7.8 74.3 
Fallopian tube 0.9 17.1 0 40.3 11.7 18.7 5.8 6.7 0 7.1 14.2 8.1 22.7 
Heart muscle 1.1 6.3 0 10.1 1.7 3.7 0 1.7 0 0 0 3.4 4.5 
Kidney 0.9 4.7 0 7.1 3.6 6.7 1 0.8 0 0.1 0.1 3 6.6 
Liver 0.3 0.8 0.1 2.6 2.2 2.1 0 0.6 0 0 0 2.8 5.7 
Lung 2.1 5.9 0 22.4 8.4 9.7 0.7 4.6 0 1.1 2.7 5.7 11.5 
Parathyroid 
gland 
1.3 9.7 0 22.3 9.5 20.4 0 6.4 0 1.5 0 9.3 10.7 
Prostate 1 8.8 0 30.1 7.7 11.3 0.1 8.9 0 0.1 0.1 7.2 23.4 
Skin 1.7 5.1 0 47.8 9.3 8.6 0 0.3 0 0 0.1 4.7 31.8 
Small intestine 0.7 2.3 0 11.7 6.1 5 1.8 1.9 0 0 0.1 2.8 25.4 
Testis 1.2 20.2 34.1 52.5 46.8 104 26 9.2 4.2 6.3 27.9 21 31.4 
Thyroid 1.5 12.6 0 20.6 5.7 13.1 0 2.7 0 0.6 0 5.8 10.8 
Urinary bladder 1.3 4.8 0 17.3 5 7.1 0 3.7 0 0 0.1 6.1 15.5 
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Table 5.2. The Human Protein Atlas dataset showing TTL protein expression in cell lines. The cell lines in the Human Protein Atlas have been 






















































ASC diff 2.2 13.8 0 12.8 5.5 7.5 0.2 1.5 0 0 0 3.7 19 
HaCaT 1.7 8 0 2.6 17.9 18.9 0 0.1 0 0 0.4 5.1 69.3 
HAP1 5 1.6 0 7 35.2 12.7 0 5.1 0 0 0 7 80 
HBEC3-KT 1.8 1.2 0 0.9 12 15.7 0 1.8 0 0 0 3.8 47.3 
HBF TERT88 6 3.4 0 2.1 22.2 28.5 0 3.6 0 0 0 4.6 8.4 
HEK 293 2.5 2.8 0.1 17.8 28.9 6.8 0 3.2 0 0 0 5.1 112.8 
HEL 2 1.7 0 12.4 17 11.4 0.1 3.6 0 0 0.4 2.3 23.8 
HeLa 2.1 0.7 0 10.4 12.3 11.6 0 3.4 0 0 0 3.5 49.9 
Hep G2 2.3 1.2 0 5.9 34.1 7.7 0 0 0 0 0 2.5 44.9 
HMC-1 1 2.1 0 20.7 11.8 10.3 0.1 0.4 0 0 0 2.6 23.2 
HUVEC 
TERT2 
3.7 9.8 0 5.2 15.8 28.3 0 2.4 0 0 0 2.3 30.5 
NB-4  1.1 4.9 0 12.3 10 8 0 0 0 0 0 2.3 41 
REH 2.7 9.9 0 6 27.9 8.8 0 0 0 0.2 0 3.1 76.9 
RPMI-8226 1 0.7 0 3.4 13.3 6.1 0 0 0 0 0.2 5.8 108 
RPTEC 
TERT1 
1.2 4.9 0 4.1 14.9 11.4 0 0.3 0 0 0 3 21.9 
SiHa 4.1 5.2 0 3.5 9.9 29.7 0 4 0 0 0 2.9 81.6 
THP-1 2.1 5.3 0 5.6 8 6.7 0 0.1 0 0 0 2.7 35.6 
TIME 3.6 9.2 0 16.3 6.6 31.6 0 0.3 0 0 0 2.6 28.7 
U-698 1.5 0.4 0 10.9 22.6 10.2 0 0.1 0 0 0 1.5 54.6 



























Figure 5.5.  In silico Blueprint River Plot for visualising the level of expression genes.  
(A) Shows each TTL family gene within the haematopoietic stem cell lineage cell types. (B) Shows and 
TTLL10 specifically. ITGA2B is also shown as a comparison due to its known high expression 
throughout the lineage. HSC, Haematopoietic stem cell; MPP, Multipotent progenitor; CLP, 
Common lymphoid progenitor; CMP; Common myeloid progenitor; GMP, Granulocyte-






5.6. Further investigation into expression levels of TTLL proteins 
Further expression analysis was carried out using platelet samples in order to elucidate the 
expression of the TTLL proteins a different stages of platelet development, as well as to see if 
there was any difference between expression in resting and activated platelets.  
5.6.1. qRT-PCR to investigate the expression of the TTLL family of genes 
A qRT-PCR panel was designed in the laboratory to examine the expression of the 13 TTLL 
proteins expressed in mammals. RNA was extracted from inducible pluripotent stem cell (iPSC) 
derived megakaryocytes; all cell culture and cell differentiation were carried out by Dr 
Abdullah Khan. These cells were harvested at differing stages of their differentiation process; 
day 1 cells (d1) are representative of haematopoietic stem cells and cells committed to 
progressing to become progenitors of megakaryocytes, day 5 cells (d5) are comprised of 
approximately 60% megakaryocytes and lastly, heparin was added to d5 cells to induce 
proplatelet formation (d5 + Hep). These latter cells were included in the investigation because 
it is not known whether TTLLs are either up- or down-regulated upon proplatelet formation.  
The results showed that the TTLL family of proteins vary in expression during the 
differentiation process and maturation of the cells (Figure 5.6 A). GAPDH was used as a 
housekeeping gene for this experiment and showed similar amplification across all 3 cell 
sample types (Figure 5.6 A). A number of the TTLLs that showed expression were taken 
forward for quantification across replicate experiments that required multiple differentiations 
of the cell types (figure 5.6. B). There was found to be a significant increase in expression of 
TTLL1 (p = 0.00181), TTLL2 (p = 0.0105), TTLL4 (p = 0.026), and TTLL10 (p = 0.0004) in the d5 + 
Hep cells when compared to d1 cells using the Delta-Delta Ct method to calculate relative fold 
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gene expression. This data shows that a number of TTLLs are upregulated during the process 



















Figure 5.6. IPSCs, megakaryocytes and proplatelets differentially express TTLL proteins 
through their development cycle. (A) Cell samples were amplified with TTLL1–13 specific 
primers or GAPDH housekeeping primers. A few of the TTLLs appeared to be upregulated 
in the more mature and proplatelet forming cells. (B) The samples from the qRT-PCR were 
taken forward and quantified using the delta-delta Ct (2ΔΔCt) method using d1 cells as 
controls to determine if there was any upregulation in TTLL expression during the process 
of platelet production. The expression of TTLL1, 2, 4, and 10 was found to be significantly 
upregulated in d5 + Hep proplatelets (* p = 0.026, ** p = 0.0105, *** p = 0.0081,  









5.7. Western blot analysis of TTLL10 
Western blots were carried out in order to determine protein expression in different cell types 
and platelet protein samples as described in Methods section 2.18.  
5.7.1. Available TTLL10 antibodies 
When planning the western blot investigations, several TTLL10 antibodies were found to be 
commercially available. Three different anti-TTLL10 antibodies were ordered from different 
suppliers (a table of antibodies used in this thesis can be seen in Table 2.2). The 3 different 
antibodies were chosen based on the regions of the protein that they were directed against; 
they all targeted a different section of amino acids. Anti-TTLL10.3 was raised to a region within 
amino acids 242–455 of human TTLL10 and anti-TTLL10.4 corresponded to a region within the 
N terminal amino acids 73–122 of human TTLL10.  
We also tested a further anti-TTLL10 antibody provided by a collaborator as well as an 
antibody that detected global polyglycylation, a polyclonal anti-polyglycine antibody 
generated by using Cys-(Gly)9 as an immunogen (Ikegami et al., 2008).  
5.7.2. Western blots with cell lines 
Firstly, cell types that were readily available and used regularly in the laboratory were used 
for the western blots in addition to platelet lysate samples from numerous healthy volunteer 
donors were tested. Cell lysates were also produced from mouse testes as following the 
investigation of TTLL10 expression, high expression was seen in testes tissue. It was thought 
that the testes lysates could act as a positive control however remaining cautious about the 
species difference which could affect levels. The different TTLL10 antibodies were used on 
these cells types in order to try to elucidate which antibody might be the most specific to the 
protein and hence the likely best antibody to use for further investigations (Figure 5.7).  
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All the antibodies that were used in the western blots were found to be non-specific to TTLL10. 
It was very difficult to make out a specific TTLL10 protein band at the molecular weight the 
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Figure 5.7. Western blot to trial different anti-TTLL10 antibodies. TTLL10 expression 
compared to GAPDH loading control. TTLL10 expression is difficult to identify therefore 
the antibodies are not specific to TTLL10. (A) anti-TTLL10.2, 5 minute exposure. (B) anti-
TTLL10.3, 1 minute exposure. (C) anti-TTLL10.4, 20 second exposure. (D) GAPDH 





TTLL10 ~45 kDa 
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5.7.3. TTLL10 protein expression in patient samples 
Platelet protein and platelet lysates were prepared from patient samples when the patients 
were recalled and attended the clinic for investigations into their unexplained bleeding 
disorder; 3 members of Family 3 and 1 member of Family 11 were included in the western blot 
experiments. The patient samples were run in parallel to healthy volunteer control platelet 
protein samples and prepared in the same way. The membrane was probed with anti-TTLL10.3 
polyclonal antibody as this antibody was thought to be the most specific as it showed a band 
at approximately the correct molecular weight as to what was described on the data sheet 
provided by the manufacturer (Figure 5.8 A). Additionally, the same samples were run on a 
gel but probed with the anti-polyglycine antibody, in order to identify polyglycylation in the 
platelet samples (Figure 5.8 B).  
There appeared to be no difference in expression of TTLL10 in the patient samples compared 
to the controls. The loading control using GAPDH did show that there were varying levels of 
protein in the samples. Despite there not being an observable decrease in expression, the 
question of the antibody specificity comes into question as it cannot be concluded that the 
band highlighted is showing the TTLL10 protein. Similarly, for the anti poly-glycylation 
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Poly-G Ab ~50 kDa 
GAPDH Ab ~37 kDa 
A 
B 
Figure 5.8. Western blot to determine the expression of TTLL10 and polyglycylation in 
patient platelet lysates. TTLL10 expression and the presence of polyglycylation was 
investigated in patients and healthy volunteer control platelet samples and compared to 
GAPDH as loading control. TTLL10 expression is difficult to identify therefore the 
antibodies are not specific to TTLL10. (A) TTLL10 expression using the anti-TTLL10 3 
polyclonal antibody. (B) Expression of polyglycylation using an anti-polygycylation 
antibody which is not commercially available. 
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5.8. Platelet spreading analysis of ‘TTLL10’ patients 
Platelet spreading was carried out as described in the Methods section 2.19. Platelets were 
spread on coverslips coated in fibrinogen and were dually stained with TTLL10 and tubulin 
antibodies. The platelet spreading assay could potentially be a method for investigating the 
role of TTLL10 in platelets as they undergo morphological changes upon activation.  
5.8.1. Control platelet spreading 
Firstly, the platelet spreading assay was carried out using healthy volunteer control platelets. 
This was because the antibodies had not previously been used for immunofluorescence using 
spread platelets and it was important to understand the normal pattern of TTLL10 staining 
seen in healthy platelets.  
The spread platelets were imaged using confocal microscopy (Figure 5.9). The TTLL10 staining 
can be seen as a strong fluorescent signal in the non-spread platelets and what seems to be 
weaker signal in the fully spread platelets. The pattern changes from punctate when the 
platelets are not spread to more diffuse when the platelet is fully spread. The reason behind 
this pattern may be due to the cytoskeletal components, of which TTLL10 is part, spreading 
out to cover a larger surface area compared to non-spread platelets and hence the signal 
seems weaker in the spread platelets.  
Immunofluorescence was also carried out on resting control platelets. These were not spread 
on fibrinogen but on poly-L-lysine therefore the platelets would not become activated. For the 
platelets to adhere to the cover slip, they were spun in a centrifuge for a short period of time. 
There was no difference in the staining pattern of TTLL10 in these resting platelets compared 

































Figure 5.9. Confocal microscopy images of spread platelets from a healthy donor after 
spreading on fibrinogen for 45 minutes. Left column shows a 2× zoom and the right column 
shows 8× zoom at a different field of view. (A) TTLL10 fluorescence. (B) Tubulin fluorescence. 
(C) Merged TTLL10 (green) and tubulin (red) fluorescence. (D) Reflectance image.  
Scale bar, 10 µm.  
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5.8.2. Patient platelet spreading 
Platelet spreading was carried out in family members from Family 3 as mentioned in Chapter 
4. A father and his 2 daughters possess a frameshift deletion (c.462delG) and a frameshift 
insertion (c.745_746insG).  
The platelet spreading images show that their platelets spread on fibrinogen which were 
stained with actin (green) and tubulin (red) (Figure 5.10). Previous work showed that the 
platelets from these affected family members are enlarged and it was thought that the genetic 
variants they harbour might affect the ability of the platelets to spread (Khan et al., 2019b).  
The platelets were counted and categorised into the different stages of spreading. If the 
platelet was fully adherent, wide and circular it was classed as ‘spread’. If the platelet was 
spikey, with microtubule extensions visible but starting to show a circular shape, this was 
classed as ‘spreading’. If the platelet was small with only one or two small microtubule 
extensions this was classed as ‘unspread’. The number of platelets per field of view was 
normalised by calculating percentages of each category of spreading. The in-house controls 
were added in order to get a range of normal spreading values that patient values could be 
compared to spreading and fully spread. A Dunnett’s test of multiple comparisons showed 
that there were a statistically significant number of spread platelets when the in-house control 
spread platelets were compared to each patient separately. There was significance found 
between the control and patient, daughter II:2 (p < 0.05) and the father, patient I:1  
(p < 0.0001) (Figure 5.11). This was an interesting finding as there was no significance between 
the control and the mother (I:2) however this is in keeping with the patient who is wild type 
for the TTLL10 variants. However, this would not explain the lack of significance seen in the 
other daughter who does have the 2 TTLL10 genetic variants mentioned above. This is of great 
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interest and may explain a platelet defect however further research still need to be done to 







































Figure 5.10. Confocal microscopy images of spread platelets from members of Family 3 
with TTLL10 genetic variants. Left column shows reflectance images and the right column 
shows merged fluorescent images with actin in red and tubulin in green (8× zoom). Family 


























Figure 5.11. The percentage of spread platelets from the patients with TTLL10 variants 
and controls. Error bars show the mean with standard deviation. A Dunnett’s test of 
multiple comparisons compared the multiple patients to a single control. There was found 
to be a statistical significance between the number of spread platelets in the in-house 







The work in this chapter was carried out when genetic variants in the same gene, TTLL10, were 
discovered in 3 unrelated families recruited to the GAPP study. All the patients affected had 
similar bleeding diathesis and bleeding histories despite having normal platelet function 
following extensive laboratory phenotyping. We found that TTLL proteins are ubiquitously 
expressed and required for numerous physiological processes (Ikegami et al., 2008). We also 
found that the expression of many of the TTLL proteins is upregulated during platelet 
differentiation, including TTLL10 (p = 0.0004). 
The TTLL10 protein expression using the patient platelet lysates by western blotting could 
benefit from repetition however, repeated patient samples are sometimes difficult to get hold 
of as the patients would be required to attend a clinic at the hospital. The antibodies that were 
detected to test for TTLL10 protein expression may not be reliable, although commercially 
available, the specificity can be variable leading to problems interpreting sound results and 
difficulty investigating the protein levels.  
In addition, the investigation of platelet spreading with TTLL10 antibodies could be 
strengthened by repeating the assay with the patients’ platelets. This would allow us to 
investigate any differences between normal healthy control platelets and the platelets from 
patients with the TTLL10 genetic variants. Further image analysis could also be performed to 
further investigate the localization of the protein within the platelet in addition to any 
colocalisation with other proteins for example, tubulin or other TTLL proteins. It would also 
be interesting to measure area and circularity of the platelets as additional parameters to 
consider in addition to TTLL10. It is well known in the field that abnormalities of the platelet 
cytoskeleton can cause moderate to severe bleeding diatheses (Freson et al., 2007). From our 
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limited knowledge of the TTLL10 protein and our findings of enlarged platelets, the TTLL10 
variants are proposed to affect the formation of tubulin microtubules. 
Due to time constraints during the course of the PhD, further work is required to fully 
understand the role of TTLL10 in platelets and confirm the cause of disease in the 3 families 
mentioned in this Chapter who all experience bleeding episodes. 
5.10. Future work 
It is notoriously difficult to generate the conditions and modification patterns that mimic those 
found in cells and to build complex microtubule arrays, assays or even effective and 
reproducible cell models. This is because there are many accessory proteins that will be 
involved in the process physiologically which would not be present in said assays in vitro. 
Furthermore, the cell dynamics and mechanical stressors are very difficult to recreate which 
also affect the formation of tubulin microtubules in vivo. Additional investigations are required 
though, to determine the functional relevance of the genetic variants in TTLL10.  
The work that should take place following the genetic findings described in this chapter is 
generally in cell lines as a starting point as they are a robust and reproducible method of 
investigation. These investigations could use an erythro-myeloid related cell line for example 
Hel/Dami cells that were established from the blood of individuals with an erythro-leukaemia 
and megakaryoblastic leukaemia respectively and have been used routinely in a laboratory 
setting for over 30 years (Martin and Papayannopoulou, 1982, Greenberg et al., 1988). These 
cells are close in the hematopoietic stem cell differentiation lineage to megakaryocytes. These 
cells would provide material to examine the protein expression and function in a similar cell 
type that produces platelets. However, as platelets are essentially fragments of 
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megakaryocytes, they are notoriously hard to work on and a study model does not exist; 
platelet experiments nearly always require human donors.  
In the last 5 years, massive progress has been made in the field of iPSCs. iPSCs are an ideal 
source of cells as they are pluripotent, self-renewing and widely available. In addition, there 
are fewer ethical issues surrounding iPSC work in the laboratory and they are relatively easy 
to grow and manipulate. A workflow has been designed to induce differentiation of iPSCs to 
produce megakaryocytes (Sugimoto and Eto, 2017). This system is now being used to produce 
reasonable numbers of megakaryocytes successfully. For future experiments, it would be 
interesting to take cells at multiple different time points through the differentiation process 
to build our understanding of the differential expression when progressing through the cell 
lineage to become platelets.  
To investigate the TTLL10 genetic variants, and their effects on platelets without the need for 
taking multiple patient blood donations, CRISPR-Cas9 genome editing technology could be 
implemented to create a TTLL10 disease model. CRISPR-Cas9 editing is now commonplace in 
most laboratories and even though it is still very experimental and often unreliable, this is a 
field that is rapidly evolving and improving (Ran et al., 2013, Khan et al., 2019b, Khan et al., 
2018). The megakaryocytes produced from this model could be used to determine specific 
effects on multiple aspects of megakaryocyte/platelet function. However, this work would still 
be in vitro as the many different factors involved in haemostasis would not be present. To 
combat this, it could be argued that an animal model using transgenic mice could be 
developed to produce an in vivo disease model. Animal models are extremely useful and 
critical for research, but they do not come without limitations. For example, some human 
diseases cannot be modelled using mice, this is because there are fundamental biological 
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differences between the species. This has been identified in certain diseases that develop very 
differently in mice.  
Lastly, previous work pertained that TTLL10 is a non-functional protein in humans (Rogowski 
et al., 2009). The work and analysis in this thesis suggest that this might not be the case. In the 
field of scientific research there are always contradictory findings and newer findings 
overriding older, previously believed ideas. Little is currently known about polymodifications 
in particular polyglycylation in platelets but it seems to have an important role. TTLL10 is an 
interesting protein and no doubt further work is warranted. This is currently being carried out 
and has opened up a window for investigation by future projects. TTLL10 will now also be 
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6. Overall discussion  
Inherited platelet and bleeding disorders are a heterogeneous group of disorders 
characterised by extensive bleeding symptoms following haemostatic challenges. The patients 
recruited to the GAPP study with bleeding symptoms vary extensively in terms of their clinical 
histories but also with regard to the demographic information. The female to male patient 
ratio and the age range of patients recruited to the GAPP study was similar to other large-
scale studies of inherited bleeding disorders previously mentioned in this thesis. Furthermore, 
the variation of the patients’ platelet characteristics also fit with other studies as the platelet 
size, platelet counts and severity of the bleeding, from mild to severe, was different across all 
patients. A unique attribute of the research undertaken in this thesis, highlighted in Chapter 
4, was the extensive genetic investigation of patients with normal platelet parameters 
following laboratory testing despite having extensive bleeding diatheses. These patients were 
studied further as genetic investigation by WES is a powerful method of identifying and 
scrutinising potential disease causing variants. In addition, the patients who were included in 
the platelet spreading assay, in Chapter 3, whose platelet morphologies were deemed 
abnormal as a result of the platelet spreading assay, would have otherwise been missed. All 
of the patients included in investigations and research carried out for this thesis might have 
otherwise been overlooked if the usual platelet function testing standard cut-off values were 
applied. Therefore, the sub-set of patients described in this thesis have offered a unique 
opportunity to investigate and provide further insights into the genetic aetiology of inherited 
platelet and bleeding disorders and could lead us to novel findings regarding haemostasis and 
thrombosis mechanisms in the near future. 
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6.1. Patient platelet phenotyping using a platelet spreading assay 
Despite the many different platelet function tests that are available, there is still a lack of a 
single and robust platelet function test, therefore diagnosis in this group of patients with 
inherited bleeding disorders can be difficult to achieve. To add to the difficulty, the 
phenotypes of patients with inherited bleeding disorders can be very heterogeneous despite 
similar genetic aetiologies. This variable phenotypic presentation suggests that patients 
should be individually considered instead of carrying out one particular method of diagnosis 
for all. 
A platelet spreading assay was carried out to assess potential abnormalities in components of 
the platelet cytoskeleton. The platelet cytoskeleton is an important feature, enabling platelets 
to change morphology upon activation and hence perform their haemostatic role correctly. 
To date, 71 patients from the GAPP study cohort have been included for phenotyping using 
this novel platelet spreading assay (Khan et al., 2019a). The data showed that patients positive 
for both area and circularity abnormalities, as well as abnormal morphology are both positive 
and negative for defects in aggregation. Furthermore, 80% of patients that were found to have 
a spreading defect, but negative for an aggregometry defect, presented with a high ISTH-BAT 
bleeding score. This is of particular interest as a large number of patients positive for a platelet 
spreading defect, and with a history of excessive bleeding, are negative for an aggregation 
defect. This all suggests that applying platelet spreading as part of a platelet testing panel can 
reveal problematic platelet morphological defects that might otherwise be missed by lumi-
aggregometry alone.  
The drawbacks of this assay include the time it takes to complete, and the specialist laboratory 
and analytical skills and equipment required to fully implement the assay. In addition, this 
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assay serves more as a platelet spreading screen rather than an exact diagnostic assay as there 
are a number of possible causes for abnormal platelet spreading and cytoskeleton 
malformations. However, this would narrow down the possible causes of bleeding and provide 
an area to target with potential genetic investigations. Furthermore, the semi-automated 
system for analysing the images is becoming commonplace in laboratory settings across the 
world with machine learning technologies becoming widely available and some software are 
even open access. A method for automating the assay further would be advantageous and 
would possibly reduce the timeframe and the need for specialist scientists. More automated 
systems are becoming preferable for high-throughput analysis such as this. Herein lies the 
question however, if whether this more specialised spreading assay has a place in a routine 
haematology laboratory? Lastly, genetic studies are now the most robust method of patient 
diagnosis. The phenotyping by this platelet spreading assay would complement genetic 
investigations by narrowing down the potential disease causing variants in the affected 
patient. The challenge arises when the genetic variant is novel or of very low incidence in the 
general population. In order to fully understand and hopefully find a diagnosis for these 
patients, a combination of phenotyping and genotyping is required, especially as these 
patients are suspected to harbour novel variants or disorders with unknown genetic aetiology. 
6.2. Patient genotyping by whole exome sequencing 
Due to limitations of platelet function testing as discussed throughout this thesis, 60% of 
patients recruited to the GAPP study have no identifiable platelet defect (Watson et al., 2013). 
Patient genotyping is an ideal approach to elucidate the cause of disease in patients with 
clinical bleeding of unknown aetiology. WES and Sanger sequencing were carried out on 18 
patients from 10 unrelated families, previously recruited to the GAPP study. These patients 
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were selected if their overall laboratory phenotyping results were all within the normal 
parameters despite having an extensive bleeding history. These patients were both paediatric 
and adult cases and all had bleeding symptoms of varying severities. Utilising WES in order to 
investigate these patients is a unique method within this patient sub-set however with the 
advent of the 100,000 Genomes Project, more and more patients are being referred for WES 
and/or WGS which overtime will strengthen investigations into all disease states (Turnbull et 
al., 2018). A custom designed bioinformatic pipeline was developed by the GAPP study 
researchers to efficiently and correctly narrow down and classify potential disease causing 
variants in affected patients.  
Overall within this thesis, genetic variants within genes previously known to cause a bleeding 
phenotype were identified in one family (1 of 10). A mother and son with a lifelong bleeding 
tendency were found to have a heterozygous variant in THBD resulting in a stop codon which 
encoded a truncated form of the glycoprotein thrombomodulin. This was confirmed as their 
cause of disease and a rare example of a gain-of-function mutation in an anticoagulant factor 
causing bleeding (Maclachlan et al., 2017a, Dargaud et al., 2015). The majority of the other 
rare variants found were missense and most of those were novel (not previously described in 
the relevant databases). When considering pathogenicity, WES analysis revealed a positive 
prediction call (classification of ‘pathogenic’ or ‘likely pathogenic’) in 8.2% (8 of 98) of variants 
across all the families. 91.8% (90 of 98) of the variants were unknown and classified as variants 
of ‘uncertain significance’ due to a lack of evidence suggesting their pathogenicity, especially 
not being implicated in platelet or bleeding disorders previously. These numbers reflect the 
sample of patients that were taken forward for WES, as by only recruiting patients with an 
unknown aetiology of disease where patients with a clinical diagnosis might be more obvious, 
were not included. Additionally, the WES method might be preventing the discovery of 
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variants as WES does not guarantee to cover all exons and does not cover intragenic or 
intergenic regions or large-scale genomic rearrangements such are duplications or deletions. 
The sequencing method might have also missed potential variants embedded in a promoter 
region(s) which can only be made possible once a particular gene promoter has been 
sufficiently characterised. The other reasons for genetic variants not being identified include: 
multigenic disease, the incidence of disease predisposing genes or a combination of these 
genes or modified genes causing different phenotypes (Cooper et al., 2013, Wright et al., 
2019). Furthermore, the multifactorial nature of disease in bleeding could be considered 
including the importance of environmental factors and as shown in Figure 6.1 
The detection rate for disease causing variants in this thesis is low however this is in line with 
other studies with similar patient cohorts, which highlights the difficulty faced by researchers 
and clinicians alike. In order to identify more potential causative genetic variants, this work 
would be strengthened by the recruitment of additional family members for those patients 
where no plausible candidate variants were identified. This would help to define the variants 
by looking at genetic segregation. Secondly, the bioinformatic pipeline could be altered to 
increase sensitivity, however this might lead to inaccuracies. In addition, it is well known that 
the parent-child trio model is powerful for hereditary disorders (Chen et al., 2013). 
Furthermore, the application of WGS in patients with no candidate variants would be 










Causal mutation Phenotype 
Modifier genes 
In the locus 
   Common or rare 
   in cis or in trans 
      Additional coding variants 
      Noncoding variants that alter level of expression 
Outside the locus 
   Common polymorphisms or rare mutations 
affecting same system or down-stream pathways 
Environmental effects 
Age, athletic training, bacterial infection, climate, 
disease, exposure to toxic chemicals, hypertension, 
occupational hazards, pollutants, pregnancy, 
substance abuse, viral infection etc.  
Post-translational and epigenetic effects 
DNA modification (e.g. methylation) 
Histone modification (e.g. acetylation) 
Translational control (e.g. microRNA) 
Post-translational modifications 
Figure 6.1: The complexities of the genotype-phenotype relationship in disease. The effect of a specific mutation in a gene is altered 
by other genetics, epigenetics and environmental stressors. Due to this, phenotypes can vary even within families of individuals with 
the same genetic mutation. There are many examples of the categories listed in this figure but as expected, there are likely many 
modifying factors that are unknown.  
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The ability to determine the genetic aetiology of unknown genes/proteins that cause bleeding 
is difficult due to the heterogeneity of disease as previously mentioned. Following genetic 
scrutiny of novel variants, functional characterisation is necessary to conclusively determine 
whether the variants are disease causing or benign. Some variants in the databases are said 
to be benign even when they have been previously associated with disease (Niroula and 
Vihinen, 2019). Another potential challenge arises with the inevitable discovery of incidental 
findings; clinicians could face difficulty with the question of should they disclose the incidental 
findings and any clinical relevance to their patients (Maclachlan et al., 2017b)? This is a 
contentious topic of discussion however the ACMG Working Group on Incidental Findings in 
Clinical Exome and Genome Sequencing have published a list of variants they recommend 
disclosing to patients if found during genetic screening. Hopefully, further studies in this field 
will strengthen overall detection rates for novel genetic variants.  
With regards to the patients studied in this thesis who are still without a diagnosis for their 
unexplained bleeding, work is still needed to functionally confirm all the variants discovered. 
If successful, this has the potential to develop our current knowledge of haemostatic 
mechanisms and creates scope for potential new therapeutics for thrombosis. Furthermore, 
it will allow the patients to have a categorised diagnosis, which is highly important for some 
individuals and for their clinical treatment and management later in life. 
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6.3. Determining the functional effects of the novel candidate TTLL10 
The work from this chapter follows after genetic variants (c.462delG, c.745_746insG and 
C.1018C>T) in the same gene, TTLL10, which were identified by WES in 3 unrelated families. 
The affected patients all presented with similar bleeding diatheses and after routine 
laboratory testing, showed results in the normal range for platelet aggregation and secretion. 
Research was carried out to investigate the functional effect of TTLL10 and investigate a 
potential role for this protein in platelet function.  
From this work, it has been shown that in the affected patients there is likely a reduction or 
total loss of polyglycylation depending on the patients’ genetic variant; the effects of glycine 
sidechains on tubulin in platelets are not currently known. However, as the variants only affect 
the TTLL10 protein function, the other types of PTM remain unaffected. The affected patients 
appear to have enlarged platelets as their mean platelet volumes are in the upper limit of the 
normal range and above. This suggests a potential role for an extending glycine sidechain in 
platelet size regulation with a downstream effect causing bleeding. This could be caused by 
the inability of the patients’ platelets to fully change their morphology when undergoing 
activation. There is always some compensation from other pathways when complex cellular 
and molecular mechanisms are involved in a process, therefore the defects seen in the 
affected patients might be more subtle that previously thought. This is seen in the patients’ 
normal platelet aggregometry results. Nevertheless, the 3 families with genetic variants in 
TTLL10 all have the same bleeding symptoms.  
TTLL10 still remains the most likely genetic candidate of disease for these patients as 
increasing lines of evidence suggest involvement of TTLL10 in platelets and bleeding. The 
phenotype of enlarged platelets is seen in many known platelet disorders, for example 
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Bernard-Soulier syndrome, which should be taken into account if additional patients with 
variants in TTLL10 are identified (Watson et al., 2013). In addition, there are other known 
disorders, for example Wiskott- Aldrich syndrome, that affect platelet activation and platelet 
cytoskeletal arrangement (Paknikar et al., 2019). Further investigations are required to fully 
prove the cause of disease as it is still very difficult to prove if a variant is disease causing, 
especially if it is novel or has a very low incidence in the population. Extensive functional work 
is required in this case and there are many different methods to achieve this.  
6.3.1. Future work to determine the functional relevance of candidate gene 
variants in novel genes including TTLL10 
The work that should take place following the genetic findings described in this thesis is 
generally in cell lines as a starting point as they are a robust and reproducible method of 
investigation. These investigations could use an erythro-myeloid related cell line. These cells 
are close in the hematopoietic stem cell differentiation lineage to megakaryocytes. These cells 
would provide material to examine the protein expression and function in a similar cell type 
that produces platelets.  
Of recent years, massive progress has been made in the field of scientific investigation using 
inducible pluripotent stem cells (iPSCs). IPSCs are an ideal source of cells as they are 
pluripotent, self-renewing and widely available. As mentioned in Chapter 5, a workflow has 
been designed to induce differentiation of iPSCs to produce megakaryocytes (Sugimoto and 




To investigate the TTLL10 genetic variants, CRISPR-Cas9 genome editing technology could be 
implemented to create a TTLL10 disease model. The megakaryocytes produced from this 
model could be used to determine specific effects on multiple aspects of 
megakaryocyte/platelet function when the genetic variant in question is inserted into the 
genome of the cell type. In addition, animal models using transgenic mice could be developed 
to produce an in vivo disease model. Animal models are extremely useful and critical for 
research, but they do not come without limitations previously mentioned in this thesis.  
Lastly, previous work pertained that TTLL10 is a non-functional protein in humans (Rogowski 
et al., 2009). The work and analysis in this thesis suggest that this might not be the case. In the 
field of scientific research there are always contradictory findings and newer findings 
overriding older previously believed ideas. Little is currently known about polymodifications 
in particular polyglycylation in platelets but it seems to have an important role. TTLL10 is an 
interesting protein and no doubt further work is warranted. 
6.4. Final conclusions 
The work carried out in this thesis focussed on improving current methods of analysis for 
diagnosing inherited bleeding disorders and the aims highlighted the platelet spreading assay 
and the WES analysis in order to complete this. Firstly, the work has shown that the platelet 
spreading assay identifies previously undiscovered platelet disorders that would have 
otherwise been missed with the standard testing. This assay could be an invaluable addition 
to the current range of platelet function tests offered to patients with bleeding of unknown 
aetiology.  
Secondly, this work has shown that WES was of great value in this investigation and for the 
patients who were included. The cause of a previously unknown disease was identified in one 
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family who were hence clinically diagnosed with a bleeding disorder due to a truncated form 
of the thrombomodulin protein. These patients are now undertaking suitable preventative 
measures before medical procedures and have been offered genetic counselling and a cascade 
genetic testing to identify at risk family members. In addition, a number of potential disease 
causing variants were identified in other families, however further investigations will now 
have to be carried out in order to functionally prove the variants are the cause of their disease.  
Lastly, preliminary evidence from the work carried out for this thesis and from broader 
literature shows that the role of PTMs on the normal function of megakaryocytes and platelets 
is more important and more involved than was expected. Not a great deal is known about 
their exact functions in platelets specifically however establishing the changes in PTMs in 
platelets will be an exciting addition to the rapidly growing field and may provide insights to 
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Figure A. The International Society of Thrombosis and Haemostasis Bleeding Assessment 
Tool, used to assist the diagnosis of bleeding disorders. 
Annexe 1: ISTH/SSC Bleeding Assessment Tool 
The clinical appreciation of the presence and severity of bleeding symptoms is a fundamental step in 
the evaluation of patients referred for a possible bleeding disorder.  In an attempt to improve the 
collection and reproducibility of the bleeding history, several Bleeding Assessment Tools (BAT) have 
been proposed and used.  Currently available BAT have some limitations, particularly regarding the 
lack of paediatric-specific symptoms in some of them and the predominance of the severity of bleeding 
symptoms over other potentially clinically important features, such as the frequency of symptoms. 
To overcome the above-mentioned limitations and to promote the standardization of the available 
BATs, a Working Group was established within the framework of the ISTH/SSC Subcommittees on VWF 
and on Perinatal/Paediatric Haemostasis (ISTH/SSC-BAT) during the 53rd SSC Annual Meeting held in 
Geneva in 2007. Members of the group first met in Toronto on January 2008 and then regularly at each 
subsequent SSC meeting. This paper presents a structured questionnaire and its clinical use agreed on 
by the ISTH/SSC-BAT together with a proposal for a new BS system to undergo validity and reliability 
testing in future studies. This new BAT is intended for inherited bleeding disorders in children and 
adults. The questionnaire should be collected by a physician or another adequately trained health-
professional. Only symptoms and related treatments, if any, before and/or at diagnosis should be 
reported. Refer to the full text for additional instructions. 
Minimal criteria defining a significant bleeding 
For each specific bleeding symptom, the ISTH/SSC joint working group proposed minimal criteria in 
order to classify a symptom as significant and thus receive a score of 1 or more (see also Table 1): 
1. Epistaxis: Any nosebleed, especially occurring after puberty that causes patient concern (e.g., 
interference or distress with daily or social activities) is considered significant. In general, epistaxis 
should not be considered significant when it lasts less than 10 minutes, has a frequency of < 5 
episodes/year, has a seasonal occurrence, or is associated with infections of the upper respiratory tract 
or other identifiable cause (e.g., dusty dry air). 
2. Cutaneous bleeding: Bruises are considered significant when 5 or more (> 1cm) in exposed areas; 
petechiae when adequately described by the patient or relatives; or hematomas when occurring 
without trauma. 
3. Minor cutaneous wound: Any bleeding episode caused by superficial cuts (e.g., by shaving razor, 
knife, or scissors) or that requires frequent bandage changes is considered significant. Insignificant 
bleeding from wounds includes those of duration < 10 minutes and lesions that usually require stitches 
in normal subjects (e.g., under the chin). Symptoms should also be manifest on more than one occasion 
to be considered significant. 
4. Oral cavity bleeding: Gum bleeding should be considered significant when it causes frankly bloody 
sputum and lasts for 10 minutes or longer on more than one occasion. Tooth eruption or spontaneous 
tooth loss bleeding should be considered significant when it requires assistance or supervision by a 
physician, or lasts at least 10 minutes (bleeding associated with tooth extraction is considered 
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separately). Bleeding occurring after bites to lips, cheek, and tongue should be considered significant 
when it lasts at least 10 minutes or causes a swollen tongue or mouth. 
5. Hematemesis, melena, and haematochezia: Any gastrointestinal bleeding that is not explained by 
the presence of a specific disease should be considered significant. 
6. Haematuria: Only macroscopic haematuria (from red to pale-pink urine) that is not explained by the 
presence of a specific urologic disease should be considered significant. 
7. Tooth extraction: Any bleeding occurring after leaving the dentist’s office and requiring a new, 
unscheduled visit or prolonged bleeding at the dentist’s office causing a delay in the procedure or 
discharge should be considered significant. 
8. Surgical bleeding: Any bleeding judged by the surgeon to be abnormally prolonged, that causes a 
delay in discharge, or requires some supportive treatment is considered significant. 
9. Menorrhagia: Any bleeding that interferes with daily activities such as work, housework, exercise or 
social activities during most menstrual periods should be considered significant. Criteria for significant 
bleeding may include any of the following: changing pads more frequently than every 2 hours; 
menstrual bleeding lasting 7 or more days; and the presence of clots > 1 cm combined with a history 
of flooding. If a patient has previously made a record of her menstrual loss using a pictorial blood loss 
assessment chart (PBAC), a PBAC score higher than 100 also qualifies for a score of 1. 
10. Post-partum bleeding. Vaginal bleeding or uterine discharge (lochia) that lasts for more than 6 
weeks. Any bleeding of lesser duration that is judged by the obstetrician as abnormally heavy or 
prolonged, that causes a delay in discharge, requires some supportive treatment, requires changing 
pads or tampons more frequently than every 2 hours, or causes progressive anaemia is also considered 
significant. 
11. Muscle hematomas or haemarthrosis. Any spontaneous joint / muscle bleeding (not related to 
traumatic injuries) is considered significant. 
12. CNS bleeding. Any subdural or intracerebral haemorrhage requiring diagnostic or therapeutic 
intervention is scored 3 or 4, respectively. 
13. Other bleeding symptoms. When these bleeding symptoms occur during infancy, they are scored 
1 or more. Their presence when reported by either the patient or a family member should always 


















1.1 Have you ever had spontaneous 
epistaxis? 
  Yes  No or trivial (skip to 2)  
1.2 Have the symptom ever required 
medical attention? 
  Yes   No (resolve 








     
 
  
If answer to 1.2 is yes, please 
specify 
  Consultation only 
 
 
  Cauterization/ Packing 
 
  Treatment with desmopressin / antifibrinolytics / iron 
therapy 
 
  Treatment  with plasma, platelet or factor 
concentrates 
      
  Blood (RBC) transfusion 
 
1.4      How many times in your life did 
you receive any of the above 
treatments (# 1.3)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
1.5      At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
1.6     Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
 
 
1.7     Duration of average single 
episode (min.) NOT requiring 
medical attention 
  1 minute or less 
 1 - 10 minutes 














2.1 Have you ever had any of the above 
cutaneous bleeding? 
  Yes  No or trivial skip to 3  
2.2 Have the symptom ever required 
medical attention? 







If answer to 2.2 is yes, please 
specify 




 Treatment with desmopressin 
 
  Treatment  with plasma, platelets or factor 
concentrates 
      
 
 Blood (RBC) transfusion 
2
2.4 
     How many times in your life did 
you receive any of the above 
treatments (# 2.3)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
2.5      At what age did you first have 
symptoms?  
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
 
2.6     Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
 
2.7     Type of bleeding   Petechiae 
 Bruises  
 Hematomas 
 
2.8     Location    Exposed sites 
 Unexposed sites 
 Both 
 
2.9     Common size    ≤ 1 cm  
 >1 cm 




2.10      How many bruises >1 cm in 
exposed areas in the most severe 
manifestation? 
  ≤ 5 
 > 5 
 










3.1 Have you ever had prolonged 
bleeding from minor wounds? 
  Yes  No or trivial skip to 4 
3.2 Have the symptom ever required 
medical attention? 





   
 
 
If answer to 3.2 is yes, please 
specify 
  Consultation only  
 
 
 Surgical hemostasis 
 
 
 Treatment with desmopressin 
      




 Blood (RBC) transfusion 
3.4      How many times in your life did 
you received any of the above 
treatments (# 3.3)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
3.5      At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
3.6     Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
 
 
3.7     Duration of average single 
episode (min.) 
  1 to 10 minutes 













4.1 Have you ever had hematuria?   Yes  No skip to 5 
4.2 If answer to 4.1 is yes, please 
specify   
   








 Kidney/ bladder 
   disease 
 
No  
Please answer the following questions only for SPONTANEOUS symptoms (answer No to 4.1) 
4.3 Have the symptom ever required 
medical attention? 









If answer to 4.3 is yes, please 
specify 
 






 Treatment with desmopressin 
      




 Blood (RBC) transfusion 
4.5      How many times in your life did 
you received any of the above 
treatments (# 4.4)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
4.6 At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
4.7     Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 










5.1 Have you ever had gastrointestinal 
bleeding ? 
  Yes  No skip to 6 
5.2 If answer to 5.1 is yes, please 
specify   
 
  














 Portal hypertension 
 Angiodysplasia 
No  
Please answer to the following questions only for SPONTANEOUS symptoms 
5.3 Have the symptom ever required 
medical attention? 
 Yes  No   skip to 5.7 
5.4 If answer to 5.3 is yes, please 
specify 
 





 Surgical haemostasis  
 
 
 Treatment with desmopressin 
 
  Treatment  with plasma, platelet or factor 
concentrates 
      
 
 Blood (RBC) transfusion 
5.5 How many times in your life did 
you received any of the above 
treatments (# 5.4)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
5.6  At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
5.7  Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 






6. Oral cavity bleeding (Tooth eruption, spontaneous or after brushing/flossing, gum bleeding, 




6.1 Have you ever had oral cavity 
bleeding? 
  Yes  No or trivial skip to 7 
6.2 Have the symptom ever required 
medical attention? 
 Yes  No   skip to 6.6 
6.3 If answer to 6.2 is yes, please 
specify 
 
 Consultation only  
 
 
 Surgery (dental packing, suture, cauterization) 
 
 
 Treatment with desmopressin / iron therapy 
 




 Blood (RBC) transfusion 
6.4      How many times in your life did 
you received any of the above 
treatments (# 6.3)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
6.5      At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
6.6     Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 
 1 every week 
 
 
6.7     Duration of average single 
episode (min.) 
  1 to 10 minutes 








7.1 Have you ever had bleeding after 
tooth (teeth) extraction? 
  Yes  No skip to 8 
7.2 If answer to 7.1 is yes, please 
specify 
 




     




Age at extraction  Type of extraction  Deciduous 
 Permanent 
 Molar 
Actions taken to prevent 
bleeding 
  None 
 Antifibrinolytics 
 Desmopressin 
 Plasma or clotting factor concentrates 
 Platelet infusion 
 
Bleeding after extraction?  Yes  No  
Actions taken to control 
bleeding 
  Resuturing 
 Packing  
 Antifibrinolytics 
 Desmopressin 
 Plasma or clotting factor concentrates 
 Platelet infusion 












8.1 Have you ever had bleeding after 
surgery or major trauma? 
  Yes  No, skip to 9 
8.2 If answer to 8.1 is yes, please 
specify 
 




     












Actions taken to prevent 
bleeding 
  None 
 Antifibrinolytics 
 Desmopressin 
 Plasma or clotting factor concentrates 
 Platelet infusion 
 
Bleeding after intervention?  Yes  No  
Actions taken to control 
bleeding 
  None 
 Resuturing 
 Packing  
 Antifibrinolytics 
 Desmopressin 
 Plasma or clotting factor concentrates 
 Platelet infusion 









9.1 Have you ever had very heavy 
menstrual bleeding (menorrhagia)? 
  Yes  No or trivial skip to 10 
     If answer to 9.1 is yes, please 
     specify 
  Changing pads/tampons more frequently than 
every 2 hours 
    Bleeding more than 7 days  
   
 Clot and flooding 
   




      Never or rarely 
      Most menses 
9.2 Have the symptom ever required 
medical attention? 
  Yes  No   skip to 9.6 
9.3 If answer to 9.2 is yes, please 
specify 
a  Consultation only  
 b  Pictorial Bleeding 
       Assessment 
Score ___________ 
 c  Antifibrinolytic therapy 
 d  Iron therapy 
 e  Hormonal therapy 
 f  Combined antifibrinolytics & Hormonal therapy 
 g  Hysterectomy / endometrial ablation / D & C 
 h  Treatment with desmopressin, plasma or factor 
concentrates, platelet transfusion  
  i  Blood (RBC) transfusion 
  l  Hospital admission and emergency treatment  
9.4      How many times in your life did 
you received any of the above 
treatments (# 9.3 a-l)? 
 
 1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
9.5      At what age did you first have 
symptoms? 
  At menarche  
 Between 14-25 years of age 
 After  25 years of age 
9.6      Have you had time off 
work/school for menorrhagia? 
 
 < twice a year 
 > twice a year 
 
9.7      Duration of menorrhagia  
  Since menarche  
 > 12 months  
 < 12 months  
 




 Yes    













10.2 Have you ever had post-partum 
haemorrhage? 
  Yes  No or trivial skip to 11 
10.3 Did it occur   In the first 24 hours after delivery (Primary) 
   
 Between 24 hours and 6 weeks postpartum 
(Secondary) 
    Both Primary and Secondary  
10.4 How long did vaginal discharge 
(lochia) last? 
  < 6 weeks 
 > 6 weeks 
 
10.5 Did it require changing 
pads/tampons more frequently than 
every 2 hours? 
  Yes   No 
10.6 Did this bleeding cause delay of 
hospital discharge/ readmission to 
hospital? 
  Yes   No 
10.7 Have the symptom ever required 
medical treatment? 
  Yes   No 
10.8 If answer to 10.7 is yes, please 
specify 
 
 Consultation only /oxytocin i.v. infusion 
   Additional uterotonic medications 
 
 
 Iron therapy 
 
 
 Antifibrinolytic therapy 
 
 
 Treatment with plasma or factor concentrates, 
platelet transfusion 





 Any procedure requiring examination under 
anaesthesia 
 Uterine balloon/package to tamponade the 
uterus  
 Any procedure requiring critical care or surgical 
intervention (includes: hysterectomy, internal iliac 
artery legation, uterine artery embolization, uterine 
brace  sutures) 
10.9      Number of deliveries that 
required any of the above 










11.1 Have you ever had muscle 
hematomas or hemarthrosis? 
 
 Yes  No or trivial skip to 12  
11.2 Have the symptom ever required 
medical attention? 
  Yes   No skip to 11.6 
11.3 If answer to 11.2 is yes, please 
specify 
  Consultation only  
 
 
 Surgical draining  
 
 
 Treatment with desmopressin 
 




 Blood transfusion 
11.4      How many times in your life did 
you receive any of the above 
treatments (# 11.3)? 
  1 - 2 
 3 to 5 
 6 to 10  
 more than 10 
 
11.5      At what age did you first have 
symptoms? 
 
 Before 1 year 
 Between 1-5 years of age 
 Between 6-12 years of age 
 Between 13-25 years of age 
 After 25 years of age 
    
 
11.6 Approximate number of episodes 
NOT requiring medical attention  
  less than 1 per year 
 1 per year 
 1-5 every six month 
 1-3 every month 












12.1 Have you ever had one of the following?  
 Excessive umbilical stump bleeding   Yes  No  
 Cephalohematoma   Yes  No  
 Bleeding at circumcision   Yes  No  
 Venipuncture bleeding   Yes  No  
 Suction Bleeding    Yes  No  
 Ovulation bleeding(in women)    Yes  No 
12.2 Have one of these symptoms ever 
required medical attention? 
  Yes   No  
12.3 If answer to 12.2 is yes, please 
specify 
 
 Consultation only  
 
 
 Surgery  
 
 
 Treatment with desmopressin 
 




 Blood (RBC) transfusion 
12.4      How many times in your life did 
you receive any of the above 
treatments (# 12.3) for this 
symptom? 
  1 - 2 
 3 to 5 
 6 to 10  





Table 1. Bleeding score 
SYMPTOMS 




§ 1§ 2 3 4 
Epistaxis  No/trivial  - > 5/year 
or 




Packing or cauterization or 
antifibrinolytic 
Blood transfusion or replacement 
therapy (use of hemostatic blood 
components and rFVIIa)  or 
desmopressin 
      
Cutaneous  No/trivial For bruises 5 or 
more (> 1cm) in 
exposed areas  
 
Consultation only* Extensive  Spontaneous hematoma requiring 
blood transfusion  
      
Bleeding from minor 
wounds 
 No/trivial  - > 5/year  
or 




Surgical hemostasis Blood transfusion, replacement 
therapy, or desmopressin 
      
Oral cavity  No/trivial Present Consultation 
only* 
Surgical hemostasis or 
antifibrinolytic 
Blood transfusion, replacement 
therapy or desmopressin 
      
260 
 






Consultation only* Surgical hemostasis, 
antifibrinolytic 
Blood transfusion, replacement 
therapy or desmopressin 
      




Surgical hemostasis,  
iron therapy 
Blood transfusion, replacement 
therapy or desmopressin 
      
Tooth extraction  No/trivial or 
none  done  
Reported in <25% 
of all procedures, no 
intervention** 
Reported in 
>25% of all 
procedures, no 
intervention** 
Resuturing or packing Blood transfusion, replacement 
therapy or desmopressin 
      
Surgery  No/trivial or 
none done 
Reported in <25% 
of all procedures, no 
intervention** 
Reported in 
>25% of all 
procedures, no 
intervention** 
Surgical hemostasis or 
antifibrinolytic 
Blood transfusion, replacement 
therapy or desmopressin 
      
Menorrhagia  No/trivial Consultation only* 
or 
- Changing pads 
- Time off 
work/school > 
- Requiring combined 
treatment with 
antifibrinolytics and hormonal 
- Acute menorrhagia requiring 
hospital admission and 




than every 2 hours 
or  
- Clot and flooding 
or 









- Present since menarche 
and > 12 months 
or 




- Requiring dilatation & curretage 
or endometrial ablation or 
hysterectomy) 
      
Post-partum 
hemorrhage 
 No/trivial or 
no deliveries  
Consultation only* 
or 
 - Use of syntocin 
or 
- Lochia > 6 weeks 
 - Iron therapy 
or 
- Antifibrinolytics 




- Requiring examination 
under anaesthesia and/or the 
use of uterin balloon/package 
to tamponade the uterus 
- Any procedure requiring critical 
care or surgical intervention (e.g. 
hysterectomy, internal iliac artery 
legation, uterine artery 





    
Muscle hematomas  
Never Post trauma, no 
therapy 
Spontaneous, 
no therapy  
Spontaneous or traumatic, 
requiring desmopressin or 
replacement therapy  
Spontaneous or traumatic, 




    
Hemarthrosis  




Spontaneous or traumatic, 
requiring desmopressin or 
replacement therapy 
Spontaneous or traumatic, 
requiring surgical intervention or 
blood transfusion 
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CNS bleeding  
Never - - Subdural, any intervention Intracerebral, any intervention 
  
     







Blood transfusion or replacement 
therapy or desmopressin 
 
     
 
In addition to the guidance offered by the table, it is mandatory to refer to the text for more detailed instructions. 
§ Distinction between 0 and 1 is of critical importance. Score 1 means that the symptom is judged as present in the patient’s h istory by the interviewer but does 
not qualify for a score 2 or more 
* Consultation only: the patient sought medical evaluation and was either referred to a specialist or offered detailed laboratory investigation  
** Example: 1 extraction/surgery resulting in bleeding (100%): the score to be assigned is 2; 2 extractions/surgeries, 1 resulting in bleeding (50%): the score to 
be assigned is 2; 3 extractions/surgeries, 1 resulting in bleeding (33%): the score to be assigned is 2; 4 extractions/surgeries, 1 resulting in bleeding (25%): the 
score to be assigned is 1 
# If already available at the time of collection  
^ Include: umbilical stump bleeding, cephalohematoma, cheek hematoma caused by sucking during breast/bottle feeding, conjunctival hemorrhage or 
excessive bleeding following circumcision or venipuncture. Their presence in infancy requires detailed investigation independently from the overall score
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Figure B. Consent form for recruitment to the GAPP study. 
 
 
INFORMED CONSENT FOR 
PATIENT / FAMILY MEMBER 
Thank you for reading the information about our research project.  If you would like to take 
part, please read and sign this form. 
 
Patient Identification Code for this study: 
 
Title of Project:  Mild bleeding disorders caused by platelet defects 
 
Contact details for research team:  
 




The study team: Mrs Gayle Halford (general enquiries), Dr Marie Lordkipanidzé and Dr Gillian 
Lowe  
Birmingham Platelet Group, Institute for Biomedical Research, School of Clinical and 
Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, 
Birmingham B15 2TT,  0121 415 8680.  Please leave a message if no-one is in the office 
and we will get back to you. 
 
Please initial all boxes 
 
1.  I have read the attached information sheet on this project, and have been given a copy to keep.  I 
have been able to ask questions about the project and I understand why the research is being done and 






2.  I agree to give a sample of blood for research in this project.  I understand how the sample will be 
collected, that giving a sample for this research is voluntary and that I am free to withdraw my approval 
for the use of the sample at any time without giving a reason and without my medical treatment or legal 
rights being affected. 
 
 
3.  I give permission for someone from the local research team to look at my medical records to get 
information on my bleeding history.  I understand that the information will be kept confidential. 
 
 
4.  I agree to answering some questions about my medical history including those needed to complete 
a bleeding assessment by questionnaire. 
 
 
5.  I understand that my referring doctor and I will be informed if any of the results of the medical tests 
done as a part of the research are important for my health. 
 
 
6.  I understand that I will not benefit financially if this research leads to the development of a new 
treatment or medical test. 
 
 




8.  Consent for storage of sample  
I agree that the sample I have given and the information gathered about me can be stored in the 
Medical Schools of the Universities of Birmingham, Bristol and Sheffield for the purpose of analysing 
platelets, bleeding tendency and detection of the gene change responsible for the platelet disorder in 
myself or a family member, for a maximum of 10 years, after which it will be destroyed.   
If I wish I may request the return of the sample after analysis has been completed. 
 
 
9.    Consent for genetic research.  
I give permission for genetic analysis to be carried out on the sample I give, as part of this project.  I 
have received written information about this test and I understand what the result could mean to me 













10.    Consent for stem cell studies 
I give permission for the stem cells in my blood sample to be used to understand how my platelets are 
produced. 
          YES 
          NO 
 
11.    Consent for RUNX1 mutation testing (ONLY FOR PARTICIPANTS WITH LOW PLATELET 
COUNTS).  
I give permission for genetic analysis to be carried out on the sample I give to specifically look at the 
RUNX1 gene.  I understand that this mutation is associated with low platelet counts and can in some 
cases predispose to certain types of leukaemia.  
          YES 
          NO 
 
12.   I want to be told the results of the tests undertaken in this study.  I understand I can change my 
mind about this later. 
          YES 
          NO 
 
………………………………………… ……………………… …………………………………… 




……………………………………….  …………………… …………………………………… 
Name of person taking consent   Date   Signature 
(if different from researcher) 
 
 
……………………………………..  …………………… …………………………………. 
Name of researcher    Date   Signature 
 
 
Thank you for agreeing to participate in this research  









Table A. List of genes included in the GAPP study gene panel utilised during the 
bioinformatic screen. 
A2M Alpha-2-macroglobulin 
ABCA12 ATP Binding Cassette Subfamily A Member 12 
ABCB4 ATP Binding Cassette Subfamily B Member 4 
ABCC4 ATP Binding Cassette Subfamily C Member 4 
ABCG5 ATP Binding Cassette Subfamily G Member 5 
ABCG8 ATP Binding Cassette Subfamily G Member  
ABI1 Abl Interactor 1 
ACE Angiotensin I Converting Enzyme 
ACP2 Acid Phosphatase 2, Lysosomal 
ACSL4 Acyl-CoA Synthetase Long-Chain Family Member 4 
ACTA1 Actin, Alpha 1, Skeletal Muscle 
ACTN1 Actinin Alpha 1 
ACTR3 ARP3 Actin-Related Protein 3 Homolog 
ACVRL1 Activin A Receptor Like Type 1 
ADAM15 ADAM Metallopeptidase Domain 15 
ADAM17 ADAM Metallopeptidase Domain 17 
ADAMTS13 ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13 
ADCY3 Adenylate Cyclase 3 
ADCY6 Adenylate Cyclase 6 
ADCY7 Adenylate Cyclase 7 
ADORA2B Adenosine A2b Receptor 
ADRA2A Adrenoceptor Alpha 2A 
ADRA2B Adrenoceptor Alpha 2B 
ADRBK1 Adrenergic, Beta, Receptor Kinase 1 
ADSS Adenylosuccinate Synthase 
AGT Angiotensinogen 
AGTR1 Angiotensin II Receptor Type 1 
AK3 Adenylate Kinase 3 
AKT1 Protein Kinase B Alpha 
AKT2 Protein Kinase B Beta 
ALDH1A1 Aldehyde Dehydrogenase 1 Family Member A1 
ALOX12    Arachidonate 12-Lipoxygenase 
ALOX5 Arachidonate 5-Lipoxygenase 
ANGPT2 Angiopoietin 2 
ANKRD12 Ankyrin Repeat Domain 12 
ANKRD18A Ankyrin Repeat Domain 18A 
ANKRD18B Ankyrin Repeat Domain 18B 
ANKRD26 Ankyrin Repeat Domain 26 
ANKRD33 Ankyrin Repeat Domain 33 
ANTXR2 Anthrax Toxin Receptor 2 
ANXA2 Annexin A2 
ANXA5 Annexin A5 
AP2B1 Adaptor Related Protein Complex 2 Beta 1 Subunit 
AP3B1 Adaptor Related Protein Complex 3 Beta 1 Subunit 
AP3D1 Adaptor Related Protein Complex 3 Delta 1 Subunit 
AP3M1 Adaptor Related Protein Complex 3 Mu 1 Subunit 
AP3S1 Adaptor Related Protein Complex 3 Sigma 1 Subunit 
APC Adenomatous Polyposis Coli 
APLN Apelin 
APLP2 Amyloid Beta Precursor Like Protein 2 
ARAF A-Raf Proto-Oncogene, Serine/Threonine Kinase 
ARHGAP1 Rho GTPase Activating Protein 1 
ARHGAP17 Rho GTPase Activating Protein 17 
ARHGAP18 Rho GTPase Activating Protein 18 
ARHGAP24 Rho GTPase Activating Protein 24 
ARHGAP32 Rho GTPase Activating Protein 32 
ARHGAP6 Rho GTPase Activating Protein 6 
ARHGDIA Rho GDP Dissociation Inhibitor Alpha 
ARHGDIB Rho GDP Dissociation Inhibitor Beta 
ARHGEF12 Rho Guanine Nucleotide Exchange Factor 12 
ARHGEF15 Rho Guanine Nucleotide Exchange Factor 15 
ARHGEF3 Rho Guanine Nucleotide Exchange Factor 3 
ARID1A AT-Rich Interaction Domain 1A 
ARRB1 Arrestin Beta 1 
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ART4 ADP-Ribosyltransferase 4 (Dombrock Blood Group) 
ASPN Asporin 
ATP5H ATP Synthase, H+ Transporting, Mitochondrial Fo Complex Subunit D 
AZIN1 Antizyme Inhibitor 1 
BAG3 BCL2 Associated Athanogene 3 
BAK1 BCL2 Antagonist/Killer 1 
BCL2 B-Cell CLL/Lymphoma 2 
BCL2L1 BCL2 Like 1 
BCOR BCL6 Corepressor 
BET1L Bet1 Golgi Vesicular Membrane Trafficking Protein Like 
BGN Biglycan  
BIVM Basic, Immunoglobulin-Like Variable Motif Containing 
BLOC1S1 Biogenesis Of Lysosomal Organelles Complex 1 Subunit 1 
BLOC1S2 Biogenesis Of Lysosomal Organelles Complex 1 Subunit 2 
BLOC1S3 Biogenesis Of Lysosomal Organelles Complex 1 Subunit 3 
BLOC1S4 Biogenesis Of Lysosomal Organelles Complex 1 Subunit 4 
BLOC1S5 Biogenesis Of Lysosomal Organelles Complex 1 Subunit 5 
BLOC1S6 Biogenesis Of Lysosomal Organelles Complex 1 Subunit 6 
BMP4 Bone Morphogenetic Protein 4 
BMP6 Bone Morphogenetic Protein 6 
BMX Non-Receptor Tyrosine Kinase 
BRD2 Bromodomain Containing 2 
BTBD9 BTB Domain Containing 9 
BTK Bruton Tyrosine Kinase 
C10orf10 Chromosome 10 Open Reading Frame 10 
C12orf11 Asunder, Spermatogenesis Regulator 
C14orf133 VPS33B Interacting Protein, Apical-Basolateral Polarity Regulator, Spe-39 Homolog 
C14orf78 AHNAK Nucleoprotein 2 
C16orf30 Transmembrane Protein 204 
C16orf63 FGFR1OP N-Terminal Like 
C19orf55 Proline And Serine Rich 3 
C20orf42  Fermitin Family Member 1 
C4orf18 Family With Sequence Similarity 198 Member B 
C6orf25 Immunoglobulin Receptor 
C7 Complement Component 7 
C9orf26 Interleukin 33 
CALCRL Calcitonin Receptor Like Receptor 
CALU Calumenin 
CAP1 Adenylate Cyclase-Associated Protein 1 
CASP7 Caspase 7 
CAV1 Caveolin 1 
CBARA1 Mitochondrial Calcium Uptake 1 
CCDC99 Spindle Apparatus Coiled-Coil Protein 1 
CCL2 C-C Motif Chemokine Ligand 2 
CCL20 C-C Motif Chemokine Ligand 20 
CCL5 C-C Motif Chemokine Ligand 5 
CD226 Platelet And T Cell Activation Antigen 1 
CD34 CD34 Molecule 
CD36 CD36 Antigen (Collagen Type I Receptor, Thrombospondin Receptor) 
CD55 CD55 Molecule (Cromer Blood Group) 
CD93 Complement Component 1, Q Subcomponent, Receptor 1 
CDC42 G25K GTP-Binding Protein 
CDCA8 Cell Division Cycle Associated 8 
CDH5 Cadherin 5 
CEP135 Centrosomal Protein 135 
CHD3 Chromodomain Helicase DNA Binding Protein 3 
CLEC1B C-Type Lectin Domain Family 1 Member B 
CLEC4F C-Type Lectin Domain Family 4 Member F 
CLIC4 Chloride Intracellular Channel 4 
CNN2 Calponin 2 
CNO Biogenesis Of Lysosomal Organelles Complex 1 Subunit 4 
CNP 2',3'-Cyclic Nucleotide 3' Phosphodiesterase 
COL18A1 Collagen Type XVIII Alpha 1 
COL3A1 Collagen Type III Alpha 1 
COPG Coatomer Protein Complex Subunit Gamma 1 
CPB2 Carboxypeptidase B2 
CAPRIN1 Cell Cycle Associated Protein 1 
CS Citrate Synthase 
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CSF2 Colony Stimulating Factor 2 
CSF5 Colony Stimulating Factor 5 
CSK C-Src Tyrosine Kinase 
CSTA Cystatin A 
CTGF Connective Tissue Growth Factor 
CTTN Cortactin 
CUL4B Cullin 4B 
CX3CL1 C-X3-C Motif Chemokine Ligand 1 
CXCR5 C-X-C Motif Chemokine Receptor 5 
CYCS Cytochrome C, Somatic 
CYR61 Cysteine Rich Angiogenic Inducer 61 
DAAM1 Dishevelled Associated Activator Of Morphogenesis 1 
DAB2 Clathrin Adaptor Protein 
DAP Death-Associated Protein 
DCTN1 Dynactin Subunit 1 
DDR2 Discoidin Domain Receptor Tyrosine Kinase 2 
DDX5 DEAD (Asp-Glu-Ala-Asp) Box Helicase 5 
DIAPH1 Diaphanous Related Formin 1 
DIAPH2 Diaphanous Related Formin 2 
DIAPH3 Diaphanous Related Formin 3 
DLC1 Rho GTPase Activating Protein 
DNAH11 Dynein Axonemal Heavy Chain 11 
DNAJC10 DnaJ Heat Shock Protein Family (Hsp40) Member C10 
DNM1L Dynamin 1-Like 
DNM2 Dynamin 2 
DNM3 Dynamin 3 
DRCTNNB1A Family With Sequence Similarity 126 Member A 
DTNBP1 Dystrobrevin Binding Protein 1 
DUSP6 Dual Specificity Phosphatase 6 
DYNC1I2 Dynein Cytoplasmic 1 Intermediate Chain 2 
DYNLL1 Dynein Light Chain LC8-Type 1 
DYSF Dysferlin 
ECE1 Endothelin Converting Enzyme 1 
ECOP Putative NF-Kappa-B-Activating Protein 055N 
ECSM1 endothelial cell specific molecule 1 
ECSM2 endothelial cell specific molecule 2 
EDG1 Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor 
EDN1 Endothelin 1 
EDN2 Endothelin 2 
EDNRA Endothelin Receptor Type A 
EFEMP1 EGF Containing Fibulin-Like Extracellular Matrix Protein 1 
EFNB1 Ephrin B1 
EFTUD2 Elongation Factor Tu GTP Binding Domain Containing 2 
EGLN2 Egl-9 Family Hypoxia-Inducible Factor 2 
EHD2 EH Domain Containing 2 
EIF2S3 Eukaryotic Translation Initiation Factor 2 Subunit Gamma 
EIF4G2 Eukaryotic Translation Initiation Factor 4 Gamma 2 
ELK3 ETS Transcription Factor 
ELOVL5 Fatty Acid Elongase 5 
ELTD1 Adhesion G Protein-Coupled Receptor L4 
EMCN Endomucin 
EMP1 Epithelial Membrane Protein 1 
ENC1 Ectodermal-Neural Cortex 1 
ENG Endoglin 
ENPP2 Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 
EPHA4 Tyrosine-Protein Kinase Receptor SEK 
EPHB1 Tyrosine-Protein Kinase Receptor EPH-2 
ERG V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 
ESM1 Endothelial Cell Specific Molecule 1 
ETS1 ETS Proto-Oncogene 1, Transcription Factor 
ETV6 ETS Variant 6 
EVI1 AML1-EVI-1 Fusion Protein 
EWSR1 Ewing Sarcoma Breakpoint Region 1 
EXOC1 Exocyst Complex Component 1 
EXOC6 Exocyst Complex Component 6 
EXOSC10 Exosome Component 10 
F10 Coagulation Factor X 
F11 Coagulation Factor XI 
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F13A1 Coagulation Factor XIII A Chain 
F13B Coagulation Factor XIII B Chain 
F2 Coagulation Factor II, Thrombin 
F2R Coagulation Factor II Thrombin Receptor 
F2RL3  F2R Like Thrombin/Trypsin Receptor 3 
F5 Coagulation Factor V 
F7 Coagulation Factor VII 
F8 Coagulation Factor VIII 
F9 Coagulation Factor IX 
FABP4 Fatty Acid Binding Protein 4 
FAM43A Family With Sequence Similarity 43 Member A 
FAM62A Extended Synaptotagmin Protein 1 
FAM8A1 Family With Sequence Similarity 8 Member A1 
FARP2  Pleckstrin Homology Domain-Containing Family C Member 3 
FASLG Fas Ligand 
FAU Finkel-Biskis-Reilly Murine Sarcoma Virus (FBR-MuSV) Ubiquitously Expressed 
FBXL3 F-Box And Leucine-Rich Repeat Protein 3 
FCER1G Fc Fragment Of IgE Receptor Ig 
FCGR2A Fc Fragment Of IgG Receptor IIa 
FERMT3 Fermitin Family Member 3 
FES FES Proto-Oncogene, Tyrosine Kinase 
FGA Fibrinogen Alpha Chain 
FGB Fibrinogen Beta Chain 
FGD3 FYVE, RhoGEF And PH Domain Containing 3 
FGD5 FYVE, RhoGEF And PH Domain Containing 5 
FGF1 Fibroblast Growth Factor 1 
FGG Fibrinogen Gamma Chain 
FGR Proto-Oncogene, Src Family Tyrosine Kinase 
FHOD1 Formin Homology 2 Domain Containing 1 
FLI1 Fli-1 Proto-Oncogene, ETS Transcription Factor 
FLII Flightless I Actin Binding Protein 
FLJ10815 Solute Carrier Family 38 Member 8 
FLJ22746 Family With Sequence Similarity 124 Member B 
FLJ39531 Chromosome 15 Open Reading Frame 54 
FLNA Filamin A 
FLNB Filamin B 
FLT1 Fms Related Tyrosine Kinase 1 
FMNL1 Formin Like 1 
FMNL2 Formin Like 2 
FMNL3 Formin Like 3 
FN1 Fibronectin 1 
FNBP1L Formin Binding Protein 1 Like 
FNTB Farnesyltransferase, CAAX Box, Beta 
FSTL1 Follistatin Like 1 
FTH1 Cell Proliferation-Inducing Gene 15 Protein 
FYN FYN Proto-Oncogene, Src Family Tyrosine Kinase 
FZD4 Frizzled Class Receptor 4 
G3BP GTPase Activating Protein (SH3 Domain) Binding Protein 1 
GANAB Glucosidase II Alpha Subunit 
GATA1 GATA Binding Protein 1 
GBE1 Glucan (1,4-Alpha-), Branching Enzyme 1 
GBP4 Guanylate Binding Protein 4 
GDI2 GDP Dissociation Inhibitor 2 
GFI1 Growth Factor Independent 1 Transcription Repressor 
GFI1B Growth Factor Independent 1B Transcription Repressor 
GGCX Gamma-Glutamyl Carboxylase 
GIMAP6 GTPase, IMAP Family Member 6 
GJA1 Gap Junction Protein Alpha 1 
GNA12 G Protein Subunit Alpha 12 
GNA13 G Protein Subunit Alpha 13 
GNAI1 G Protein Subunit Alpha I1 
GNAI2 G Protein Subunit Alpha I2 
GNAI3 G Protein Subunit Alpha I3 
GNAQ G Protein Subunit Alpha Q 
GNAS Guanine Nucleotide Binding Protein (G Protein), Alpha Stimulating Activity Polypeptide 1 
GNAZ G Protein Subunit Alpha Z 
GNB2 G Protein Subunit Beta 2 
GNB3 G Protein Subunit Beta 3 
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GNE Glucosamine (UDP-N-Acetyl)-2-Epimerase/N-Acetylmannosamine Kinase 
GNG11 G Protein Subunit Gamma 11 
GNG12 G Protein Subunit Gamma 12 
GNG13 G Protein Subunit Gamma 13 
GNG5 G Protein Subunit Gamma 5 
GP1BA Glycoprotein Ib Platelet Alpha Subunit 
GP1BB Glycoprotein Ib Platelet Beta Subunit 
GP5  Glycoprotein V Platelet 
GP6 Glycoprotein VI Platelet 
GP9 Glycoprotein IX Platelet 
GPI Glucose-6-Phosphate Isomerase 
GPR177 G Protein-Coupled Receptor 177 
GPR4 G Protein-Coupled Receptor 4 
GPR56 Adhesion G Protein-Coupled Receptor G1 
GRAP2 Growth Factor Receptor-Binding Protein 
GRB2 Growth Factor Receptor Bound Protein 2 
GRK5 G Protein-Coupled Receptor Kinase 5 
GRK6 G Protein-Coupled Receptor Kinase 6 
GRN Granulin 
GRWD1 Glutamate-Rich WD Repeat Containing 1 
GSN Gelsolin 
GSTO1 Glutathione S-Transferase Omega 1 
GTF3C4 General Transcription Factor IIIC Subunit 4 
GTF3C5 General Transcription Factor IIIC Subunit 5 
GTPBP4 GTP Binding Protein 4 
GUCY1A3 Guanylate Cyclase 1, Soluble, Alpha 3 
GUCY1B3 Guanylate Cyclase 1, Soluble, Beta 3 
HBB Hemoglobin Subunit Beta 
HDAC6 Histone Deacetylase 6 
HDLBP High Density Lipoprotein Binding Protein 
HEL308 Helicase, POLQ-Like 
HEXB Hexosaminidase Subunit Beta 
HEY1 Hes Related Family BHLH Transcription Factor With YRPW Motif 1 
HHIP Hedgehog Interacting Protein 
HNRPH1 Heterogeneous Nuclear Ribonucleoprotein H1 (H) 
HOOK3 Hook Microtubule-Tethering Protein 3 
HOXA11 Homeobox A11 
HPS1 Hermansky-Pudlak Syndrome 1 
HPS3 Hermansky-Pudlak Syndrome 3 
HPS4 Hermansky-Pudlak Syndrome 4 
HPS5 Hermansky-Pudlak Syndrome 5 
HPS6 Hermansky-Pudlak Syndrome 6 
HRG Histidine Rich Glycoprotein 
HSPA8 Lipopolysaccharide-Associated Protein 1 
HSPD1 Heat Shock Protein Family D (Hsp60) Member 1 
HTR2A 5-Hydroxytryptamine Receptor 2A 
HYOU1 Hypoxia Up-Regulated 1 
ICAM1 Intercellular Adhesion Molecule 1 
ICAM2 Intercellular Adhesion Molecule 2 
IFI16 Interferon Gamma Inducible Protein 16 
IFI27 Interferon Alpha Inducible Protein 27 
IFNB1 Interferon Beta 1 
IKBKE Inhibitor Of Kappa Light Polypeptide Gene Enhancer In B-Cells, Kinase Epsilon 
IL11 Interleukin 11 
IL1B Interleukin 1 Beta 
IL1RL1 Interleukin 1 Receptor Like 1 
IL3 Interleukin 3 
IL6 Interleukin 6 
IL7 Interleukin 7 
INPP5D Inositol Polyphosphate-5-Phosphatase D 
INTS3 Integrator Complex Subunit 3 
ITGA2 Integrin Subunit Alpha 2 
ITGA2B Integrin Subunit Alpha 2b 
ITGA5 Integrin Subunit Alpha 5 
ITGAV Integrin Subunit Alpha V 
ITGB1 Integrin Subunit Beta 1 
ITGB3 Integrin Subunit Beta 3 
ITPR1 nositol 1,4,5-Trisphosphate Receptor Type 1 
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JAK2 Janus Kinase 2  
JAM2 Junctional Adhesion Molecule 2 
JMJD1C Jumonji Domain Containing 1C 
KCTD15 Potassium Channel Tetramerization Domain Containing 15 
KDELC1 KDEL Motif Containing 1 
KIAA0174 Putative MAPK-Activating Protein PM28 
KIAA0195 Transmembrane Protein 94 
KIAA0652 Autophagy Related 13 
KIAA0690 Ribosomal RNA Processing 12 Homolog 
KIAA1109 Fragile Site-Associated Protein 
KIAA1539 Family With Sequence Similarity 214 Member B 
KIAA2018 Upstream Transcription Factor Family Member 3 
KLK3 Kallikrein Related Peptidase 3 
LAIR1 Leukocyte Associated Immunoglobulin Like Receptor 1 
LAMA4 Laminin Subunit Alpha 4 
LAT Linker For Activation Of T-Cells 
LCP2  Lymphocyte Cytosolic Protein 2 
LDB2 LIM Domain Binding 2 
LDLR Low Density Lipoprotein Receptor 
LENG4 Lysophosphatidylinositol Acyltransferase 
LGALS1 Lectin, Galactoside Binding Soluble 1 
LIFR Leukemia Inhibitory Factor Receptor Alpha 
LMAN1 Lectin, Mannose Binding 1 
LMNA Lamin A/C 
LOC645638   
LOC646195   
LOC646999 Akirin 1 Pseudogene 
LOC653105   
LOC653352   
LOC653949   
LOX Lysyl Oxidase 
LPAR1 Lysophosphatidic Acid Receptor 1 
LRRC41 Leucine Rich Repeat Containing 41 
LRRC8C Leucine-Rich Repeat Containing 8 Family Member C 
LTA4H Leukotriene A4 Hydrolase 
LTBP1 Latent Transforming Growth Factor Beta Binding Protein 1 
LTBR Lymphotoxin Beta Receptor 
LY6G6F Lymphocyte Antigen 6 Complex, Locus G6F 
LYN LYN Proto-Oncogene, Src Family Tyrosine Kinase 
LYST LYST 
MAN2B1 Mannosidase Alpha Class 2B Member 1 
MANSC1 MANSC Domain Containing 1 
MAP1LC3B Microtubule Associated Protein 1 Light Chain 3 Beta 
MAP2K2 Mitogen-Activated Protein Kinase Kinase 2 
MAP2K3 Mitogen-Activated Protein Kinase Kinase 3 
MAP2K4 Mitogen-Activated Protein Kinase Kinase 4 
MAP3K8 Mitogen-Activated Protein Kinase Kinase Kinase 8 
MAPK1 Mitogen-Activated Protein Kinase 1 
MAPK13 Mitogen-Activated Protein Kinase 13 
MAPK14 Mitogen-Activated Protein Kinase 14 
MAPK8 Mitogen-Activated Protein Kinase 8 
MAPRE1 Microtubule Associated Protein RP/EB Family Member 1 
MASTL Microtubule Associated Serine/Threonine Kinase Like 
MAT2A Methionine Adenosyltransferase 2A 
MBTPS1 Membrane Bound Transcription Factor Peptidase, Site 1 
MCAM Melanoma Cell Adhesion Molecule 
MCFD2 Multiple Coagulation Factor Deficiency 2 
MDS1 Myelodysplasia Syndrome-Associated Protein 1 
MED28 Mediator Complex Subunit 28 
MEF2A Myocyte Enhancer Factor 2A 
METAP2 Methionyl Aminopeptidase 2 
MGAT1 Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,2-N-Acetylglucosaminyltransferase 
MKL1 Megakaryoblastic Leukemia (Translocation) 1 
MLK1 Mitogen-Activated Protein Kinase Kinase Kinase 9 
MLPH Melanophilin 
MMP1 Matrix Metallopeptidase 1 
MMP17 Matrix Metallopeptidase 17 
MMP2 Matrix Metallopeptidase 2 
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MMP9 Matrix Metallopeptidase 9 
MMRN1 Multimerin 1 
MMRN2 Multimerin 2 
MMS19L MMS19 Homolog, Cytosolic Iron-Sulfur Assembly Component 
MNX1 Motor Neuron And Pancreas Homeobox 1 
MOAP1 Modulator Of Apoptosis 1 
MOV10 Moloney Leukemia Virus 10 Protein 
MOV10L1 Mov10 RISC Complex RNA Helicase Like 1 
MPL Myeloproliferative Leukemia Protein 
MRPS34 Mitochondrial Ribosomal Protein S34 
MT2A Metallothionein 2A 
MUC16 Mucin 16, Cell Surface Associated 
MUC2 Mucin 2, Oligomeric Mucus/Gel-Forming 
MUS81 MUS81 Structure-Specific Endonuclease Subunit 
MUTED Biogenesis Of Lysosomal Organelles Complex 1 Subunit 5 
MVP Major Vault Protein 
MYB Proto-Oncogene, Transcription Factor 
MYCT1 Myc Target 1 
MYD88 Myeloid Differentiation Primary Response 88 
MYH10 Myosin, Heavy Chain 10, Non-Muscle 
MYH13 Myosin, Heavy Chain 13, Skeletal Muscle 
MYH9 Myosin, Heavy Chain 9, Non-Muscle 
MYL9 Myosin Light Chain 9 
MYLK Myosin Light Chain Kinase 
MYLK2 Myosin Light Chain Kinase 2 
MYO18B Myosin XVIIIB 
MYO1C Myosin IC 
MYO3A Myosin IIIA 
MYO5A Myosin VA 
MYO5B Myosin VB 
NAPA NSF Attachment Protein Alpha 
NAPG NSF Attachment Protein Gamma 
NBEA Neurobeachin 
NBEAL2 Neurobeachin Like 2 
NCL Nucleolin 
NDRG1 N-Myc Downstream Regulated 1 
NDUFS1 NADH:Ubiquinone Oxidoreductase Core Subunit S1 
NFE2 Nuclear Factor, Erythroid 2 
NFE2L1 Nuclear Factor, Erythroid 2 Like 1 
NIPSNAP3A Nipsnap Homolog 3A 
NOD27 NLR Family, CARD Domain Containing 5 
NONO Non-POU Domain Containing, Octamer-Binding 
NOS2 Nitric Oxide Synthase 2 
NOS3 Nitric Oxide Synthase 3 
NOSTRIN Nitric Oxide Synthase Trafficking 
NOTCH1 Notch 1 
NOX1 NADPH Oxidase 1 
NPPB Natriuretic Peptide B 
NPR1 Natriuretic Peptide Receptor 1 
NQO1 NAD(P)H Quinone Dehydrogenase 1 
NRCAM Neuronal Cell Adhesion Molecule 
NRG3 Neuregulin 3 
NRP1 Neuropilin 1 
NSF N-Ethylmaleimide Sensitive Factor 
NUCB1 Nucleobindin 1 
NUMB Endocytic Adaptor Protein 
NUP54 Nucleoporin 54kDa 
NUPL1 Nucleoporin 58kDa 
NXF1 Nuclear RNA Export Factor 1 
OCLN Occludin 
OGDH Oxoglutarate Dehydrogenase 
OGFOD1 2-Oxoglutarate And Iron Dependent Oxygenase Domain Containing 1 
ORAI1 ORAI Calcium Release-Activated Calcium Modulator 1 
OS9 Osteosarcoma Amplified 9, Endoplasmic Reticulum Lectin 
P2RX1 Purinergic Receptor P2X 1 
P2RY1 Purinergic Receptor P2Y1 
P2RY12 Purinergic Receptor P2Y12 
P2RY13 Purinergic Receptor P2Y13 
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P4HB Prolyl 4-Hydroxylase Subunit Beta 
PALMD Palmdelphin 
PAPSS1 3'-Phosphoadenosine 5'-Phosphosulfate Synthase 1 
PARN Poly(A)-Specific Ribonuclease 
PCBP4 Poly(RC) Binding Protein 4 
PCDH1 Protocadherin 1 
PCDH12 Protocadherin 12 
PCSK7 Proprotein Convertase Subtilisin/Kexin Type 7 
PDE2A Phosphodiesterase 2A 
PDE3A Phosphodiesterase 3A 
PDE4D Phosphodiesterase 4D 
PDE5A Phosphodiesterase 5A 
PDPK1 3-Phosphoinositide Dependent Protein Kinase 1 
PDZD3 PDZ Domain Containing 3 
PDZK1 PDZ Domain Containing 1 
PEAR1 Platelet Endothelial Aggregation Receptor 1 
PECAM1 Platelet And Endothelial Cell Adhesion Molecule 1 
PF4 Platelet Factor 4 
PGD Phosphogluconate Dehydrogenase 
PGM2 Phosphoglucomutase 2 
PGM3 Phosphoglucomutase 3 
PHF8 PHD Finger Protein 8 
PHOX2A Paired Like Homeobox 2a 
PI4K2B Phosphatidylinositol 4-Kinase Type 2 Beta 
PIGG Phosphatidylinositol Glycan Anchor Biosynthesis Class G 
PIGT Phosphatidylinositol Glycan Anchor Biosynthesis Class T 
PIK3CA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha 
PIK3CB Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta 
PIK3CD Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta 
PIK3CG Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma 
PIK3R1 Phosphoinositide-3-Kinase Regulatory Subunit 1 
PIK3R3 Phosphoinositide-3-Kinase Regulatory Subunit 3 
PIK3R5 Phosphoinositide-3-Kinase Regulatory Subunit 5 
PITRM1 Pitrilysin Metallopeptidase 1 
PLA1A Phospholipase A1 Member A 
PLA2G4A Phospholipase A2 Group IVA 
PLA2G4C Phospholipase A2 Group IVC 
PLAT Plasminogen Activator, Tissue Type 
PLAU Plasminogen Activator, Urokinase 
PLCB2 Phospholipase C Beta 2 
PLCB3 Phospholipase C Beta 3 
PLCG2 Phospholipase C Gamma 2 
PLD2 Phospholipase D2 
PLDN Biogenesis Of Lysosomal Organelles Complex 1 Subunit 6 
PLG Plasminogen 
PLOD1 Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 1 
PLOD3 Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 3 
PLS3 Plastin 3 
PMM2 Phosphomannomutase 2 
PODXL Podocalyxin Like 
POLR2L Polymerase (RNA) II Subunit L 
POLR3H Polymerase (RNA) III Subunit H 
POSTN Periostin 
PPIA Peptidylprolyl Isomerase A 
PPIL2 Peptidylprolyl Isomerase Like 2 
PPM1F Protein Phosphatase, Mg2+/Mn2+ Dependent 1F 
PPM1G Protein Phosphatase, Mg2+/Mn2+ Dependent 1G 
PPP1CA Protein Phosphatase 1 Catalytic Subunit Alpha 
PPP1CB Protein Phosphatase 1 Catalytic Subunit Beta 
PPP1CC Protein Phosphatase 1 Catalytic Subunit Gamma 
PPP1R12A Protein Phosphatase 1 Regulatory Subunit 12A 
PPP1R12C Protein Phosphatase 1 Regulatory Subunit 12C 
PPP1R14A Protein Phosphatase 1 Regulatory Inhibitor Subunit 14A 
PPP1R2 Protein Phosphatase 1 Regulatory Inhibitor Subunit 2 
PPP2R1A Protein Phosphatase 2 Regulatory Subunit A, Alpha 
PPP2R1B Protein Phosphatase 2 Regulatory Subunit A, Beta 




PRG1 P53-Responsive Gene 1 
PRKACA Protein Kinase CAMP-Activated Catalytic Subunit Alpha 
PRKACB Protein Kinase CAMP-Activated Catalytic Subunit Beta 
PRKACG Protein Kinase CAMP-Activated Catalytic Subunit Gamma 
PRKAR1A Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha 
PRKAR2A Protein Kinase CAMP-Dependent Type II Regulatory Subunit Alpha 
PRKCA Protein Kinase C Alpha 
PRKCB Protein Kinase C Beta 
PRKCD Protein Kinase C Delta 
PRKCQ Protein Kinase C Theta 
PRKCSH Protein Kinase C Substrate 80K-H 
PRKD1 Protein Kinase D1 
PRKG1 Protein Kinase, CGMP-Dependent, Type I 
PRKG2 Protein Kinase, CGMP-Dependent, Type II 
PROC Protein C, Inactivator Of Coagulation Factors Va And VIIIa 
PROS1 Protein S (Alpha) 
PRSS23 Protease, Serine 23 
PSAP Prosaposin 
PSME3 Proteasome Activator Subunit 3 
PTEN Phosphatase And Tensin Homolog 
PTGIR Prostaglandin I2 (Prostacyclin) Receptor (IP) 
PTGIS Prostaglandin I2 (Prostacyclin) Synthase 
PTGS1 Prostaglandin-Endoperoxide Synthase 1 
PTK2 Protein Tyrosine Kinase 2 
PTPN1 Protein Tyrosine Phosphatase, Non-Receptor Type 1 
PTPN11  Protein Tyrosine Phosphatase, Non-Receptor Type 11 
PTPN12 Protein Tyrosine Phosphatase, Non-Receptor Type 12 
PTPN18 Protein Tyrosine Phosphatase, Non-Receptor Type 18 
PTPN2 Protein Tyrosine Phosphatase, Non-Receptor Type 2 
PTPN6 Protein Tyrosine Phosphatase, Non-Receptor Type 6 
PTPN7 Protein Tyrosine Phosphatase, Non-Receptor Type 7 
PTPN9 Protein Tyrosine Phosphatase, Non-Receptor Type 9 
PTPRA Protein Tyrosine Phosphatase, Receptor Type A 
PTPRC Protein Tyrosine Phosphatase, Receptor Type C 
PTPRF Protein Tyrosine Phosphatase, Receptor Type F 
PTPRJ Protein Tyrosine Phosphatase, Receptor Type J 
PTRF Polymerase I And Transcript Release Factor 
PTTG1IP Pituitary Tumor-Transforming 1 Interacting Protein 
PXDN Peroxidasin 
QSER1 Glutamine And Serine Rich 1 
RAB27A GTP-Binding Protein Ram 
RAB27B Member RAS Oncogene Family 
RAB38 Member RAS Oncogene Family 
RAB4A Member RAS Oncogene Family 
RABGGTA Rab Geranylgeranyltransferase Alpha Subunit 
RAC1 Ras-Related C3 Botulinum Toxin Substrate 1 
RAD54L2 Androgen Receptor-Interacting Protein 4 
RAF1 Raf-1 Proto-Oncogene, Serine/Threonine Kinase 
RAI1 Retinoic Acid Induced 1 
RALA Ras Family Small GTP Binding Protein RALA  
RALB V-Ral Simian Leukemia Viral Oncogene Homolog B 
RANBP1 RAN Binding Protein 1 
RAP1B RAP1B, Member Of RAS Oncogene Family 
RAP1GAP RAP1 GTPase Activating Protein 
RAP1GAP2 RAP1 GTPase Activating Protein 2 
RAP1GDS1 Rap1 GTPase-GDP Dissociation Stimulator 1 
RAPGEF3 Rap Guanine Nucleotide Exchange Factor 3 
RASGRP2 RAS Guanyl Releasing Protein 2 
RBM8A RNA Binding Motif Protein 8A 
RGS1 Regulator Of G-Protein Signaling 1 
RGS10 Regulator Of G-Protein Signaling 10 
RGS18 Regulator Of G-Protein Signaling 18 
RGS19 Regulator Of G-Protein Signaling 19 
RGS20 Regulator Of G-Protein Signaling 20 
RGS4 Regulator Of G-Protein Signaling 4 
RGS5 Regulator Of G-Protein Signaling 5 
RGS9 Regulator Of G-Protein Signaling 9 
RHOA Ras Homolog Family Member A 
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RHOB Ras Homolog Family Member B 
RHOBTB1 Rho Related BTB Domain Containing 1 
RHOBTB3 Rho Related BTB Domain Containing 3 
RHOC Ras Homolog Family Member C 
RHOF Ras Homolog Family Member F (In Filopodia) 
RHOJ Ras Homolog Family Member J 
RNASE1 Ribonuclease A Family Member 1, Pancreatic 
RNF4 Ring Finger Protein 4 
RNF40 Ring Finger Protein 40 
RNU2 RNA, U2 Small Nuclear 1 
ROBO4 Roundabout Guidance Receptor 4 
ROCK1 Rho Associated Coiled-Coil Containing Protein Kinase 1 
ROCK2 Rho Associated Coiled-Coil Containing Protein Kinase 2 
RPAP1 RNA Polymerase II Associated Protein 1 
RPL13A Ribosomal Protein L13a 
RPL17 Ribosomal Protein L17 
RPL19 Ribosomal Protein L19 
RPL24 Ribosomal Protein L24 
RPL26 Ribosomal Protein L26 
RPL27A Ribosomal Protein L27a 
RPL30 Ribosomal Protein L30 
RPL31 Ribosomal Protein L31 
RPL32 Ribosomal Protein L32 
RPL36 Ribosomal Protein L36 
RPL37 Ribosomal Protein L37 
RPL37A Ribosomal Protein L37a 
RPL41 Ribosomal Protein L41 
RPL5 Ribosomal Protein L5 
RPLP1 Ribosomal Protein Lateral Stalk Subunit P1 
RPLP2 Ribosomal Protein Lateral Stalk Subunit P2 
RPN1 Ribophorin I 
RPS12 Ribosomal Protein S12 
RPS13 Ribosomal Protein S13 
RPS14 Ribosomal Protein S14 
RPS15 Ribosomal Protein S15 
RPS15A Ribosomal Protein S15a 
RPS18 Ribosomal Protein S18 
RPS20 Ribosomal Protein S20 
RPS24 Ribosomal Protein S24 
RPS25 Ribosomal Protein S25 
RPS26 Ribosomal Protein S26 
RPS27 Ribosomal Protein S27 
RPS27A Ribosomal Protein S27a 
RPS7 Ribosomal Protein S7 
RPS8 Ribosomal Protein S8 
RUNX1 Runt Related Transcription Factor 1 
S100A6 S100 Calcium Binding Protein A6 
S100A8 S100 Calcium Binding Protein A8 
SCAMP2 Secretory Carrier Membrane Protein 2 
SCAMP4 Secretory Carrier Membrane Protein 4 
SCAMP5 Secretory Carrier Membrane Protein 5 
SCARB2 Scavenger Receptor Class B Member 2 
SCFD1 Sec1 Family Domain Containing 1 
SDCBP Syndecan Binding Protein 
SDF4 Stromal Cell Derived Factor 4 
SDPR Serum Deprivation Response 
SEC14L1 SEC14 Like Lipid Binding 1 
SELE Leukocyte-Endothelial Cell Adhesion Molecule 2 Selectin E 
SELL Leukocyte-Endothelial Cell Adhesion Molecule 1 Selectin L 
SELP Platelet Activation Dependent Granule-External Membrane Protein Selectin P 
SELPLG Selectin P Ligand 
SEPN1 Selenoprotein N, 1 
SERINC3 Serine Incorporator 3 
SERP1 Stress-Associated Endoplasmic Reticulum Protein 1 
SERPINB5 Serpin Family B Member 5 
SERPINC1 Serpin Family C Member 1 
SERPIND1 Serpin Family D Member 1 
SERPINE1 Serpin Family E Member 1 
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SERPINE2 Serpin Family E Member 2 
SERPINH1 Serpin Family H Member 1 
SFRS1 PC4 And SFRS1 Interacting Protein 1 
SGK Serum/Glucocorticoid Regulated Kinase 1 
SH2B3 SH2B Adaptor Protein 3 
SHC1 SHC (Src Homology 2 Domain Containing) Transforming Protein 1 
SHQ1 H/ACA Ribonucleoprotein Assembly Factor 
SIRPA Signal Regulatory Protein Alpha 
SLC29A1 Solute Carrier Family 29 Member 1 (Augustine Blood Group) 
SLC35A2 Solute Carrier Family 35 Member A2 
SLC35A5 Solute Carrier Family 35 Member A5 
SLC35D3 Solute Carrier Family 35 Member D3 
SLC35F2 Solute Carrier Family 35 Member F2 
SLC39A9 Solute Carrier Family 39 Member 9 
SLC7A7 Solute Carrier Family 7 Member 7 
SLC9A3R1 SLC9A3 Regulator 1 
SLC9A3R2 SLC9A3 Regulator 2 
SLFN14 Schlafen Family Member 14 
SMAD1 SMAD Family Member 1 
SMAD6 SMAD Family Member 6 
SMARCA4 SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4 
SMG6 Nonsense Mediated MRNA Decay Factor 
SMURF2 SMAD Specific E3 Ubiquitin Protein Ligase 2 
SNAP23 Synaptosome Associated Protein 23kDa 
SNAP25 Synaptosome Associated Protein 25kDa 
SNAP29 Synaptosome Associated Protein 29kDa 
SNAPIN SNAP Associated Protein 
SND1 Staphylococcal Nuclease And Tudor Domain Containing 1 
SNRK SNF Related Kinase 
SNX1 Sorting Nexin 1 
SNX12 Sorting Nexin 12 
SOD1 Superoxide Dismutase 1, Soluble 
SOX7 SRY-Box 7 
SPARC Secreted Protein Acidic And Cysteine Rich 
SPARCL1 High Endothelial Venule Protein 
SPG20 Spastic Paraplegia 20 (Troyer Syndrome) 
SPHK1 Sphingosine Kinase 1 
SPINK5 Serine Peptidase Inhibitor, Kazal Type 5 
SPRR3 Small Proline Rich Protein 3 
SPTLC1 Serine Palmitoyltransferase Long Chain Base Subunit 1 
SRA1 Steroid Receptor RNA Activator 1 
SRC SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase 
SRF Serum Response Factor 
SRPX Sushi Repeat Containing Protein, X-Linked 
SRPX2 Sushi Repeat Containing Protein, X-Linked 2 
STAB1 Stabilin 1 
STARD4 StAR Related Lipid Transfer Domain Containing 4 
STIM1 Stromal Interaction Molecule 1 
STOM Stomatin 
STX11 Syntaxin 11 
STX12 Syntaxin 12 
STX2 Syntaxin 2 
STX4 Syntaxin 4 
STX6 Syntaxin 6 
STX7 Syntaxin 7 
STXBP1 Syntaxin Binding Protein 1 
STXBP2 Syntaxin Binding Protein 2 
STXBP3 Syntaxin Binding Protein 3 
STXBP4 Syntaxin Binding Protein 4 
STXBP5L Syntaxin Binding Protein 5 Like 
STXBP6 Syntaxin Binding Protein 6 
SURF4 Surfeit 4 
SUZ12 SUZ12 Polycomb Repressive Complex 2 Subunit 
SYK Spleen Tyrosine Kinase 
SYTL3 Synaptotagmin Like 3 
SYTL4 Synaptotagmin Like 4 
TAF15 TATA-Box Binding Protein Associated Factor 15 
TAL1 T-Cell Acute Lymphocytic Leukemia 1 
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TAOK1 TAO Kinase 1 
TARDBP TAR DNA Binding Protein 
TBXA2R Thromboxane A2 Receptor 
TBXAS1 Thromboxane A Synthase 1 
TCF4 Transcription Factor 4 
TCF8 Zinc Finger E-Box Binding Homeobox 1 
TEC Tec Protein Tyrosine Kinase 
TEK TEK Receptor Tyrosine Kinase 
TFPI Tissue Factor Pathway Inhibitor 
TFPI2 Tissue Factor Pathway Inhibitor 2 
TGFBR3 Transforming Growth Factor Beta Receptor 3 
TGM2 Transglutaminase 2 
THBD Thrombomodulin 
THBS1 Thrombospondin 1 
THPO Thrombopoietin 
THRAP4 Mediator Complex Subunit 24 
TIE1 Tyrosine Kinase With Immunoglobulin Like And EGF Like Domains 1 
TIMP1 TIMP Metallopeptidase Inhibitor 1 
TINAGL1 Tubulointerstitial Nephritis Antigen Like 1 
TLN1 Talin 1 
TLR2 Toll Like Receptor 2 
TM6SF1 Transmembrane 6 Superfamily Member 1 
TMBIM1 Transmembrane BAX Inhibitor Motif Containing 1 
TMCC2 Transmembrane And Coiled-Coil Domain Family 2 
TMEM154 Transmembrane Protein 154 
TMEM43 Transmembrane Protein 43 
TMSB10 Thymosin Beta 10 
TMSB4X Thymosin Beta 4, X-Linked 
TNF Tumor Necrosis Factor 
TNFRSF1A Tumor Necrosis Factor Receptor Superfamily Member 1A 
TNFSF10 Tumor Necrosis Factor Superfamily Member 10 
TNFSF18 Tumor Necrosis Factor Superfamily Member 18 
TNNC2 Troponin C2, Fast Skeletal Type 
TNPO1 Transportin 1 
TP53 Tumor Protein P53 
TPD52L2 Tumor Protein D52 Like 2 
TPM1 Tropomyosin 1 (Alpha) 
TPM4 Tropomyosin 4 
TPP1 Tripeptidyl Peptidase 1 
TRAF4 TNF Receptor Associated Factor 4 
TRAM2 Translocation Associated Membrane Protein 2 
TREML1 Triggering Receptor Expressed On Myeloid Cells Like 1 
TRPM7 Transient Receptor Potential Cation Channel Subfamily M Member 7 
TSN Translin 
TTC37 Tetratricopeptide Repeat Domain 37 
TTLL5 Tubulin Tyrosine Ligase Like 5 
TTLL10 Tubulin Tyrosine Ligase Like 10 
TUBA3C Tubulin Alpha 3c 
TUBB1 Tubulin Beta 1 Class VI 
TUBB6 Tubulin Beta 6 Class V 
TXNDC5 Thioredoxin Domain Containing 5 
TXNRD1 Thioredoxin Reductase 1 
TYK2 Tyrosine Kinase 2 
TYMP Thymidine Phosphorylase 
UACA Uveal Autoantigen With Coiled-Coil Domains And Ankyrin Repeats 
UBA52 Ubiquitin A-52 Residue Ribosomal Protein Fusion Product 1 
UBAP2 Ubiquitin Associated Protein 2 
UBC Ubiquitin C 
UBE1C Ubiquitin Like Modifier Activating Enzyme 3 
UBE3C Ubiquitin Protein Ligase E3C 
UBL5 Ubiquitin Like 5 
UBN1 Ubinuclein 1 
UGDH UDP-Glucose 6-Dehydrogenase 
UNC13A Unc-13 Homolog A (C. Elegans) 
UNC13B Unc-13 Homolog B (C. Elegans) 
UNC45A Unc-45 Myosin Chaperone A 
VAMP2 Vesicle Associated Membrane Protein 2 
VAMP3 Vesicle Associated Membrane Protein 3 
278 
 
VAMP7  Vesicle Associated Membrane Protein 7 
VAMP8 Vesicle Associated Membrane Protein 8 
VAT1 Vesicle Amine Transport 1 
VAV1 Vav Guanine Nucleotide Exchange Factor 1 
VAV2 Vav Guanine Nucleotide Exchange Factor 2 
VAV3 Vav Guanine Nucleotide Exchange Factor 3 
VCAM1 Vascular Cell Adhesion Molecule 1 
VCP Valosin Containing Protein 
VEGFA Vascular Endothelial Growth Factor A 
VEPH1 Ventricular Zone Expressed PH Domain Containing 1 
VIM Vimentin 
VIPAS39 VPS33B Interacting Protein, Apical-Basolateral Polarity Regulator, Spe-39 Homolog 
VKORC1 Vitamin K Epoxide Reductase Complex Subunit 1 
VPS11 VPS11, CORVET/HOPS Core Subunit 
VPS16 VPS16, CORVET/HOPS Core Subunit 
VPS18 VPS18, CORVET/HOPS Core Subunit 
VPS33A VPS33A, CORVET/HOPS Core Subunit 
VPS33B Late Endosome And Lysosome Associated 
VPS39 VPS39, HOPS Complex Subunit 
VPS41 VPS41, HOPS Complex Subunit 
VPS4B Vacuolar Protein Sorting 4 Homolog B 
VPS52 VPS52, GARP Complex Subunit 
VPS8 VPS8, CORVET Complex Subunit 
VWF Von Willebrand Factor 
WARS Tryptophanyl-TRNA Synthetase 
WAS Wiskott-Aldrich Syndrome 
WASF2 WAS Protein Family Member 2 
WBP2 WW Domain Binding Protein 2 
WDR1 WD Repeat Domain 1 
WDR46 WD Repeat Domain 46 
WDR6 WD Repeat Domain 6 
WDR66 WD Repeat Domain 66 
WSB1 WD Repeat And SOCS Box Containing 1 
WWP2 WW Domain Containing E3 Ubiquitin Protein Ligase 2 
WWTR1 WW Domain Containing Transcription Regulator 1 
XLKD1 Lymphatic Vessel Endothelial Hyaluronan Receptor 1 
XPO6 Exportin 6 
XRCC6 X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 6 
ZFPMI   
ZNF207 Zinc Finger Protein 207 
ZNF346 Zinc Finger Protein 346 
ZNF521 Zinc Finger Protein 521 
ZNF586 Zinc Finger Protein 586 
ZNF827 Zinc Finger Protein 827 
 
 
 
 
 
 
 
 
 
 
 
